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Abstract 
 
 
The Mechanism of β-adrenergic preconditioning (β-PC) 
 
Ischaemic preconditioning (IPC), a potent endogenous protective intervention against myocardial 
ischaemia, is induced by exposure of the heart to repetitive short episodes of ischaemia and 
reperfusion. The protective effects of this phenomenon have been demonstrated to be mediated by 
release of autocoids such as adenosine, opioids and bradykinin.  Release of endogenous 
catecholamines and activation of the beta-adrenergic receptors (β-AR) have also been shown to be 
involved in ischaemic preconditioning. However, the exact mechanism whereby activation of the β-
adrenergic signal transduction pathway leads to cardioprotection, is still unknown. 
 
In view of the above, the aims of the present study were to evaluate:  
(i) the respective roles of the β1-, β2- and β3-AR receptors as well as the contribution of Gi 
protein and PKA to β-adrenergic preconditioning,  
(ii)  the role of the prosurvival kinases, PKB/Akt and ERK 44/p42 MAPKinase in β-drenergic 
preconditioning,  
(iii) whether β-AR stimulation protect via ischaemia and the formation of adenosine; the 
respective roles of the A1-, A2-, A3-adenosine receptors as well as the involvement of the 
PI3-K/PKB/Akt and ERKp44/p42 signal transduction pathways, in the cardioprotective 
phenomemon of β-adrenergic preconditioning and 
(iv) the contribution of the mitochondrial KATP channels (mKATP), reactive oxygen species and NO 
to the mechanism of β-AR-induced cardioprotection.  
 
Methods: Isolated perfused rat hearts were subjected to 35 min regional ischaemia (RI) and 
reperfusion. Infarct size (IS) was determined using tetrazolium staining (TTC) and data were 
analyzed with ANOVA. Hearts were preconditioned with 5 min isoproterenol 0.1 µM (β1/β2-AR 
agonist), or formoterol 1 nM (β2-AR agonist) or BRL 37344 1 µM (β3-AR agonist) followed by 5 
min reperfusion. The roles of the β1-, β2- and β3-ARs as well as NO were explored by using the 
selective antagonists CGP-20712A (300 nM), ICI -18551 (50 nM), SR59230A (100 nM) and NOS 
inhibitors L-NAME (50 µM) or LNNA (50 µM) respectively.  Involvement of ROS and the mK+ATP 
channels was studied by administration of N-acetyl cysteine (NAC, 300 µM) and the mitK+ATP 
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channel blocker 5-HD (100 µM) during the triggering phase.  The role of PKA and PI3-K/Akt was 
investigated by the administration of the blockers Rp-8-CPT-cAMPs (16 µM) and wortmannin (100 
nM) respectively, prior to RI or at the onset of reperfusion. Pertussis toxin (PTX), 30 µg kg-1 was 
administered i.p., 48 h prior to experimentation. 
 
The role of adenosine and the adenosine A1, A3, A2A and A2B receptors was studied by using 
adenosine deaminase and the selective antagonists DPCPX (1 µM), MRS 1191(1 µM), ZM241385 
(1 µM) and MRS1754 (1 µM). Activation of PKB/Akt and ERKp44/p42 was determined by 
Western blot.  
 
Results: Infarct sizes of hearts preconditioned with isoproterenol of formoterol were significantly 
smaller compared to those of non-preconditioned hearts.  This was associated with an improvement 
in postischaemic mechanical performance. However the β3-AR agonist BRL37344 could not reduce 
infarct size.  The β1- and β2-AR blockers CGP-20712A and ICI-118551 completely abolished the 
isoproterenol-induced reduction in infarct size and improvement in mechanical recovery, while the 
β3-AR blocker was without effect.  
 
Both Rp-8-CPT-cAMPs and wortmannin significantly increased infarct size when administered 
before β1/β2-AR preconditioning or at the onset of reperfusion while it reduced mechanical 
recovery during reperfusion. PTX pretreatment had no significant effect on the reduction in infarct 
size induced by β1/β2-AR or β2-AR preconditioning, however it reduced mechanical recovery in the 
latter.  The NOS inhibitors had no effect on the reduction in infarct size induced by β1/β2-AR 
preconditioning, but depressed mechanical function during reperfusion.   
 
The significant reduction in infarct size by β1/β2-PC, was associated with activation of ERKp44/p42 
and PKB/Akt during the triggering phase, as well as during reperfusion. DPCPX (A1-AdoR 
antagonist) had no effect on the β1/β2-PC-induced reduced infarct size or ERK p44/p42 and PKB 
activation.  
 
A2A-AdoR, but not A2b-AdoR, blockade during the trigger phase abolished the reduction in  infarct 
size of β1/β2-PC.  Both antagonists significantly reduced ERK and PKB activation in the trigger 
phase. In addition, when applied at the onset of reperfusion they significantly reduced ERK p44 / 
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p42 MAPK and PKB/Akt activation to an even greater extent.  MRS-1191 (A3-AdoR antagonist) 
blocked β1/β2-PC when applied prior to index ischaemia or when added during early reperfusion, 
significantly inhibiting both ERK p44 and PKB activation. 
 
Cardioprotection of β1/β2-PC was abolished by inhibition of ROS generation with NAC in the 
triggering phase as well as at the start of reperfusion.  However, the mitoK+ATP channel blocker 5-
HD was without effect. 
 
Conclusions: Protection afforded by an acute transient stimulation of the β-ARs, depends on the 
activation of both β1-AR and β2-ARs but not the β3-AR.  PKA as well as PI3-K activation prior to 
sustained ischemia and at the onset of reperfusion were essential for cardioprotection. With 
functional recovery as endpoint, it appears that NO is involved in β1/β2-AR preconditioning, while 
the Gi protein may play a role in β2-AR preconditioning. 
 
The production of endogenous adenosine induced by transient β1/β2 stimulation of the isolated rat 
heart is involved in β−AR preconditioning. Cardioprotection was shown not to be dependent on the 
A1AdoR while activation of the A3-AdoR occurs during both the triggering and mediation phases. 
Both the adenosine A2A and, to a lesser extent, the adenosine A2B receptors participate in the 
triggering phase of β1/β2-PC. Generation of ROS during the triggering and reperfusion phases is 
involved in eliciting protection, but no role for the mKATP channels could be demonstrated. Finally, 
activation of the RISK pathway (PKB/Akt and ERKp44/p42) during the triggering phase is a 
prerequisite for protection. In addition, cardioprotection by β-AR is characterized by activation of 
the RISK pathway during reperfusion. 
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Uittreksel 
 
 
Die Meganisme van β-adrenerge prekondisionering (β-PC) 
 
Iskemiese prekondisionering (IPC) is ‘n kragtige endogene beskerming teen miokardiale iskemie, 
wat deur blootstelling van die hart aan kort opeenvolgende episodes van iskemie en herperfusie, 
ontlok word. Hierdie beskerming word medieer deur vrystelling van outakoïede soos adenosine, 
opioïede en bradikinien. Vrystelling van endogene katekolamiene en aktivering van die beta-
adrenerge reseptore (β-AR) is bewys om ook by hierdie proses betrokke te wees. Die presiese 
meganismes waardeur aktivering van die β-adrenerge seintransduksiepad tot miokardiale 
beskerming lei, is nog onbekend. 
 
In die lig van bogenoemde, was die doel van die huidige studie om die volgende te evalueer: (i) die 
onderskeie rolle van die β1-, β2- en β3-AR sowel as die bydrae van die Gi proteïen en PKA in β-
adrenerge prekondisionering, (ii) of β-AR stimulasie beskerming ontlok via iskemie en vorming van 
adenosien, die onderskeie rolle van die A1-, A2-, A3-adenosien reseptore (AdoRs) sowel as die PI3-
K/PKB/Akt en ERKp44/p42 seintransduksie paaie, (iv) die mitochondriale KATP (mKATP) kanale, 
vry suurstof radikale en NO in β−AR prekondisionering. 
 
Metodes: Geïsoleerde, geperfuseerde rotharte is aan 35 minute streeksiskemie en herperfusie 
onderwerp.  Infarktgrootte (IS) is deur die tetrazolium (TTC)-kleuringsmetode bepaal.  Data is met 
behulp van ANOVA analiseer. Harte is geprekondisioneer vir 5 min met isoproterenol 0.1 µM 
(β1/β2-AR agonist), of formoterol 1 nM (β2-AR agonist) of BRL 37344 1 µM (β3-AR agonist), 
gevolg deur 5 min herperfusie, voor streeksiskemie.  Die belang van die β1-, β2- en β3-ARs sowel 
as NO is ondersoek, deur onderskeidelik gebruik te maak van selektiewe antagoniste nl CGP-
20712A (300 nM), ICI -18551 (50 nM), SR59230A (100 nM) en NOS inhibitore L-NAME (50µM) 
of LNNA (50µM). Die rol van die mK+ATP kanale en ROS is bepaal deur die toediening van die 
mK+ATP kanaal blokker 5-HD (100 µM) en die vrye-radikaal opruimer, N-asetiel cysteine (NAC, 
300 µM).  Die belang van PKA en PI3-K/Akt is bepaal deur toediening van die PKA blokker Rp-8-
CPT-cAMPs (16µM) en wortmannin (100nM) respektiewelik.  Pertussis toxin (PTX), 30 µg kg-1 is 
i.p toegedien, 48 uur voor eksperimentasie. 
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Die rol van adenosien en die adenosien A1, A2A, A2B en A3 reseptore is bestudeer, deur gebruik te 
maak van adenosien deaminase en die selektiewe antagoniste DPCPX (1 µM), MRS 1191(1 µM), 
ZM241385 (1 µM) and MRS1754 (1 µM),repektiewelik.  Die middels is deurgaans toegedien tydens 
die prekondisioneringsprotokol (“snellerfase”) of tydens vroeë herperfusie. Aktivering van PKB/Akt 
en ERK p44/p42 is deur Western blot analise bepaal.  
 
Resultate: Infarktgrootte van harte wat geprekondisioneer is met of isoproterenol (β1/β2-PC) of 
formoterol (β2-PC), was beduidend kleiner as díe van ongeprekondisioneerde harte.  Dit is 
geassosieer met ‘n toename in postiskemiese meganiese herstel.  Die β3-AR agonis BRL37344 (β3-
PC) het egter geen effek op infarktgrootte gehad nie.  Die selektiewe β1- en β2-AR blokkers CGP-
20712A en ICI-118551 het die afname in infarktgrootte heeltemal opgehef, asook die verbetering in 
meganiese herstel tydens herperfusie terwyl die β3-AR blokker geen effek getoon het nie. Beide Rp-
8-CPT-cAMPs en wortmannin het infarktgrootte beduidend vergroot en meganiese herstel 
beduidend verlaag, wanneer dit net voor β1/β2-prekondisionering of tydens die begin van 
herperfusie toegedien is.  PTX voorafbehandeling het geen beduidende effek op die vermindering 
van infarktgrootte (geïnduseer deur β1/β2-PC of β2-PC) gehad nie. Meganiese herstel is egter 
verminder in die geval van β2-PC. Die NOS inhibitore het geen effek op die vermindering in 
infarktgrootte geïnduseer deur β1/β2 gehad nie, maar het ook meganiese herstel onderdruk. 
 
Die beduidende afname in infarktgrootte deur β1/β2 prekondisionering is gekenmerk deur 
aktivering van ERKp42/p44 en PKB/Akt tydens die snellerfase.  Soortgelyke aktivering van hierdie 
kinases is ook tydens herperfusie van β-AR geprekondisioneerde harte waargeneem. 
  
DPCPX (A1-AdoR antagonis) het geen effek op die infarkt-verminderde effek van β1/β2-
prekondisionering of op ERK p44/p42 en PKB aktivering gehad nie. A2A-AdoR, maar nie A2b –
AdoR, blokkade tydens die snellerfase, het die effek van β-AR prekondisionering op infarktgroottee 
opgehef. Beide antagoniste het die aktivering van ERKp42/p44 en PKB/Akt tydens die snellerfase 
onderdruk. Wanneer toegedien tydens herperfusie, het dit die aktivering van hierdie kinases tot ‘n 
groter mate onderdruk.  MRS-1191 (A3-AdoR antagonis) het infarktgrootte beduidend verhoog en 
β1/β2-prekondisionering geblokkeer, beide wanneer dit voor indeks-iskemie toegedien is of tydens 
vroeë herperfusie, tesame met inhibisie van PKB en ERK p44/p44 aktivering. 
 viii 
 
 
Die kardiobeskerming van β1/β2-prekondisionering is opgehef deur middel van opruiming van vry 
suurstof radikale deur NAC in die snellerfase sowel as aan die begin van herperfusie.  Die mK+ATP 
kanaal blokker 5-HD het geen effek op β-AR prekondisionering gehad nie. 
 
Gevolgtrekking: Kardiobeskerming teweeggebring deur ‘n kort periode van stimulasie van die β-
ARs, is afhanklik van die aktivering van beide β1-AR en β2-ARs, maar nie β3-AR nie.  PKA sowel 
as PI3-K aktivering, net voor volgehoue iskemie en tydens vroeë herperfusie, is aangedui om 
noodsaaklik vir β1/β2-AR prekondisionering te wees. Waar funksionele herstel as eindpunt gebruik 
is, blyk dit dat NO wel betrokke is by β1/β2-AR prekondisionering, terwyl die Gi protein ‘n rol mag 
speel in β2-AR prekondisionering.   
 
Vorming van endogene adenosien tydens β-adrenerge stimulasie is betrokke by β-AR 
prekondisionering.  Hierdie beskerming is nie van die A1-AdoR afhanklik nie, maar aktivering van 
die A3-AdoR is nodig tydens beide die sneller en herperfusie fases.  Beide die A2A-AdoR, en tot ‘n 
mindere mate die A2B–AdoR, is ook betrokke by die snellerfase.  Vorming van vry suurstof radikale 
is nodig vir β-AR prekondisionering, nterwyl die mKATP  kanale nie betrokke is nie.  Ten slotte, 
aktivering van die RISK seintransduksiepad (ERKp42/p44 en PKB/Akt) tydens die snellerfase is ‘n 
voorvereiste vir die ontlokking van beskerming. Daarbenewens word β-AR prekondisionering 
gekarakteriseer deur aktivering van hierdie pad tydens herperfusie. 
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Chapter 1 
 
 
Introduction 
 
 
Myocardial cell death due to ischaemia-reperfusion is a major cause of morbidity and mortality.  It 
has been debated whether cardiomyocytes suffer irreversible injury primarily during ischaemia, 
which may be revealed at the start of reperfusion, or whether additional injury occurs during 
reperfusion (reperfusion injury). This point has important clinical implications, because if additional 
injury occurs on reperfusion, this would allow an opportunity to intervene with cardioprotective 
strategies at this time. It has become clear that the myocardial response to ischaemia-reperfusion can 
be manipulated to delay injury, which in turn has motivated intense study of the mechanisms of 
cardioprotection. It follows then that cardioprotection should be aimed at the prevention of 
perioperative infarction, fewer myocardial infarct-associated ventricular arrhythmias and less 
mortality. 
 
A large number of studies have investigated the capability of cardioprotective drugs or strategies 
administered at the onset of reperfusion to reduce infarct size. Postconditioning, characterized by  
short cycles of reperfusion/ischaemia applied at the onset of reperfusion [Zhao et al., 2003], Na+-H+ 
exchange inhibitors [Karmazyn, 1988], activation of kinases [Hausenloy, Mocanu and Yellon, 
2004], perfusion with erythropoietin [Hanlon et al., 2005], inhibitors of protein kinase C (PKC-δ) 
[Inagaki et al., 2003], inhibitors of the mitochondrial permeability transition pore (MPT) 
[Hausenloy, Duchen and Yellon, 2003], inhibition of glycogen synthase kinase (GSK)-3β [Gross, 
Hsu and Gross, 2004] and other interventions have been reported to protect the myocardium when 
administered at the time of reperfusion. However, from failed clinical trails [Bolli et al., 1988; 
Flaherty et al., 1994] it appears that the window of opportunity during reperfusion is very limited. 
Although protection can be initiated at reperfusion, injury also occurs during ischaemia, and the 
relative proportion of each event likely depends on the duration of ischaemia [Stephanou et al., 
2001]. Thus, if cardioprotective strategies can be initiated before or during ischaemia, it is likely that 
they will enhance protection, especially with longer durations of ischaemia [Murphy, and 
Steenbergen, 2007]. 
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Early attempts to salvage myocardium exposed to ischaemia-reperfusion have been intensely 
explored but results obtained in these studies have mostly been unsatisfactory and controversial. 
However, in 1986 it was discovered that the heart has an endogenous protective mechanism, the so-
called phenomenon of ischaemic preconditioning (IPC) [Murry et al., 1986]. This can be defined as 
a phenomenon whereby exposure of the myocardium to one or more brief episodes of ischaemia and 
reperfusion markedly reduces tissue necrosis induced by a subsequent prolonged period of 
ischaemia. IPC was shown to exert a very powerful anti-infarct effect, reduce reperfusion 
arrhythmias [Shiki and Hearse, 1987], reduce energy metabolism during the early stages of 
ischaemia [Murry et al., 1990] and improve post-ischaemic developed tension [Cave and Hearse, 
1992]. This discovery led to intensive research into the mechanism(s) and signaling pathways 
involved since it is believed that this could lead to the development of new cardioprotective 
strategies and drugs aimed at salvage of ischaemic tissues. Several comprehensive reviews on 
ischaemic preconditioning have appeared in recent years, thus only some of the major findings in 
this regard are summarized below. 
 
IPC has been shown to reduce infarct size in all species tested including rats [Liu and Downey, 
1992], rabbits [Liu et al., 1991], pigs [Vahlhaus et al., 1996], dogs [Przyklenk et al., 1995] and mice 
[Miller and Winkle, 1999]. It was also illustrated that recovery of function in isolated human atrial 
trabeculae after an extended period of hypoxia was greatly enhanced by earlier hypoxic 
preconditioning [Speechly-Dick et al., 1995].  
 
Furthermore, a standard ischaemic preconditioning stimulus of one or more brief episodes of non-
lethal ischaemia and reperfusion elicits a bi-phasic pattern of cardioprotection. The first phase 
manifests almost immediately following the IPC stimulus and lasts for 1-2 hours after which its 
effects disappears (termed classic or early preconditioning) [Murray, Jennings and Reimer, 1986; 
Lawson and Downey, 1993]. The second phase of cardioprotection appears 12-24 hours later and 
lasts for 48-72 hours and is termed the Second Window of Protection [SWOP], delayed or late 
ischaemic preconditioning [Marber et al., 1993; Kuzuya et al., 1993]. The cardioprotection 
conferred by delayed IPC is robust and ubiquitous but not as powerful as early IPC. Although there 
are some similarities in the mechanisms underlying early and delayed IPC, one of the major 
distinctions between the two is the latter’s requirement for de novo protein synthesis of distal 
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mediators such as iNOS, HSP and COX-2 which mediate the cardioprotection 24 hours after the IPC 
stimulus [for review see Hausenloy and Yellon, 2010]. 
 
The signal transduction cascades of IPC can be divided into a trigger and a mediator phase and in 
recent years it has become a major objective to identify the various triggers, mediators and end 
effectors that are activated in this phenomenon. Triggers are activated during the preconditioning 
ischaemia and reperfusion cycle(s), and blockade of a trigger during this time will attenuate or 
abolish the cardioprotection of IPC. Mediators are important during prolonged index ischaemia and 
the first few minutes of reperfusion after sustained ischaemia. Similarly, blockade of mediators 
during this time will abolish the cardioprotection of IPC. Elucidation of the signaling mechanisms 
involved in the cardioprotective effects of identified triggers and / or mediators in IPC could lead to 
the development of pharmacological applications to be used in clinical settings. 
 
Although the protection of ischaemic or pharmacological preconditioning is powerful, it could not 
be effectively employed in patients with acute myocardial infarction since preconditioning has to be 
introduced before the onset of ischaemia. But if IPC exerts its protection at reperfusion, then 
therapeutic salvage could still be possible even after ischaemia had begun by intervening at 
reperfusion.  
 
1.1   Receptor dependent triggers of early preconditioning 
 
In the heart, adenosine (Ado) has been proposed to act as a regulatory “metabolite” in ischaemia 
[Berne et al., 1963] in view of its ability to limit oxygen demand by causing negative inotropy and 
chronotropy and increase oxygen delivery by vasodilation. As an antiarrhythmic agent, the effects of 
adenosine on the mammalian heart were first reported in 1929 by Drury and Szent-Gyorgyi. In 
1991, Liu et al. discovered that stimulation of the Gi-coupled adenosine A1 receptor was necessary 
to trigger IPC. An increase in interstitial adenosine concentration during preconditioning was shown 
to occur in rats [Kuzmin et al 2000], rabbits [Lasley et al., 1995], dogs [Mei et al., 1998], and pigs 
[Schulz  et al., 1998]. Attenuation of the increase in interstitial adenosine concentration in pigs 
[Schulz et al., 1995] or blocking the adenosine A1- and A3-, but not the A2- receptors [Liu et al., 
1991; Thornton et al., 1992] almost completely abolished the infarct size reduction achieved by IPC. 
The role of the opioid receptors in the preconditioning stimulus has been widely studied, and 
evidence indicated the involvement of the δ opioid receptor type [Schultz, 1995; Genade et al., 
2001; Lochner et al, 2001]. 
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Several studies suggest that bradykinin contributes to infarct size reduction in IPC [Wall et al., 1994; 
Jalowy et al., 1998] and it was also illustrated that bradykinin and adenosine act synergistically as 
triggers of preconditioning [Goto et al., 1995]. 
  
The hypothesis that the cardioprotective effects of IPC are due to release of an endogenous 
substance derived from the cyclo-oxygenase pathway of arachidonic acid metabolism such as 
prostacyclin (PGI), was substantiated when cyclo-oxygenase inhibition in the dog heart prevented 
the anti-arrhythmic effect of preconditioning [Vegh et al., 1990]. However, the cardioprotective 
effects of IPC could not be prevented by aspirin, suggesting that this was not mediated by 
prostanoids in a rat model [Li and Kloner, 1992] or in an in situ and a blood perfused isolated heart 
model, respectively [Liu, Stanley and Downey, 1992].  
 
However the prostanoids prostaglandin I2 (PGI2) and prostaglandin E2 (PGE2) were shown to 
mediate the protective effects of ischaemia-induced late preconditioning in rabbits and mice [Gao et 
al., 2000; Shinmura et al., 2000 and 2002]. In the rat heart it was later confirmed that the 
cardioprotective effects of the late phase of δ-opioid receptor-induced preconditioning appear to be 
linked to the functional coupling between COX-2 and upregulation of PGI2 [Shinmura et al., 2002].  
 
More recently, it was reported that certain arachidonic acid metabolites of the cytochrome P-450 
epoxygenase (CYP) pathway, the epoxyeicosatrienoic acids (11, 12-EET and 14, 15-EET) produced 
similar cardioprotection as IPC and postconditioning (POC) when applied prior to sustained 
ischaemia or at the start of reperfusion, respectively [Nithipatikom et al., 2006]. It was later 
established in dog hearts that endogenous EETs had an essential role in both these cardioprotective 
strategies [Gross et al., 2008].  Interestingly, it was recently shown in a rat model, that the major 
cardioprotective effects of the EETS are dependent on activation of a Gi protein coupled δ- and / or 
κ-opioid receptor [Gross et al., 2010]. 
 
There are other neurohormonal agonists which can precondition the heart when administered 
exogenously which may not be released in sufficient quantities by the ischaemic myocardium to 
trigger protection endogenously, such as norepinephrine, endothelin and angiotensin. Therefore, 
administration of antagonists to α-adrenergic receptors [Moolman et al., 1996; Bugge and Ytrehus, 
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1995], angiotensin [Tanno et al., 2000; Liu et al., 1995], or endothelin [Wang et al., 1996] has no 
effect on the process of IPC. 
 
1.2   Receptor independent triggers  
Reports regarding the participation of NO in the signaling of classic (early) preconditioning have 
been quite controversial. Wolfson and coworkers (1995) were the first to test for the involvement of 
NO in IPC. Isolated rabbit hearts were treated with L-NAME, a NOS inhibitor, which had no effect 
on cardioprotection. However, they noted that L-NAME reduced infarct size of non-preconditioned 
hearts. On the other hand, using NO donors, NO was shown to be an important trigger of 
cardioprotection in the isolated rat heart [Lochner et al., 2000]. Loss of protection was also observed 
in a pacing model of preconditioning when NOS inhibitors were administered [Ferdinandy et al., 
1997]. Furthermore, a study by Qin et al., (2004) illustrated that exogenous NO triggers the 
preconditioning effect in the isolated rabbit heart. Conversely, it was shown that exogenous NO 
could not trigger the preconditioning state [Cohen, Yang and Downey, 2006]. In addition, Nakano 
and co-workers (2000) could not demonstrate a role for endogenous NO in the cardioprotection of 
classic preconditioning [Nakano et al., 2000). Despite these initial controversies, it is generally 
accepted that endogenous NO plays an important role in the downstream signaling during the 
triggering phase of IPC [for review see Downey et al., 2008].  
 
However, NO is very important role player in SWOP and the first indication that NO triggered this 
process was provided by a study in which a nonselective blocker of NOS (L-NA) blocked the 
development of delayed protection against myocardial stunning [Bolli et al., 1997]. Also, pre-
treatment with NO donors in the absence of ischaemia induced a delayed protective effect against 
both myocardial stunning and infarction that was indistinguishable from that observed during the 
late phase of ischaemic preconditioning [Takano et al., 1998; Bolli, 2001]. 
 
Redox signaling in preconditioning is still not completely understood, but it is widely accepted that 
transient, low concentrations of ROS (Reactive Oxygen Species: O2- and H2O2) and / or RNS 
(Reactive Nitrogen Species: NO . , HNO and ONOO-) may trigger protective mechanisms. Some of 
these may be included among the triggers of preconditioning and it is likely that they collaborate in 
inducing cardioprotection [for review see Penna et al., 2009; Baines et al., 1997; Cleveland et al., 
1997; Vanden Hoek et al., 1998; Das et al., 1999].  
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The role of calcium in preconditioning is unclear. Calcium L-type channel blockade prevents IPC in 
the human myocardium [Cain et al., 2000], whereas no attenuation of ischaemic preconditioning 
could be illustrated in the anesthetized pig model using calcium antagonists [Wallbridge et al., 
1996].  
  
1.3   The signaling pathway of IPC (Fig. 1.1) 
 
It is generally accepted that simultaneous activation of the adenosine, bradykinin and opioid 
receptors as well as the release of oxygen free radicals during the brief ischaemia / reperfusion 
episodes, all contribute to the triggering of IPC. It was hypothesized that this scheme would require 
the convergence of all stimuli on a common distal pathway, which appears to be protein kinase C 
(PKC), since inhibition of PKC effectively inhibit the cardioprotection associated with adenosine 
[Sakamoto et al., 1995], bradykinin [Goto et al., 1995], opioid receptor [Miki et al., 1998] as well as 
oxygen free radicals [Baines et al., 1997]. In addition, studies in the rabbit [Ytrehus et al 1994] and 
in the rat [Mitchell et al., 1995] concluded that PKC activation is central to the protection by IPC.  
 
Adenosine, bradykinin and opioids act via Gi-proteins to activate very divergent pathways despite 
the fact that their signaling converges on a single target. Adenosine receptors are thought to activate 
PKC via the phospholipases synthesizing diacylglycerol from membrane phospholipid [Cohen, 
Yang and Liu et al., 2001]. Opioid receptors are proposed to depend on metalloproteinase-mediated 
transactivation of the epidermal growth factor receptor (EGFR) which activates PI3-K [Cohen, 
Philipp and Krieg, 2007]. The receptor tyrosine kinase auto-phosphorylates its tyrosine residues 
when bound to its triggering growth factor. Bradykinin also triggers through PI3-K activation but is 
independent of EGFR [Cohen et al., 2007]. The steps downstream of PI3-K for both opioids and 
bradykinin appear to be similar. PI3-K causes phosphorylation of Akt through the phospholipid-
dependent kinases. Phosphorylated Akt subsequently activates eNOS to produce NO, which then 
stimulates guanylyl cyclase to produce cGMP which in turn stimulates PKG [Cohen, Yang and Liu 
et al., 2001; Oldenburg et al., 2004]. 
 
Ligands to several other Gi-coupled receptors in the heart were also found to have the ability to 
mimic preconditioning through PKC activation including catecholamines [Banerjee et al., 1993], 
angiotensin II [Liu et al., 1995] and endothelin [Wang et al., 1996]. However, inhibition of the 
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receptors for any of these additional ligands does not raise the threshold for IPC, indicating that 
these substances are not released by ischaemia in large enough quantities to participate in IPC. 
 
Reactive oxygen species, previously categorized as a receptor independent trigger, can 
simulate the protection of IPC by transient exposure of the heart to an oxygen radical generating 
system [for review see Yang, Cohen and Downey 2010], and conversely a ROS scavenger can 
abolish the cardioprotection of IPC [Baines, Goto and Downey, 1997; Tritto, D’Andrea and Eramo, 
1997]. The cardioprotection from ROS could be blocked by a PKC inhibitor indicating that the ROS 
signal occurred upstream of PKC [Kuno et al., 2008]. 
 
The source of ROS appears to be the mitochondria where the mitoKATP channels play an essential 
role. It is proposed that activation of PKG opens the mitoKATP channels on the inner mitochondrial 
membrane permitting K+ to enter the matrix along its electrochemical gradient [Costa et al., 2005]. 
However, the mitoKATP channels are localized on the inner mitochondrial membrane which is not 
accessible to cytosolic PKG and the connection between PKG and PKC-ε [Costa et al., 2005] 
dependent opening of the mitoKATP channel is not known [for review see Yang, Cohen and Downey, 
2010]. Opening of the channels and the resulting K+ influx is balanced by electrogenic H+ efflux 
driven by the respiratory chain which consequently results in increased amounts of ROS generation 
[Costa and Garlid, 2008]. Generation of free radicals leads to activation of PKC. According to 
Downey and co-workers (2010) PKC activation signifies the end of the trigger phase and kinase 
activity is the first step in the mediatory phase. Interestingly, although the adenosine receptors 
activate PI3-K, they can also directly couple to PKC and thus circumvent the mitochondrial pathway 
and the mitoKATP channel. 
 
However, it is still controversial which PKC isozyme mediates this protection but it seems that both 
PKC-ε and PKC-δ are involved [for review see Yang 2010; Dorn et al., 1999; Ping et al., 2001]. 
Also, peptide inhibitors of PKC-ε abolished ischaemic / hypoxic or pharmacological preconditioning 
in mice, rats, rabbits and pigs [Dorn et al., 1999; Gray et al., 1997; Inagaki K et al., 2005].  
 
Another unresolved issue is the target of PKC. Because protection from a PKC activator could be 
aborted by adenosine A2B receptor blocker [Philipp et al., 2006], and since PKC inhibition does not 
affect A2B receptor mediated protection [Kuno et al., 2007], it is believed that the adenosine A2B 
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receptor resides downstream of PKC and that PKC sensitizes the adenosine A2B receptor to the 
heart’s endogenous adenosine. Consequently, the adenosine A2B receptor was shown to an essential 
element in the cardioprotection of IPC [Solenkova et al., 2006], as well as in postconditioning 
[Philipp et al., 2006]. It should not be surprising that an important kinase like PKC has many targets 
and it is known that PKC can directly or indirectly modulate components, associated with 
mitochondrial membranes such as the mitoKATP channel, mPTP, BAX / BAD and Bcl-2 [Costa et 
al., 2005 and 2006; Murphy, 2004] which are important molecules in the determination of cell 
survival or death.   
 
1.3.1   IPC exerts its protection at reperfusion 
 
It was proposed that IPC protects the heart by inducing activation of PI3-K /Akt and MEK1/2 / ERK 
1/2 cascades at reperfusion [Hausenloy et al., 2005], the so-called “Reperfusion Injury Salvage 
Kinases” or RISK pathway. Pharmacological inhibition of either these cascades early in reperfusion 
abolishes IPC-induced cardioprotection. It was then concluded that IPC actually exerts its protection 
early in reperfusion following lethal ischaemia. This provided enormous hope for the clinical 
translation of IPC, especially when blood supply to the affected area is restored after clinical 
procedures. Indeed, in the past several years it was found that many pharmacological agents can 
protect the myocardium when given at the time of reperfusion, e.g. insulin [Baines et al., 1999], the 
adenosine A1 / A2 agonist Bay 60-6583 [Xu et al., 2000], transforming growth factor-β1 [Baxter et 
al., 2001], urocortin [Schulman, Latchman and Yellon, 2002], the adenosine agonist 5’-(N-
ethylcarboxyamido) adenosine (NECA) [Yang et al., 2004], bradykinin [Yang et al., 2004], 
erythropoietin [Cai and Semenza, 2004], natriuretic peptide [Yang et al., 2006], cyclosporine A 
[Hausenloy, Ong and Yellon, 2009]. Like IPC, all of these reagents except cyclosporine A depend 
on the activation of PI3-K /Akt and MEK1/2 / ERK 1/2 cascades for protection to occur. 
 
1.3.2   GSK-3β and the mPTP 
 
As described above the end effector of IPC may be PKC-ε 2 which acts to inhibit the opening of of 
the mitochondrial permeability transition pore (mPTP) and it is currently thought to be a major role 
player in determining cell death or survival [Hunter et al. (1976)], despite the fact that its molecular 
structure is still unknown.   
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The immunosuppressant drug cyclosporine A can inhibit mPTP opening induced by calcium, 
phosphatase and oxidative stress [Crompton, Ellinger and Costi, 1988], providing an important 
pharmacological tool for investigating the function of mPTP in cardioprotection. It was found that 
the mPTP remained closed during ischaemia and open only in the first few minutes of ischaemia, a 
convenient time-point for clinical therapeutic intevention [Griffiths and Halestrap, 1995]. However, 
it is not yet kown how IPC actually inhibits opening of the pore at reperfusion. Although 
phosphorylation and thus inhibition of GSK-3β mimics IPC by reducing infarct size [Tong, 
Imahashi, Steenbergen and  Murphy, 2002; Juhaszova et al., 2004], the role of this kinase in IPC is 
still not clear. It has been shown that the survival kinases PKB/Akt and ERK form tight couplings 
with the mPTP [Juhaszova et al., 2004] to prevent mPTP formation in the reperfused heart model 
[Solenkova et al., 2006]. 
 
In summary, after more than 20 years since the discovery of IPC, and despite the vast amounts of 
knowledge that have evolved from studies of intracellular events, the exact mechanism of this 
endogenous protective phenomenon still remains to be fully elucidated. Most of the studies aimed at 
elucidating the mechanisms of ischaemic preconditioning have used a pharmacological approach. 
This has led to an array of suggested receptors and signaling pathways and an increased focus on 
events during reperfusion. However, it is also believed that meticulous elucidation of events during 
an IPC protocol will yield more insight in the mechanis(s) of cardioprotection. In this regard, it was 
observed that cyclic increases in tissue cAMP characterizes a multi-cycle IPC protocol, suggesting a 
role also for activation of the β-adrenergic signaling pathway. The significance of these changes, 
was underscored by the fact that β-adrenergic receptor blockade abolishes IPC [Lochner et al., 
1999].  
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Fig. 1.1: A cartoon showing the sequence of signaling events involved in triggering the precondi- 
tioned state prior to the ischemic insult (events above the dividing line) and those that 
mediate protection in the first minutes of reperfusion (events below the dividing line). See 
text for details [Tissier, Cohen, and Downey, 2007; Downey, Krieg, Cohen, 2008].  
 
 
1.4   β-adrenergic preconditioning (β-PC) 
 
As referred to in the previous section, cardiovascular disease remains a leading cause of morbidity 
and mortality in the Western world. Thus there is continued interest in developing new drugs and 
interventions that will limit the extent of infarction and prevent cell death and explains the enormous 
effort investigated in elucidating the mechanism of IPC. 
 
 11 
 
It is now well established that three endogenous triggers are released during exposure of the heart to 
short episodes of ischaemia/reperfusion, namely, adenosine, opioids and bradykinin [Downey, 
Davis, Cohen, 2005, 2007]. However, the role of the release of endogenous catecholamines in 
eliciting preconditioning has received surprisingly little attention. Ischaemia-mediated release of 
catecholamines and a concomitant increase in tissue cAMP have been known for many years 
[Schömig et al, 1984].  Even though the α1-adrenergic receptor was advocated to play a role in this 
regard, our laboratory could not find evidence for this receptor or PKC activation in the mechanism 
of IPC [Moolman et al., 1996]. In retrospect, this could be due to the perfusion model (working 
heart), and endpoint (functional recovery) used in these early studies. 
 
The approach employed in our laboratory was that thorough investigation of events during an IPC 
protocol should serve as a guide for further studies.  Thus the observation that the cyclic nucleotide 
cAMP increased in a cyclic fashion at the end of each preconditioning episode suggested a role for 
the β-AR signal transduction system [Lochner et al., 1998, 2000) as trigger in the preconditioning 
process.  Should this be the case, then pharmacological activation of this pathway should be able to 
elicit protection against ischaemia.  This was first demonstrated by Asimakis et al. (1994) who 
reported that pharmacological preconditioning with isoproterenol protected against ischaemia.  It 
was subsequently reported that transient β-AR stimulation with ligands such as isoproterenol and 
dobutamine mimicked IPC and elicited protection against a subsequent period of ischaemia-the so-
called phenomenon of β-preconditioning (β-PC) [Lochner et al., 1999; Miyawaki and Ashraf, 1997;  
Nasa, Yabe, Takeo, 1997). 
 
The role of β1-AR activation as trigger in β-PC was indicated by the use of blockers: (i) propanolol 
(a non-selective β-blocker) and atenolol (a more selective β1-blocker) abolished isoproterenol-
induced protection, while the selective β2-blocker ICI-118551 was without effect [Francis et al., 
2003]; (ii) the specific β1-adrenergic agonist xamoterol could elicit protection against ischaemia, 
which could be attenuated atenolol and PKA inhibition [Robinet, Hoizy and Millart, 2005];  (iii) 
hypoxic preconditioning was attenuated by a β1-selective blocker metoprolol [Mallet et al., 2006]; 
(iv) desflurane and sevoflurane preconditioning was shown to be dependent on β1-AR activation, 
since it could be blocked by esmolol and H89, a β1-AR blocker and PKA inhibitor respectively 
[Lange et al., 2006]. These findings suggest that ischaemic and anaesthetic preconditioning share a 
common pathway, namely the β1-AR signal transduction pathway. 
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The fact that activation of most membrane receptors coupled to the Gi protein are able to elicit 
cardioprotection, suggests that the β2-AR may also be a strong  candidate for triggering β-PC.  
Indeed, Tong and coworkers (2005) found that preconditioning could not be triggered by 
isoproterenol in transgenic β2-AR knockout mice.  Furthermore, it was found that the Gi inhibitor 
pertussis toxin blocked isoproterenol-induced improvement in postischaemic function and reduction 
in infarct size [Tong et al., 2005].  As far as we know, no information is available regarding a role 
for the β3-AR in β-AR preconditioning and this possibility should still be investigated 
 
1.4.1  Downstream events 
 
As stated above, elevation in tissue cAMP levels during a preconditioning protocol by ischaemia or 
isoproterenol, appear to be pivotal in eliciting cardioprotection.  However, the significance of 
downstream events such as PKA and p38MAPK activation has not yet been established without a 
doubt.  Using isolated perfused hearts, 55% and 87% increases in PKA activation after ischaemia 
(1x10 min) or β-AR preconditioning with forskolin (0.3x10-6 M; 1x5 min), respectively, have been 
observed (Makaula et al., 2006). Cyclic elevations in PKA during a preconditioning protocol were 
also observed by others [Lan, Wang and Zhang, 2005; Inserte et al., 2004]. 
 
As in the case of cAMP, activation of PKA during ischaemia is potentially harmful, for example, 
causing phosphorylation and activation of the L-type Ca2+ channels, thereby promoting the harmful 
effects of Ca2+ into the cardiomyocyte [Tsien et al., 1983; Buneman et al., 1999] and 
hyperphosphorylation of the ryanodine receptor to liberate excess amounts of Ca2+, as may occur in 
heart failure [Marks, 2003]. The harmful effects of cAMP accumulation during ischaemia may 
therefore be due to, at least in part, to activation of PKA. However, activation of PKA has also been 
linked to cardioprotection. Brief exposure to β-agonists [Sanada et al., 2004; Lochner et al., 1999] or 
an adenylyl cylase activator [Lochner et al., 1999; Makaula et al., 2005] or phosphodiesterase type 
III inhibitors [Sanada et al., 2001; Nomura et al., 2003], all which cause rapid activation of PKA, 
protect the heart against subsequent ischaemia, independently from PKC. 
 
The necessity of PKA activation for successful preconditioning is demonstrated by the fact that 
PKA inhibitors such as H89 [Sanada et al., 2004; Inserte et al., 2004] and Rp-cAMPs [Sanada et al., 
2004] blunted ischaemic and dibutyryl-cAMP-induced preconditioning. 
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The putative role of PKA activation after β1-AR stimulation with xamoterol was further conformed 
by the finding that both atenolol and H89 completely abolished protection [Robinet, Hoizy and 
Millart, 2005]. These workers also showed that, besides PKA, transduction mechanisms following 
β1-AR stimulation, also involved PI3-K and PKC, with PKA activation occurring prior to PKC. 
 
It should be kept in mind that PKA-independent cAMP pathways may be activated by the 
preconditioning trigger to promote contractile recovery and to decrease infarct size following  
ischaemia / reperfusion. Many of the cAMP functions previously attributed to PKA, may be 
dependent on the cAMP receptor protein, the guanine nucleotide exchange factor Epac  [Kawasaki 
et al.,1998; Mei et al., 2002]. In HEK cells activation of Epac leads to a prosurvival response via 
phosphatidylinositol-3-kinase dependent kinase PKB (Akt) activation while stimulation of PKA 
inhibits Akt [Mei et al., 2002]. Recent studies from our laboratory showed that Epac is rapidly 
activated by ischaemia as well as by β-AR preconditioning and is enhanced by simultaneous PKA 
inhibition. The latter confirms the evidence of an alternative β-AR signaling pathway in the 
myocardium [Marais and Lochner, unpublished observations]. 
 
 
1.4.2   p38MAPK and HSP27 
 
Each subfamily of the MAPK family, ERK, JNK and p38MAPK, has been suggested to play a role 
in cardioprotection elicited by prior IPC [Schulz et al., 2002]. In our laboratory the involvement of 
p38MAPK activation was demonstrated in the triggering phase of β-PC, but not IPC, in the isolated 
rat heart model, using functional recovery as endpoint [Marais et al., 2001].  Downstream of 
p38MAPK, activation of the 27kDa small-heat shock protein (HSP27) may protect against 
ischaemic stress [Martin et al., 1997].  Interestingly, the marked but transient activation of 
p38MAPK during a multi-cycle IPC protocol was associated with sustained activation of HSP27 
[Marais et al., 2005]. As in the case of HSP27, CREB was activated by exposure of the heart to 5 
min of ischaemia, followed by reperfusion, and it remained activated throughout a multi-cycle IPC 
protocol [Marais et al., 2008]. CREB activation by events downstream of receptor activation 
included activation of PKA, PKC, ERK, MSK-1 as well as p38MAPK and these observations 
indicate that CREB may be a convergence point for several signaling pathways during the triggering 
process of preconditioning [Marais et al., 2008]. 
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1.4.3   Possible mechanisms of β−PC: a decrease of cAMP during sustained ischaemia 
 
The role of cAMP accumulation during a long period of ischaemia in mediating necrosis and 
arrhythmias is well recognized [Marks, 2003].  Previous studies have shown that accumulation of 
intracellular cAMP levels during sustained ischaemia was less in ischaemic preconditioned hearts 
than in controls, both in rats [Moolman et al.,1996] and rabbits [Sandhu et al. 1996,1997], and 
interventions such as β-AR blockade and depletion of endogenous catecholamines by prior reserpine 
treatment mimicked the effects of preconditioning, causing less cAMP accumulation during 
ischaemia and resulting in functional protection [Moolman et al., 1996]. These observations 
suggested a decrease in β-AR signal transduction during sustained ischaemia.   
 
The above observations raised the question as to the mechanism of the decrease in cAMP, and 
whether the decrease in cAMP during sustained ischaemia was responsible for the protective effect 
of preconditioning.  A study of the state of the β-AR signal transduction system in terms of β-
adrenergic receptor density and affinity, forskolin stimulated adenylyl cyclase activity and PKA 
activity immediately  following the preconditioning protocol, i.e. immediately prior to sustained 
ischaemia showed an increase in density and affinity of the β-receptor following an IPC protocol of 
3x5 min ischaemia/ reperfusion (Bmax increased by 39% and Kd decreased by 35%, with a 
significant increase in adenylyl cyclase activity and PKA activity with each cycle of 
preconditioning) (Lochner et al., 1999). The effect of these changes was assessed by investigating 
cAMP generation in response to isoproterenol of hearts preconditioned with a 3x5 min cycle of 
ischaemia/reperfusion.  cAMP increased significantly in non-preconditioned hearts but remained 
unchanged in preconditioned hearts, indicating desensitization. These findings were supported by 
Simonis, Weinberger and Strasser [2003] who found that β-AR density increased with repeated 
cycles, but sensitization of adenylyl cyclase was lost after more than one cycle of 5 min 
ischaemia/reperfusion.  These findings suggest reduced responsiveness of the β-AR signal 
transduction pathway in IPC hearts as the mechanism of reduced cAMP accumulation during 
sustained ischaemia.  However, this seems to differ from rabbits, as Sandhu et al. [1996] found no 
evidence for reduced responsiveness to isoproterenol in preconditioned rabbit hearts, and based on 
results obtained with propranolol concluded that reduced cAMP accumulation in preconditioned 
rabbit hearts was mediated by attenuated norepinephrine release. 
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The question remained how reduced cAMP accumulation during sustained ischaemia related to the 
mechanism of IPC. Administration of forskolin to preconditioned hearts resulted in an increase in 
cAMP during sustained ischaemia, but did not abolish protection in an isolated working rat heart 
model [Moolman et al., 1996].  Sandhu and coworkers [1996] used NKH477 to activate adenylyl 
cyclase and increase cAMP in preconditioned hearts during ischaemia, and likewise found no loss of 
protection as measured with infarct size in rabbits.  These data strongly suggests that the 
preconditioned-induced reduction in cAMP accumulation seen during sustained ischaemia is a 
reflection of protection and not a causal factor. 
 
Previous studies from our laboratory suggested a dual role for p38 MAPK in both ischaemic and β-
adrenergic preconditioning [Marais et al., 2005]: activation of the kinase during the preconditioning 
protocol had a triggering action, while attenuation of its phosphorylation during sustained ischaemia 
may act as mediator of protection. Significant phosphorylation of cytosolic and myofibrillar HSP27 
also occurred during both protocols; this was maintained throughout the sustained ischaemic period. 
It was subsequently hypothesized that attenuation of p38 MAPK activation and elevation of HSP27 
phosphorylation during sustained ischaemia are prerequisites for cardioprotection. However, 
contradictory results regarding the exact role of p38 MAPK have been published (Mocanu et al., 
2000, Steenbergen, 2002) and the matter warrants further investigation. The cardioprotective actions 
of the small heat shock proteins are by now well established (Chi and Karliner, 2004). However, 
how they confer protection is still unclear.  Amongst others, they may act as chaperones 
(Georgopolous and Welch, 1993), stabilize the cytoskeleton (Larsen et al., 1997) or inhibit apoptosis 
(Rane et al., 2003). 
 
 
1.4.4   The role of adenosine in mechanism of beta-adrenergic protection 
 
The mechanism of β-AR has not been fully elucidated, but knowledge about it is evolving.  It is 
conceivable that β-AR activation causes demand ischaemia, resulting in adenosine production and 
the downstream activation of its effectors. Indeed, Thornton et al. (1993) showed that induction of 
preconditioning by tyramine mediated release of endogenous catecholamines in rabbits was blocked 
by the non-selective adenosine blocker PD115,199, thus suggesting a role for adenosine in 
adrenergic mediated preconditioning.  
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Yabe et al. (1998) subsequently showed that β-PC elicited by isoproterenol was abolished by the 
PKC inhibitor polymyxin B.  If this was true, one would expect β-AR to share another characteristic 
of adenosine mediated preconditioning, such as independence from activation of the mitoKATP 
channel. 
 
 
1.4.5   Beta-adrenergic preconditioning and protection against apoptosis 
 
The spectrum of protection against ischaemia elicited by ischaemic preconditioning was initially 
studied in the context of necrosis and dysrhythmias, and later found to include protection against 
apoptosis (Piot et al., 1999).  The mechanism of the anti-apoptotic effect of IPC involve a host of 
factors, such as the generation of reactive oxygen species, an altered Bcl-2/Bax ratio and 
concomitant reduction in cytochrome c release from mitochondria, reduced activation of caspase 
activity and reduced ceramide production during ischaemia (Zhao and Vinten-Johansen, 2002).  
Beta-adrenergic stimulation per se is known to be pro-apoptotic (Patterson et al., 2004), an effect 
attributed to its activation of calmodulin kinase II (Zhu et al., 2001).  In view of the finding that 
isoproterenol could mimic IPC, the question was asked whether a proapoptotic agonist could protect 
against apoptosis. Using PARP cleavage and caspace-3 activation as end-points, it was shown that 
β-PC with one cycle of 10-7 M isoproterenol for 5 minutes resulted in significantly less apoptosis at 
the end of reperfusion than in control hearts, and a reduced infarct size, accompanied by 
significantly less activation of p38 MAPK. To further evaluate the role of p38 MAPK activation, its 
antagonist SB203580 was administered 10 min prior to sustained ischaemia: this caused a 
significant reduction in p38 MAPK activation, which concurred with a marked anti-apoptotic effect 
as well as a reduction in infarct size (Moolman et al., 2006). 
 
On the whole, results previously obtained on our laboratory showed that β-PC reduces both 
apoptosis and necrosis:  these events are associated with attenuated activation of p38 MAPK during 
ischaemia and reperfusion. Whether this is the cause or the result of the cardioprotection still 
remains to be established. 
 
 
1.4.6   Late preconditioning with pharmacological beta-adrenergic preconditioning 
 
Whereas the mechanism of classic preconditioning involved rapid kinase activation, without the 
production of new peptides, it became clear that late preconditioning had a different mechanism.  
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Bolli (2000) elucidated the important role of NO as final common pathway in late preconditioning. 
Interestingly, it was found that very small doses of isoproterenol (4 x 0.0004 mg/kg), administered 
at 4 hourly intervals could elicit late preconditioning after 24 h (Moolman and Lochner, unpublished 
observations). Furthermore, co-administration of the NOS inhibitor L-NA completely abolished the 
effects of β-AR late preconditioning, suggesting a role for NO production in this scenario 
(unpublished observations), as is the case for late preconditioning elicited by ischaemia. 
 
 
1.4.7   Summary and Conclusions 
 
The role of β-adrenergic activation as mediator of ischaemic damage is undisputed. It is however 
becoming clear that activation of the β-adrenergic signal transduction pathway can elicit protective 
responses in the myocardium. Activation of the β-adrenergic signal transduction pathway occurs, 
and participates in the protective effect of ischaemic preconditioning, although ischaemic 
preconditioning is not solely dependent on this particular signal transduction.  Attenuation of this 
pathway during sustained ischaemia is associated with cardioprotection, as reflected by a reduction 
in infarct size, apoptosis and an improvement in functional recovery during reperfusion. 
Pharmacological activation of the β-adrenergic signal transduction pathway per se can elicit both 
classical and late preconditioning.  
 
In view of the above the rest of the literature survey will be devoted to a detailed description of the 
β-AR signaling pathway and the possible role players in β-PC.  
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1.5    β-adrenergic receptor (β-AR) subtypes 
 
Sympathetic stimulation (via circulating catecholamines) of the β-adrenergic receptor (β-AR), a 
prototypical G protein-coupled receptor, regulates a wide range of biological processes from heart 
pacemaker activity, myocardial contractility and relaxation, vascular and bronchial smooth muscle 
tone, to metabolic regulation, such as glucose and lipid metabolism, cell growth, cell survival and 
cell death. Ahlquist (1948) was the first to differentiate the adrenergic receptors pharmacologically 
into α- and β-adrenergic receptors. Using appropriate agonists and antagonists, these early workers 
classified the adrenergic receptors into α1-, α2-, β1-, and β2-adrenergic receptor subtypes [Lands et 
al., 1967; Ablad et al., 1974]. The β3-adrenergic receptor was indentified at a later stage [Tan et al., 
1983; Emorine et al., 1989; Granneman et al., 1991]. 
 
Adrenergic receptors belongs to the superfamily of G protein-coupled receptors which shares the 
common feature of 7-transmembrane spanning domains and are involved in the response to neuro- 
and autocrine transmitters [Dixon et al., 1986; Yarden et al., 1986]. At least three human genes that 
express the β1-, β2- and β3-AR subtypes have been identified using pharmacological and cloning 
methods [Emorine et al., 1989; Byland et al., 1995; Ihl-Vahl et al., 1996]. The existence of a fourth 
β-adrenergic receptor was suggested, based on the effects of nonconventional agonists observed in 
vitro in several species [Kaumann and Molenaar, 1997]. 
 
In the heart, β-AR stimulation by catecholamines (norepinephrine and epinephrine) serves as a 
powerful regulatory mechanism to enhance cardiac performance in response to stress, injury or 
exercise [Lohse et al., 2003; Hata et al., 2004]. Sympathetic adrenergic stimulation increases the 
release of norepinephrine and epinephrine (from the adrenal medulla) to all parts of the heart. 
Contrary to this, the parasympathetic nervous system or cholinergic system acts through the vagal 
nerve to release acetylcholine (Ach) which generally opposes the effects of the sympathetic 
stimulation to keep blood pressure within narrow limits [Opie, 1998]. 
 
The superfamily of G-protein coupled receptors is characterized by an extracellular glycosylated 
amino (N) terminus, an intracellular carboxyl (C) terminus region with serine and threonine residues 
that are potential phosphorylation sites and seven transmembrane domains (TD) linked by three 
extracellular loops and three intracellular loops [Dixon et al., 1986; Yarden et al., 1986].  
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Ligand binding induces a conformational change in the GPCR, which disrupts the ionic interactions 
between the third cytoplasmic loop and the sixth transmembrane segment and allows for coupling 
with the heterotrimeric guanine-nucleotide regulatory proteins (G-proteins) [Wess, 1997; Han et al., 
1998].  
 
The phosphorylation sites of PKA localized on the third intracellular loop of the receptor [Benovic 
et al., 1985], are believed to play a role in agonist promoted uncoupling, subsequent rapid 
desensitization and down regulation of the receptor [Benovic et al., 1985]. The C-terminal serine 
and threonine residues, when phosphorylated by the G-protein receptor kinase / β-adrenergic 
receptor kinase (GRKs / βARKs) also promote desensitization of the receptor [Benovic et al., 1985; 
Lohse et al., 1996].  
 
Although, all three β-AR subtypes are found in variety of tissues they form an integral part of 
membrane proteins present in the heart of different species [Skeberdis et al., 1997; Bylund et al., 
1998].  The β1-AR is equally distributed in all parts of the heart [Brodde, 1991; Myslivecek et al., 
2006]. Stimulation of the cardiac β1-AR leads to an increase in automaticity, conduction velocity 
(chronotropy), excitability and contraction force (inotropy) [Kaumann, 1989; Bristow et al., 1990]. 
In the nonfailing heart, the β1-AR group of receptors mediates the majority of the tensile responses 
to nonselective agonists [Brodde, 1991].  
 
β1-AR and β2-AR functionally coexist in cardiomyocytes of many mammalian species including 
humans, with striking qualitative and quantitative differences in their functions and signaling 
mechanisms [Xiao et al., 1999]. In the human heart the β1-AR is the predominate receptor [Brodde, 
1991]: it expresses β1- and β2-adrenergic receptors at a ratio of about 70-80 % : 30-20 % in the 
ventricle and 60-70 % : 40-30 % in atria, both of which increase cardiac frequency and contractility. 
 
The β3-AR subtype was identified in a variety of tissues.  This receptor subtype is found to a large 
extent in the coronary vascular bed [Strosberg, 1997] and in adipose tissue [Emorine et al., 1989] 
where it mediates thermogenesis in brown (BAT) and lipolysis in white adipose tissue (WAT) 
[Arch, 1989]. This receptor subtype reduces contractile force in human ventricular muscle [Gauthier 
et al., 1996] and stimulates L-type calcium current in human atrial myocytes [Skeberdis et al., 
1999]. 
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β3-AR differs from β1-AR and β2-AR with regard to their molecular structure as well as their 
pharmacological profile [Bylund et al., 1994]. The β1- and β2-ARs show 48.9 % homology in their 
amino acid sequences, whereas β3-AR exhibits 50.7 % and 45.5 % homology in amino acid 
sequences with the other two receptors, respectively [Dixon et al., 1986; Yarden et al., 1986; 
Emorine et al., 1989]. 
 
 
1.6   β-adrenergic receptor signaling 
 
Ligand binding induces a conformational change in the GPCR, which disrupts the ionic interactions 
between the third cytoplasmic loop and sixth transmembrane segment and allows for coupling with 
the heterotrimeric guanine-nucleotide regulatory proteins (G-proteins) [Wess,1997; Han., et al., 
1997] upon which the signals of ligand binding are relayed to the inside of the cell. These G protein-
coupled receptors (GPCRs) activate a small but diverse subset of effectors, including the adenylyl 
cyclases (ACs), phospholipases and various ion channels [Gilman, 1987, 1990; Karoor et al., 1996]. 
 
The G-proteins are composed of Gαβγ heterotrimers [Gilman, 1987; Byland et al., 1998]. In the 
basal state, heterotrimeric G proteins have GDP bound to their catalytic site of GTPase on their Gα 
subunit. After interactions with the receptor, their activation requires association of GTP to the Gαβγ 
in exchange for GDP, leading to the dissociation of the complex into GTP Gα and Gβγ subunits. 
The dissociated Gα and βγ subunits subsequently either positively or negatively regulate a host of 
effector systems which result in changes in intracellular second messenger signaling [Northhup et 
al., Birnbaumer, 1992]. 
 
Hydrolysis of GTP to GDP by the complex results in the reassociation of the Gα and Gβγ subunits 
to commence the next cycle of activation [Helper and Gilman, 1992]. To date, at least 20 Gα, 5 Gβ 
and 11 Gγ subtypes of G proteins have been identified. The Gα subunits differ significantly from 
each other, whereas the Gβ and the Gγ subunits do not vary remarkably among the G proteins. The 
four primary families of Gα proteins [Gαs, Gαi, Gαq and Gα11/12] [Rockman et al., 2002] diverge at 
this point with respect to downstream signaling molecules and subsequent physiological processes. 
Dissociated Gα subunits couple with an effector, an enzyme such as adenylyl cyclase (AC) and 
phospholipase Cβ, or an ion channel [Rockman et al., 2002]. 
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Dissociated Gβγ subunits target a range of signaling pathways involved in desensitization, 
downregulation, apoptosis and ion channel activation (IKach) [Rockman et al., 2002; Lefkowitz, 1988; 
Krapivinsky et al., 1995].   
 
 
1.7   The classical / traditional view of β-AR signaling and distinct β-AR 
         subtype actions in the heart 
 
β-AR subtypes have different affinities for different ligands. [Hoffmann et al., 2004]. The different 
subtypes expressed in the heart are important for normal cardiac function and in heart failure. β-AR 
function is of course dynamically regulated and is a component of normal physiological adaptation 
to maintain homeostasis. 
 
Agonists (catecholamines) initiate β-AR signaling by binding to the receptor and cause it to undergo 
conformational change that results in activation of the classical Gs-adenylyl cyclase (AC)-cAMP-
PKA signaling pathway. This, in turn, phosphorylates target proteins involved in metabolic 
regulation, growth control, muscle contraction and cell survival or death. In the heart, PKA 
phosphorylates a multitude of Ca2+ handling proteins, including sarcolemmal L-type Ca2+ channels 
[Zhao et al., 1994; Gerhardstein et al., 1999], sarcoplasmic reticulum (SR) membrane proteins, 
phospholamban (PLB) [Simmerman and Jones, 1998], ryanodine receptors [Marx et al., 2000], 
troponin I and C protein [Sulakhe and Vo,1995], myosin binding protein-C (MyBP-C) [Kunst et al., 
2000] and protein phosphatase inhibitor-1 [Zhang et al., 2002]. This affects cardiomyocyte 
contractile behaviour by increasing Ca2+ influx into the sarcoplasmic reticulum (phospholamban / 
SERCA), and modulating myofilament Ca2+ sensitivity (troponin 1, MyBP-C) (Fig. 1.2). 
 
Despite many similarities, β1-AR and β2-AR are genetically and pharmacologically distinct entities 
and couple to distinct signal transduction pathways to elicit different cellular responses with regard 
to G protein coupling, cAMP handling, target protein phosphorylation and most important, the 
modulation of cardiac EC coupling. 
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1.8   Coupling of β1-AR to Gs versus the Dual coupling of β2-AR to Gi as  
        well as Gs regulatory proteins 
 
Failure of the β2-AR to produce a proportional contractile response in rodent and canine hearts is 
possibly due to differences in the manner in which these receptors are coupled to G proteins. 
Stimulation of β2-AR but not β1-AR activates Gi proteins in adult rat cardiomyocytes [Zhang et al., 
1995], while both β-AR subtypes are able to stimulate the classic / traditional Gs-AC-cAMP-PKA 
signaling pathway [Xiao et al., 1995] as illustrated in HEK293 cells [Daaka et al., 1997] and in 
human heart [Kilts et al., 2000]. Gi coupling qualitatively and quantitatively modifies the outcome 
of Gs signaling and subsequently exhibit important cardiac protective effects (Fig. 1.2). 
 
In many biological systems, regulatory Gs and Gi proteins engage in cross talk, which is mediated 
through different receptor families, e.g. activation of muscarinic or adenosine receptors, prototypic 
Gi-coupled receptors, markedly antagonizes positive inotropic effects of  β-AR stimulation 
[Landzberg et al., 1994; Newton et al., 1996]. β2-AR couples to both Gs and Gi proteins [Asano et 
al., 1984] and more recent studies, using a photoaffinity labeling technique illustrated such coupling 
of the β2-AR in intact cardiomyocytes, as manifested by the incorporation of a photoreactive 
analogue, 32P GTP-azidoanilide, into α subunits of Gi2 and Gi3 in addition to Gs [Xiao et al., 1999]. 
Thus, β2-AR signaling represents a unique mode of receptor – G protein interaction where a given 
receptor simultaneously activates more that one class of G protein giving rise to functionally 
opposing pathways.  
 
Mechanisms underlying the differential coupling of β-AR subtypes to G proteins are not well 
understood but it has been shown that replacement of the cytoplasmic loop (for the binding of the G 
protein) of the muscarinic receptor with that of β2-AR can induce Gs activation in response to 
muscarinic agonists [Wong, Parker and Ross, 1990]. In addition, it has been shown that the proline 
region in the third intracellular loop determines the different Gs coupling and sequestration of β1-AR 
versus β2-AR [Green and Liggett, 1994].  
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Fig. 1.2:   Subtype-specific signaling pathways of cardiac β-ARs (Lohse, Engelhardt and  
                 Eschenhagen, 2003; Zheng et al., 2005) 
 
 
1.9   β-AR subtypes differentially regulate Ca2+ handling and contractility 
 
Cardiac EC coupling is initiated by a Ca2+ influx through the voltage-dependent sarcolemmal L-type 
Ca2+ channels during an action potential. However, this Ca2+ influx is insufficient to produce 
contraction, but triggers a larger Ca2+ release from the SR via ryanodine receptors through a Ca2+ 
induced Ca2+ release mechanism [Fabiato, 1985]. The resultant intracellular Ca2+ (Cai) transient 
activates contractile proteins, producing contraction; Cai is subsequently removed from the 
cytoplasm by the SR Ca2+ -ATPase (Ca2+pump) and the Na+ -Ca2+ exchanger. 
  
β-AR stimulation modulates most of these important components of the cardiac ECC cascade and 
therefore plays a prominent role in the regulation of cardiac performance. 
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However, there are several prominent physiological differences between β1-AR and β2-AR subtypes. 
In general, signaling cascades from β1-AR and β2-AR indicate important differences in their ability 
to affect downstream events, for example cAMP formation, PKA activation and PLB 
phosphorylation and camodulin kinase II (CAMKII) activation [Steinberg, 1999: Xiao et al., 1999]. 
 
In rat ventricular myocytes, stimulation of both β-AR subtypes increases L-type Ca2+ currents (Ica), 
Cai transients, and contraction amplitude (positive inotropic effect) but only β1-AR stimulation 
markedly accelerates the Cai decay and contractile relaxation (positive lusitropic or relaxant effect) 
[Xiao and Lakatta, 1993]. This trend has also been observed in other mammalian species, e.g. cat 
and sheep [Lemoine and Kaumann, 1991; Borea et al., 1992]. In addition, increased SR Ca2+ uptake 
and decreased myofilament Ca2+ sensitivity contribute to the relaxant effect after stimulation of β1-
AR but not β2-AR. Only β1-AR stimulation increases the resting cytosolic Ca2+ oscillations in 
several mammalian species [Xiao and Lakatta, 1993; Cerbai et al., 1990; Parratt, 1988], indicating 
that β1-AR may be more prone than β2-AR to elicit Ca2+ -dependent arrhythmias.  
 
As stated previously, β1-AR stimulation affects the phosphorylation of sarcolemmal L-type Ca2+ 
channels and the aforementioned regulatory proteins remote from the sarcolemma, thus increasing 
the multitude and kinetics of intracellular Ca2+ transients and conduction [Xiao and Lakatta, 1993; 
Kuschel et al., 1999; Xiao, 2001]. In contrast, a large body of evidence has demonstrated that β2-AR 
stimulation specifically modulates sarcolemmal L-type Ca2+ handling without affecting the above 
intracellular regulatory proteins in cardiomyocytes from mammalian species, including rat and dog 
[Kuschel, et al., 1999; Xiao, 2001].  
 
Although β2-AR stimulation in the human heart is able to increase cAMP formation or PKA-
dependent phosphorylation of intracellular regulatory proteins (PLB,TnI and C protein), for a given 
elevation in cAMP production or PKA activation, the positive inotropic effect of β2-AR stimulation 
is significantly smaller compared to that induced by β1-AR stimulation [Kaumann et al., 1996, 1998, 
1999]. 
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In rat and canine cardiomyocytes, the β2-AR mediated increase in cAMP is dissociated from its 
contractile response [Xiao et al., 1994; Altschuld et al., 1995; Zhou et al., 1997]. Also, in mouse 
cardiomyocytes, β2-AR induced cAMP formation results in a minor positive inotropic effect [Xiao 
et al., 1999]. In rat ventricular myocyte preparations, the dose-response curve of total cAMP 
accumulation induced by β1-AR stimulation with norepinephrine overlaps with that induced by β2-
AR stimulation with zinterol [Xiao et al., 1994]. However, the maximal increase in the particulate 
cAMP induced by the β2-AR agonist, zinterol is about 50 % of that caused by β1-AR stimulation, 
suggesting differential compartmentalization of cAMP depending on β-AR subtype stimulation 
[Xiao et al., 1994]. 
 
In human paced atrial strips, stimulation with zinterol caused a positive inotropic and lusotropic 
effects with EC50 values of 3 and 2 nM, respectively [Kaumann et al., 1996]. The zinterol-evoked 
effects were unaffected by β1-AR selective antagonists, but were significantly blocked by the β2-AR 
selective antagonist ICI 118551 [Kaumann et al., 1996]. Contrary to the belief that zinterol is a 
selective agonist for the β2-AR, recent work investigating the action of this drug at β3-AR level, in 
mouse primary adipocytes and Chinese hamster ovary cells (CHO-K1) expressing human β1-AR and 
β3-AR only, revealed that it significantly increased cAMP levels, an effect which was totally 
abolished in adipocytes from β3-AR knock-out mice.  
 
In CHO-K1 cells expressing human β3-AR, zinterol and L755507 (selective β3-AR agonist) caused a 
robust concentration-dependent increase in cAMP accumulation which was enhanced after 
pretreatment with PTX, indicating that human β3-AR couples to both Gi and Gs regulatory proteins 
[Sato et al., 2006]. Zinterol is therefore one of few beta-adrenergic agonists with high potency and 
efficacy for the human β3-AR [Huchinson et al., 2006]. 
 
 
1.10   Compartmentalized / Localized cAMP signaling during cardiac β2-AR  
          stimulation 
 
Observations thus far demonstrating that the effect of the β1-AR is more widespread while β2-AR 
signaling modulates intracellular Ca2+ but cannot phophorylate regulatory proteins remote from the 
cell surface membrane, suggesting that β2-AR is tightly localized near the subsarcolemmal 
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microdomain, in the vicinity of the L-type Ca2+ channels. More direct evidence supporting localized 
β2-AR signaling has emerged from cell patch-clamp single L-type Ca2+ channel recordings: the L-
type Ca2+ channel responds only to local (agonist in pipette solution) but not to remote (agonist 
added to bathing solution) β2-AR stimulation [Sham et al., 1998]. 
 
These results are in general agreement with the observation that in frog cardiomyocytes, in which 
the β2-AR predominates, β-AR stimulation by isoproterenol applied to one end of the cell has little 
stimulatory effect on remote L-type Ca2+ channels [Jurevicius and Fischmeister, 1996]. These results 
evoked doubts as to whether the β2-AR cardiac response is mediated by a cAMP-dependent 
signaling pathway. However, accumulating evidence indicates that the effect of β2-AR stimulation 
on intracellular Ca2+ is mediated exclusively by a cAMP-dependent mechanism [Kuschel et al., 
1999; Hartzell et al., 1991; Xiao et al., 1999]. To delineate a role of cAMP-dependent PKA 
activation in β-AR subtype signaling, specific inhibitors of PKA, including Rp-cAMP, H-89 and a 
peptide PKA inhibitor (PKI) have been used.  
 
Most studies have demonstrated that PKA inhibitors (for example, Rp-cAMP and H-89) not only 
block the effect of β1-AR stimulation but also completely reverse the effects of β2-AR [Kuschel et 
al., 1999; Zhou et al., 1997; Xiao et al., 1999]. Similarly, in human and frog cardiac myocytes, the 
β2-AR-induced augmentation of intracellular Ca2+ is totally prevented by PKI [Skeberdis et al., 
1997]. Collectively, several lines of evidence support the idea that cAMP-dependent PKA activation 
is mandatory for β2-AR mediated cardiac responses, but in some species this is highly localized to 
the surface membrane.  
 
 
1.11   The involvement of  PKA;  RhoA / Rho-kinase  signaling pathways in 
          Cardioprotection 
 
Protein kinase A (PKA) is a ubiquitous cellular multi-kinase that phosphorylates serine and 
threonine residues in response to adenylyl cyclase (AC)-mediated cAMP [Niswender et al., 1975]. 
The widespread expression of PKA subunit genes, coupled with the many mechanisms by which 
cAMP is regulated within the cell, suggest that PKA signaling is of extreme importance in cellular 
function. 
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In the heart, PKA is a key regulatory enzyme in the catecholamine-mediated control of excitation-
contraction coupling as well as in many other functions including activation of transcription factors 
and control of metabolic enzymes. 
 
PKA consist of two catalytic (C) subunits and a regulatory (R) subunit [Corbin et al., 1988; Taylor, 
Beuchler and Yonemoto, 1990]. When the regulatory subunits are activated by cAMP, the catalytic 
units are released as active haloenzymes [Taylor, Buechler and Yonemoto, 1990]. In general, Cα is 
expressed ubiquitously expressed in all tissues, while Cβ shows  a more restricted pattern of 
expression in the brain [Brandon et al., 1998], liver [Enns et al., 2009b] and hematopoietic cells. In 
addition to having different tissue-specific expression patterns, the Cα and Cβ subunits of PKA are 
believed to have unique functions [Gamm et al., 1996] and are known to phosphorylate different 
downstream targets [Yu et al., 2004]. 
 
It has been shown that the AKAPs (A kinase anchoring proteins), a family of proteins that act as 
molecular scaffolds to anchor PKA in the vicinity of specific substrate molecules [Wong and Scott, 
2004], contribute largely to the specificity of PKA thus directing PKA activity toward relevant 
substrate molecules. Spatial control of cAMP formation may represent another mechanism which 
could contribute to the specificity of PKA [Zaccolo and Pozzan, 2002]. Cardiac myocytes express 
all four types of PKA, PKA-RIα, PKA-RIIα, PKA-RIβ and PKA-RIIβ [Scholten et al., 2007]. These 
isoforms have different subcellular localizations, with PKA-RII being mainly associated with the 
cellular particulate fraction, whereas PKA-RI has been found mainly in the cytosol [Corbin et al., 
1977; Brunton, Hayes and Mayer, 1981]. Even though PKA isoforms have distinct biochemical 
properties and specific subcellular localizations, it is still not established as to how the individual 
PKA isoforms serve to deliver a specific response. 
 
The importance of β-adrenergic receptor stimulation and presumeably PKA in the pathogenesis and 
treatment of heart failure (HF) is well accepted [Lohse et al., 2003]. Excessive β-adrenergic receptor 
stimulation in HF that could lead to adverse effects on myocardial function as has been shown in the 
context of ischaemia / reperfusion [Rona, 1985; Waldenstrom, Hjalmarson and Thornell, 1978]. 
Myocardial ischaemia / reperfusion is characterized by cAMP accumulation and activation of PKA 
[Sakai, Shen and Pappano, 1999], increased phosphorylation and opening of L-type Ca2+ channels 
and consequently the development of cytosolic Ca2+ overload [Shine and Douglas, 1983; Du Toit 
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and Opie, 1992]. The role of PKA in the cardioprotection elicited by IPC, still needs to be evaluated. 
Makaula and coworkers (2005) showed that inhibition of PKA prior to sustained ischaemia, 
enhanced the cardioprotection of IPC, suggesting a harmful role for this kinase in this regard. 
However, activation of the β-adrenergic pathway is essential for cardioprotection, since β-adrenergic 
blockade during a preconditioning protocol abolishes protection [Lochner et al., 1999]. 
 
It was also demonstrated that transient preischaemic activation of PKA reduces infarct size through 
Rho-kinase inhibition during sustained ischaemia, implicating a novel mechanism for 
cardioprotection by IPC independent of PKC [Sanada et al., 2004]. It was demonstrated that 
increased cAMP levels followed by PKA activation cause temporary inhibition of the small GTPase 
RhoA [Dong et al., 1998; Manganello et al., 2003] and its downstream kinase Rho-kinase [Dong et 
al., 1998]. Apart from its protective effects [Sanada et al., 2004], the RhoA / Rho-kinase mediated 
pathway plays an important role in vascular smooth muscle contraction, actin cytoskeleton 
organization, cell adhesion and motility, cytokinesis and gene expression, all of which may be 
involved in the pathogenesis of atherosclerosis [Shimokawa, 2002].  
 
 
1.12   The role of β2-AR/Gi coupling in localized control of β2-AR stimulated 
           cAMP signaling 
 
During acute receptor stimulation, the β2-AR-Gi coupling activates phosphoinositide 3-kinase (PI3-
K), which in turn mediates compartmentalization of the concurrent Gs-cAMP signaling [Kuschel et 
al., 1999; Jo et al., 2002] (Fig.1.2). Inhibition of phoshatidylinositol 3-kinase (PI3-K), enables β2-
AR-activated cAMP/PKA signaling to reach intracellular substrates, as indicated by the marked 
increase in PLB phosphorylation, significant relaxant and greater positive inotropic  effects [Jo et 
al., 2002]. Blocking Gi or Gβγ signaling completely, prevents the potentiating effects of PI3-K 
inhibition, suggesting that the pathway restricting β2-AR-cAMP signaling sequentially involves Gi, 
Gβγ and PI3-K [Jo et al., 2002], despite early studies showing that PTX pre-treatment had no 
significant effect on β2-AR-mediated global cAMP accumulation or PKA activation [Zhou et al., 
1997; Kuschel et al., 1999]. 
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PTX pre-treatment eliminates the role of Gi proteins and permits β2-AR stimulation to induce a 
dose-dependent increase in PLB phosphorylation, associated with significant contractile relaxation 
and positive inotropic effects [Xiao, Ji and Lakatta, 1995; Xiao et al., 1998; Gupta, Neumann and 
Watanabe, 1993], very similar to those induced by β1-AR stimulation which is insensitive to PTX 
pre-treatment [Xiao, Ji and Lakatta, 1995; Kuschel et al., 1999], showing that Gi proteins are not 
involved. 
 
Thus, in addition to its very important role in cell growth and cell survival (Fig.1.1), PI3-K 
constitutes a key downstream event of acute β2-AR-Gi signaling that confines and counteract the 
concurrent β2-AR/Gs-mediated cAMP signaling [Zheng et al., 2004]. These studies indicate that in 
rat cardiomyocytes the β2-AR/Gi coupling underlies the functional compartmentalization of the β2-
AR/Gs – directed cAMP/PKA signaling, which may largely account for the qualitative and 
quantitative differences between β1-AR and β2-AR mediated cardiac responses [Xiao et al., 1999].  
 
 
1.13   Switch from PKA to calmodulin-dependent protein kinase II- 
          dependent signaling during sustained β1-AR activation 
 
As summarized in the preceding sections, stimulation of both β2- and β1-AR mediates increases in 
contractility via the Gs-dependent adenylyl cyclase- cAMP- PKA pathway [Xiao and Lakatta, 
1997]. The β2-AR is also coupled to the pertussis toxin (PTX)-sensitive signaling pathway mediated 
by the Gi regulatory protein which qualitatively and quantitatively modifies the outcome of Gs 
signaling [Xiao et al., 1995; Daaka, Luttrell and Lefkowitz, 1997; Communal et al., 1999]. It was 
thought that the functional consequences of either acute or chronic β1-AR activation might be 
exclusively mediated by the classic Gs- AC- cAMP- PKA signaling pathway. This idea has been 
challenged by more recent studies, which illustrated that persistent β1-AR activation augments 
myocyte contractility and intracellular Ca2+ transients via Ca2+ / Calmodulin-dependent protein 
kinase II (CaMK II) signaling which is independent of the cAMP-PKA pathway in adult rat cardiac 
myocytes (Fig.1.2). 
 
Inhibition of the PKA pathway could not block prolonged β1-AR stimulation-mediated increases in 
myocyte contraction and Ca2+ transients, whereas the inhibition of CaMK II activation, fully 
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abolished the effects of sustained β1-AR stimulation without affecting those targets excited by acute 
β1-AR stimulation [Wang et al., 2004]. In contrast, inhibition of PKA but not CaMK II prevents 
transient β1-AR signaling-mediated positive inotropic and lusitropic effects [Wang et al., 2004]. In 
addition, progressive and consistent CaMK II activation is accompanied by rapid desensitization of 
the cAMP-PKA signaling [Hausdorf et al., 1990] indicating that β1-AR signaling undergoes a time 
dependent switch from the PKA dominant pathway to the CaMK II dominant pathway after receptor 
stimulation [Wang et al., 2004].  
 
Thus, the time dependent β1-AR signaling switch from PKA to the CaMK II dominant pathway may 
be clinically relevant and CaMK II inhibition may be a potential target to prevent adverse cardiac 
remodeling, particularly myocyte hypertrophy and apoptosis in the context of enhanced β1-AR 
signaling, which is characteristic of CHF.  
 
 
1.14   Coupling of the β3-AR to regulatory Gs and / or Gi protein 
 
During the 1980s, the classification of β-adrenergic receptors into two types (β1- and β1-AR) [Lands 
et al., 1967] was challenged. It is now known that 3 different subtypes, β1- , β2- , and β3- may 
participate in the regulation of cardiovascular function. β3-AR differs from the other two subtypes 
by its molecular structure and pharmacological profile. The gene encoding human β3-AR was cloned 
in 1989 [Emorine et al., 1989]. Since then, the gene has been identified in the rat, mice, bovine, 
monkey, dog [for review, see Strosberg, 1997], sheep and goat [Forrest and Hickford, 2000; for 
review, see Moens et al., 2010]. 
 
The β3-AR differs from classical β1- and β2-AR in their regulatory properties. It is known that 
desensitization of β1- and β2-AR responses upon agonist stimulation involves phosphorylation of the 
occupied receptor, uncoupling and internalization [Summers et al., 1997]. Both β1- and β2-AR have 
serine and threonine residues in the intracellular C-terminus tail that act as substrates for G protein-
coupled receptor kinases and for phosphorylation by cAMP-dependent protein kinase (PKA). The 
β3-AR lacks a PKA phosphorylation site and has fewer serine and threonine residues in the C-
terminus tail which may explain the resistance of the β3-AR to short term agonist-promoted 
desensitization [Liggett et al., 1993]. 
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Furthermore, the β3-AR is activated at higher concentrations of catecholamines than the β1- and β2-
adrenergic receptors [Lafontan et al., 1994] and once activated the receptor would deliver a more 
sustained intracellular signal [Granneman, 1995]. Together these data suggest that following 
prolonged activation by the sympathetic nervous system, the β3-AR-mediated response might be 
preserved, whereas the β1- and β2-adrenergic mediated responses are diminished. 
 
β3-ARs are pharmacologically characterized by a set of criteria that include (1) high affinity for 
selective agonists such as BRL 37344 and SR 58611A [Arch and Kaumann, 1993; Emorine et al., 
1994]; (2) partial agonistic activity for several β1- and/or β2-AR antagonists, such as CGP 12177A 
[Liggett, 1992; Blin et al., 1993], bucindolol [Blin et al., 1993] and pindolol [Blin et al., 1993]; (3) 
atypically low affinity for conventional β-AR antagonists such as propranolol and nadolol. β3-ARs 
are blocked by nonselective β-AR antagonists such as bupranolol [Langin et al., 1991] and the 
selective β3-AR antagonist SR 59230A [Kaumann and Molenaar, 1996; Arch, 2002].  
 
Recent studies using the β2-AR agonist, zinterol showed that in primary adipocytes, zinterol was a 
full agonist at increasing cAMP levels and this effect was totally abolished in adipocytes from β3-
AR knock-out mice. It was also shown that human β3-AR couples to both Gs and Gi [Sato et al., 
2007].  
 
In the heart, β-AR pathways are the primary means of increasing cardiac performance response to 
acute or chronic stress. However, depending on the tissue, β3-AR stimulation leads to either opposite 
or comparable functional effects to those produced by stimulation of β1- and β2-ARs, e.g. β3-AR 
activation produces a negative inotropic effect in human ventricles [Gauthier et al., 1998] and they 
are capable of exerting positive inotropic effects in isolated atria [Emorine et al., 1994; Skeberdis 
VA et al., 1999]. However, their actual contribution to cardiac contractile function has yet to be 
defined more accurately. 
 
The β3-AR was shown to possess the same intracellular signaling pathways as β1- and β2-ARs, i.e. 
activation of adenylyl cyclase and cAMP-dependent phosphorylation, e.g. in human atrial myocytes 
the activation of β3-AR leads to the phosphorylation of calcium channels and increase of 
intracellular Ca2+ [Emorine et al., 1989; Skeberdis et al., 1999; 2008], suggesting, that the β3-AR 
may be coupled to the stimulatory Gs protein as well.  
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The linkage of the β3-AR to Gi proteins, may explain why stimulation of this receptor inhibits 
cardiac contraction and relaxation [Gauthier et al., 1998; Cheng et al., 2001; Gauthier et al., 2000; 
Kitamura et al., 2000]. Tavernier et al. (2003), found that cardiac overexpression of human β3-AR in 
mice reproduces negative inotropic effects. Although the exact physiological and pathophysiological 
role of the β3-AR remains uncertain, recent reports propose that in normal heart, β3-AR participate in 
NO-mediated negative feedback control over contractility [Gauthier et al., 1998] (Fig 1.2).   
 
It has been shown that β3-AR in human ventricular muscle stimulated the production of nitric oxide 
(NO) through the activation of eNOS present in ventricular myocytes  as well as endothelial cells 
[Gauthier et al., 1998; Brunner et al., 2001]. NO causes the generation of cGMP and inhibition of 
phosphodiesterase 3 (PDE3) and/or activation of PDE2, which can reduce cAMP induced 
stimulation of contractility (Fig. 1.2). However, β3-AR agonist activation mechanisms in the 
cardiovascular system are complex. The response to β3-AR stimulation differs not only among 
species but also among different anatomical regions within the myocardium [Gauthier et al., 2000]. 
For example, a study in isolated rodent atria, illustrated that both cAMP and NO-cGMP (via nNOS) 
are involved in the β3-AR mediated positive chronotropic effect of agonists [Sterin-Borda et al., 
2006].  
 
It was also demonstrated that modulation of eNOS activity and an increase in NO formation after 
the application of BRL 37344 is specifically coupled to a stimulation of the cardiac β3-AR. On the 
other hand activation of eNOS, either via translocation or via phosphorylation, was absent in β3−/− 
mice after the application of BRL 37344.  
 
β3-AR coupled NO production via nNOS has recently been demonstrated in diabetic and aged rat 
hearts [Maffei et al.,2005; Birenbaum et al., 2008]. These two studies suggest that while β3-AR's 
functional significance may not be apparent in healthy subjects, it has the capability to signal 
through nNOS and can become important in altering contractile response to β-AR stimulation in 
conditions with increased β3-AR expression. 
 
There is very limited information available on β3-AR's association with iNOS. The β1-blocker, 
nebivolol, which is also a β3-AR agonist, induces NO via an iNOS-dependent manner, not eNOS nor 
nNOS [Maffei et al.,2005]. 
 33 
 
In a recent publication, Maffei et al. demonstrated that β3-antagonist SR 59230A inhibits nebivolol-
induced NO in an in vitro Langendorff model, suggesting a possible role for β3-adrenergic receptors 
in regulating iNOS-dependent NO [Maffei et al.,2005]. There is a need for more research pertaining 
to this area of study. 
 
 
1.15   β-AR desensitization and down regulation 
 
The mechanisms involved in receptor desensitization, may be divided into acute (uncoupling) and 
chronic responses (internalization and downregulation). This phenomenon has been almost 
exclusively investigated for the β2-AR. However, the mechanisms can probably be extrapolated to 
other G-protein coupled receptors regulated by phosphorylation [Hoebeke, 1996]. Mechanisms 
contributing to desensitization of β-adrenergic receptors include (i) rapid functional uncoupling of 
the β-AR from the Gsα-protein; (ii) rapid sequestration of receptors away from the cell surface into 
an as yet ill-defined membrane compartment; (iii) a slow reduction of the total cellular receptor 
complement, a process that is called down-regulation. 
 
Desensitization of β-adrenergic receptors is an agonist induced process and is often divided into a 
homologous and heterologous form. Homologous desensitization refers to phenomena which are 
agonist-specific, i.e. changes which affect only the β-AR. Heterologous desensitization, on the other 
hand, is a process whereby activation of one type of receptor causes desensitization of other types as 
well. It has been shown that both PKA-dependent [Harden, 1983; Benovic et al., 1988] and PKA-
independent [Shear et al., 1976; Harden, 1983; Benovic et al., 1988] mechanisms contribute to 
agonist-induced desensitization of β-adrenergic receptors in intact cells. It has been suggested that 
PKA, which phosphorylates many other proteins and not exclusively the β-adrenergic receptors, 
plays a major role in heterologous desensitization, whereas βARK and receptor sequestration are 
more associated with homologous desensitization. 
 
Ligand binding to / stimulation of GPCRs activate G proteins and promotes the dissociation of G 
proteins into Gα and Gβγ subunits, both of which activate target effectors [Clapham and Neer, 1993; 
Xiao, 2001]. Gβγ-dependent targets include activation of certain isoforms of adenylyl cyclase [Tang 
and Gilman, 1991], PI3-K [Naga Prasad et al., 2000] and β-adrenergic receptor kinase (βARK1 or 
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GRK2) [Koch et al., 1993]. Rapid functional uncoupling of receptors occurs after binding of the 
agonist to its specific receptor and subsequent phosphorylation of the receptor on its cytosolic 
domains by protein kinases. This agonist induced process is initiated within seconds to minutes and 
can be triggered by the phosphorylation of receptors either by cAMP-dependent PKA or by β-
adrenergic receptor kinase (βARK1 or GRK2), a specific cytosolic kinase that phosphorylates only 
the active, agonist-occupied form of the G-protein –coupled receptors [Benovic et al., 1986; 
Benovic et al., 1990]. Receptor phosphorylation by βARK promotes the binding of another protein, 
β-arrestin, which prevents the coupling of the Gsα to the adenylyl cyclase, blocking signal 
transduction [Rapacciuolo and Rockman, 1999].  
 
Recent work suggests that homologous desensitization of GPCRs, triggered by βARK1 
phosphorylation and β-arrestin binding, targets receptors to endosomes through an internalization 
process [Kohout et al., 2003] and that PI3-K and phophoinositide products play a critical role this 
process [Gaidarov and Keen, 1999]. There is increasing evidence that in addition to leading to 
receptor desensitization, the βARK1 / β-arrestin complex can lead to the activation of mitogen-
activated protein kinase (MAPK) [McDonald et al., 2000]. 
 
A final step which is directly related to downregulation of β-adrenergic receptors is the cAMP-
dependent destabilization of the receptor mRNA and decreasing synthesis of the receptor molecule 
[Hadcock, Ros and Malbon, 1989].  
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1.16   The involvement of PKB/Akt and the mitogen activated protein kinases  
         (MAPK) in cardiac function and protection 
 
1.16.1   PI3-K - PKB/Akt 
 
Phosphoinositide 3-kinase (PI3-Ks) is a family of enzymes that have the unique capacity to function 
as lipid and protein kinases. Mammalian PI3-Ks have been divided into three classes (I, II and III) 
based on their substrate specificity, mode of action and molecular structure [Oudit et al., 2004]. 
Activated PI3-Ks convert phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-
triphosphate (PIP3), which acts as a second messenger by recruiting various downstream effectors, 
such as phosphoinositide-dependent kinase-1 (PDK1/2) which phosphorylates and activates a 
number of kinases including protein kinase B (PKB/Akt) [Burgering and Coffer, 1995] (Fig. 1.3). 
 
Class I PI3-K can be divided into two subclasses. Class IA PI3-K are heterodimers of a 110-kDa 
catalytic subunit (p110α, p110β, p110δ) and a regulatory subunit of 85 or 55 kDa (p85/p55), 
whereas class IB PI3-K (PI3-Kγ) comprises of a p110γ catalytic subunit and a p101 regulatory  
subunit. Subclasses 1A and 1B are the main isoforms expressed in cardiomyocytes [Naga Prasad et 
al., 2003]. Class 1A PI3-Ks are activated by receptor tyrosine kinase pathways and regulate cardiac 
growth [Vanhaesebroeck et al., 2001; Luo et al., 2005]. Class 1B (PI3-Kγ) is coupled to GPCR and 
has emerged as an important regulator of cardiac contractility [Crackower et al., 2002; Nienaber et 
al., 2003; Patrucco et al., 2004] because of its ability to modulate cAMP metabolism in 
compartmentalized microdomains within ventricular myocytes [Kerfant et al., 2005]. PI3-Kγ has 
also been shown to be a critical regulator for the induction of hypertrophy, fibrosis and cardiac 
dysfunction in response to long term β-AR stimulation in an in vivo mouse model. Thus, PI3-Kγ 
may represent a novel therapeutic target for the treatment of decreased cardiac function in heart 
failure [Oudit et al., 2003]. 
 
Insulin or IGF-1 signaling is mediated in part via tyrosine kinase phosphorylation of the insulin 
receptor substrate -1 (IRS-1) and IRS-2 which activates PI3-K and as previously mentioned, PI3-K 
in turn stimulates the formation of PIP3 as well as activation of PKB/Akt. In addition, PI3-K can 
also be stimulated by the platelet-derived growth factor receptor (PDGFR) [Ishii et al., 1994] and 
epidermal growth factor receptor (EGFR) [Kamohara et al., 1995] (Fig. 1.3).  
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The convergence of GPCRs and RTK signaling pathways in the activation of PI3-K is supported by 
observations that at least three RTKs, those for platelet-derived growth factor receptor (PDGFR) 
[Linseman et al., 1995], epidermal growth factor receptor (EGFR) [Daub et al., 1996] and insulin-
like growth factor (IGF-1) [Rao, 1995], become tyrosine phophorylated after GPCR activation. The 
proximal mediators of GPCRs / RTK transactivation are largely undefined. However, the cytosolic 
non-receptor tyrosine kinase, Src kinase was shown to play a key role in this transactivation process 
[Maulik et al., 1996; Johnson et al., 2000]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3:   The PI3-K / PKB / Akt signaling cascade with respect to other signaling pathways 
to deliver cellular regulation (Hawkins and Stephens, 2007)  
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The serine / threonine kinase Akt (PKB) plays a central role in the regulation of cellular growth, 
survival and metabolism across many species. In mammalian cells there are 3 distinct Akt isoforms 
(Akt1,-2, and -3; also known as PKB α, -β, -γ), which are the products of distinct genes [Bellacosa 
et al., 2004]. Akt isoforms can be activated in response to various growth factors and hormones, 
including insulin, insulin growth factor-1 (IGF-1), VEGF and β-adrenergic receptor stimulation. In 
the cardiovascular system, PKB/Akt plays an important role in the regulation of cardiac 
hypertrophy, angiogenesis and apoptosis [Oudit et al., 2004] and the observation that transient 
activation of PKB/Akt in cardiomyocytes in vivo and in vitro protects against apoptosis after 
ischaemia / reperfusion injury, raised hopes that PKB/Akt activation could be an important 
therapeutic strategy for limiting myocardial injury [Matsui et al., 2001].  
 
Pharmacological evidence suggested that β1-AR and β2-AR may exert different effects on cardiac 
apoptosis [Communal et al., 1999; Zaugg et al., 2000]. This was highlighted in the following study 
in which it was revealed that stimulation of a single class of receptors, β2-AR, elicits concurrent 
apoptotic and survival signals in cardiac myocytes which was shown to be mediated via the Gi- 
Gβγ- PI3-K- PKB/Akt signaling pathway [Zhu et al., 2001]. Also, the importance of β-AR 
transactivation of PI3-K- PKB/Akt in cardioprotection was clearly illustrated when transient β-AR 
stimulation with isoproterenol resulted in increased tyrosine kinase-associated PI3-K activity and 
phosphorylation of PKB/Akt and p70S6K in cardiomyocytes. This was shown to be mediated via β-
AR-mediated transactivation of cardiac PI3-Kα and the sequential involvement of Gαi- Gβγ, Src and 
PDGFR [Yano et al., 2007; Yano et al., 2008]. 
 
Because PKB/Akt is a serine / threonine kinase, which can be activated by β-AR as well as insulin 
receptor stimulation, it was hypothesized and shown that after β-AR stimulation, PKB/Akt 
phosphorylates the β-subunit of IRS-1 [Sandra et al., 1979]. Also, β-AR stimulation has a biphasic 
effect on insulin-stimulated glucose uptake and short-term stimulation induces an additive effect on 
insulin-induced glucose uptake [Morisco et al., 2005; Liu et al., 1997], which was shown to be PI3-
K independent, but occurs via PKA and CaMK.  
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1.16.2   PI3-K- PKB/Akt signaling in cardioprotection 
 
It has been demonstrated in the myocardium that the activation of this pathway by procedures such 
as ischaemic pre- or postconditioning or by the administration of pharmacological agents is crucial 
for the salvage of the ischaemic / reperfused myocardium. It has also been shown that activation of 
the PI3-K/Akt pathway either before the lethal ischaemic insult [Tong et al., 2000; Mocanu et al., 
2002] or at reperfusion following a sustained ischaemic period [Hausenloy et al., 2004] is associated 
with cardioprotection.  
 
As expected, a large number of pharmacological agents, which are known to activate PI3-K/Akt 
signaling pathway, have also been shown to protect against myocardial infarction. In this regard, 
insulin [Jonassen et al., 2001], urocortin [Brar et al., 2001], atorvastatin [Bell and Yellon, 2003a], 
bradykinin [Bell and Yellon, 2003b], erythropoietin [Tramontano et al., 2003] and glucagon-like 
peptide 1 [Bose et al., 2005] have all been shown to reduce infarct size following a lethal ischaemic 
insult. These observations support the hypothesis that pharmacological manipulation and 
upregulation of this pro-survival kinase is essential to protect the myocardium from ischaemia / 
reperfusion-induced cell death [Hausenloy and Yellon, 2004]. 
 
PKB/Akt once activated, may induce its antiapoptotic effects via the phosphorylation of two types 
of substrate: (a) the proapoptotic substrates such as glycogen synthase kinase-3-beta (GSK-3β) 
[Nishihara et al., 2006] or Bad [Jonassen et al., 2001], which, after phosphorylation exhibits an 
increased affinity for the cytosolic 14-3-3 proteins and becomes inactive by binding to them or (b) 
the antiapoptotic substrates such as p70s6 kinase [Jonassen et al., 2001] or eNOS (endothelial nitric 
oxide synthase) [Bell and Yellon, 2003b], which, after phosphorylation become activated and 
stimulate cellular processes essential for an increased survival.  
 
However, it must also be noted that the chronic activation of this pathway may lead to hypertrophy. 
As such there appears to be a fine balance between the potentially beneficial effects of activating 
this signaling pathway acutely and the potentially harmful effects of sustained activation of this 
pathway [Franke et al., 2003]. The principal factor protecting against the long-term activation of the 
PI3-K/Akt pathway in normal cells is PTEN (phosphatase and tensin homolog deleted on 
chromosome ten), a unique dual protein–lipid phosphatase [Leslie and Downes, 2004] which 
dephosphorylates PKB/Akt. 
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1.16.3   Mitogen-activated protein kinases (MAPK) 
 
All eukaryotic cells possess multiple MAPK pathways, which coordinately regulate diverse cellular 
activities, including gene expression, mitosis, differentiation, metabolism, motility, cell survival and 
apopotosis [Roux and Blenis, 2004]. The following distinct groups of MAPK have been 
characterized in mammals: extracellular signal-regulated kinases (ERKs) 1 and 2 (ERK 1/2), c-Jun 
amino-terminal kinases (JNKs) 1, 2 and 3, p38 isoforms α, β, γ and δ , ERKs 3, 4 and 5 [Chen et al., 
1992; Kyriakis and Avruch, 2001]. MAPKs can be activated by a variety of stimuli, but in general, 
ERK1 and 2 are preferentially activated in response to growth factors and phorbol esters, while JNK 
and p38 MAPK are more responsive to stress stimuli ranging from osmotic shock, ionizing radiation 
to cytokine stimulation [Enslen  and Davis, 2001] (Fig. 1.4). 
 
Each family of MAPKs is composed of a set of three conserved sequentially acting kinases: a 
MAPK, a MAPK kinase (MAPKK) and a MAPKK kinase (MAPKKK). The MAPKKKs, which are 
serine / threonine kinases, are often activated through phosphorylation and /or as a result of their 
interaction with a small GTP-binding protein of the Ras/Rho family in response to extracellular 
stimuli [Kolch, 2000]. MAPKKK activation leads to the phosphorylation and activation of a 
MAPKK, which in turn stimulates MAPK activity through dual phosphorylation on threonine and 
tyrosine residues. Once activated, MAPKs phosphorylate target substrates on serine or threonine 
residues followed by proline. Importantly, MAPK cascade specificity is also mediated through 
interaction with scaffolding proteins which organize pathways in a manner that binds several 
components simultaneously.  A wide range of functions of the MAPKs are mediated through 
phosphorylation of several substrates, including phospholipases, transcription factors and 
cytoskeletal proteins. MAPKs also catalyze the phosphorylation and activation of several protein 
kinases, termed MAPK-activated protein kinases (MKs), which represents an additional enzymatic 
amplification step in the MAPK catalytic cascades.  
 
The MK family comprises the ≈90-kDA ribosomal S6 kinases (RSKs), the mitogen- and stress-
activated kinases (MSKs), the MAPK-interacting kinases (MNKs), MAPK-activated protein kinases 
2 and 3 (MK2 and -3, formally termed MAPKAP-K2 and -3) and the MAPK-activated protein 
kinases 5 (MK5, formally termed MAPKAP-K5). The MKs are related kinases that mediate a wide 
range of biological functions in response to mitogens and stress stimuli (Fig. 1.4). 
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Fig. 1.4: Signaling cascades leading to the activation of MAPKs, subtrate kinase and transcription 
factors (Armstrong, 2003; Roux and Blenis, 2004)  
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1.16.3.1   ERK 1/2 or ERK p44/p42 MAPK 
 
The mammalian ERK 1/2 cascade is also known as the classical mitogen kinase cascade and 
consists of the MAPKKKs A-Raf, B-Raf and Raf-1, the MAPKKs MEK1 and MEK2, and the 
MAPKs ERK 1 and  ERK 2 (Fig. 1.4). 
 
ERK 1 and ERK 2 have 83% amino acid homology and are expressed to various extents in all 
tissues [Chen et al., 1992]. They are strongly activated by growth factors, serum and phorbol esters 
and to a lesser extent by ligands of the heterotrimeric GPCRs, cytokines, osmotic stress and 
microtubule disorganization [Lewis et al., 1998]. Typically, cell surface receptors such as tyrosine 
kinases (RTK) and GPCRs transmit activating signals to the Raf/MEK/ERK cascade through 
different isoforms of the small GTP-binding protein Ras [Neufeld et al., 2000; Campbell et al., 
1998]. 
 
Activation of membrane-associated Ras is achieved by the recruitment of SOS (son of sevenless), a 
Ras-activating guanine nucleotide exchange factor, allowing Ras to interact with a wide range of 
downstream effector proteins, including isoforms of the serine/threonine kinase Raf [Geyer and 
Wittinghofer, 1997]. The exact mechanism of Raf activation is still elusive but it is known to require 
Ras binding as well as multiple phosphorylation events at the membrane [Chong et al., 2003]. 
Activated Raf binds to and phosphorylates the dual specificity kinases MEK1 and 2, which in turn 
phosphorylate ERK 1/2 [Hallberg et al., 1994] (Fig. 1.4). 
 
ERK 1/2 are distributed throughout quiescent cells but upon stimulation a significant proportion 
accumulates in the nucleus [Gonzalez et al., 1993; Lenormand et al., 1993]. The mechanisms 
involved in nuclear accumulation of ERK 1/2 are still unclear but nuclear retention, dimerization, 
phosphorylation and release from the cytoplasmic anchors have been shown to play a role 
[Pouyssegur et al., 2003]. Activated ERK1/2 phosphorylate numerous substrates in all cellular 
compartments, including various membrane proteins (CD 12a, Syk and calnexin), nuclear substrates 
(Src-1, Pax6, NF-AT, Elk-1, MEF2, c-Fos, cMyc and STAT3), cytoskeletal proteins (neurofilaments 
and paxillin) and several MKs [Chen et al., 2001]. 
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1.16.3.2   p38  MAPK 
 
The p38 cascade consists of several MAPKKKs, including MEKKs 1 to 4, (MEK1-4), MLK2 and -
3, DLK, ASK1, Tpl2 (Cot) and Tak1, the MAPKKs, MEK3 and MEK6 (MKK3 and MKK6) and the 
four known p38 isoforms (α, β, γ and δ) [for review see Kariakis and Avruch, 2003] (Fig. 1.4). In 
mammalian cells, p38 isoforms are strongly activated by environmental stresses and inflammatory 
cytokines but not significantly by mitogenic stimuli. Most stimuli that activate p38 also activate 
JNK, but only p38 is inhibited by the anti-inflammatory drug SB203580, which has been extremely 
useful in delineating its function [Lee et al., 1994].  
 
MEK3 and MEK6 are activated by a plethora of MAPKKKs which become activated in response to 
various physical and chemical stresses, such as oxidative stress, UV radiation, hypoxia, ischaemia 
and various cytokines, such as interleukin-1 (IL-1), and tumor necrosis factor alpha [Chen et al., 
2001]. MEK3 and MEK6 show a high degree of specificity for p38, since they do not activate ERK 
1/2 or JNK. MEK4 is a known JNK kinase that possess some MAPKK activity toward p38, 
suggesting that MEK4 represents a site of integration for p38 and JNK pathways [Meier et al., 
1996]. While MEK6 activates all p38 isoforms, MEK3 is somewhat selective, since it preferentially 
phosphorylates the p38α and p38β isoforms. This kinase was shown to be present in both the 
nucleus and cytoplasm of quiescent cells but upon stimulation the distribution of p38 is not well 
understood but some evidence suggests that p38 translocates to the nucleus after activation [Ben-
Levy et al., 1995]. Some other data show that p38 is also present in the cytoplasm under these 
conditions [Raingeaud et al., 1995]. p38 activity is critical for normal immune and inflammatory 
responses [Ono and Han, 2000]. 
 
Even though the exact mechanism in p38 in immune responses is only starting to emerge, activated 
p38 has been shown to phosphorylate several targets, including cytosolic  phospholipase A2, the 
microtubule-associated protein Tau, and the transcription factors ATF1 and -2, MEF2A, Sap-1, Elk-
1, NF-κB, Ets-1 and p53 [Kyriakis and Avruch, 2001]. 
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1.16.3.3   JNK  MAPK 
 
JNK1, JNK2 and JNK3 (also known as SAPKα,  SAPKβ, SAPKγ respectively) exist in 10 or more 
different spliced forms and are ubiquitously expressed, although JNK3 is primarily expressed in the 
brain. The JNKs are strongly activated in response to cytokines, UV irradiation, growth factor 
deprivation, DNA-damaging agents and to a lesser extent by some G protein-coupled receptors, 
serum and growth factors [Kyriakis and Avruch, 1990]. Like ERK 1/2 and p38, JNK activation 
requires dual phosphorylation on tyrosine and threonine residues within a conserved Thr-Pro-Tyr 
(TPY) motif. The MAPKKs that catalyze this reaction are known as MEK4 and MEK7, which are 
phosphorylated and activated by several MAPKKKs, including MEKK1-4,  MLK2 and -3, TPL-2, 
DLK, TAO1 and -2, TAK1,  ASK1 and -2 ([Kyriakis and Avruch, 1990] (Fig. 1.4).  
 
 
1.16.3.4   The role of MAPKs in cardioprotection 
 
A cardiac protective role of the ERK cascade in the mechanisms of cell survival is supported by the 
observations that several growth factors such as insulin-like growth factors [Buerke et al., 2001], 
fibroblast growth factors [Htun et al, 1998], cardiotrophin-1 [Gosh S et al., 2000; Kuwahara et al., 
2000] that activate ERKs [Kuwahara et al., 2000], also exert anti-apoptotic effects [Parrizas et al., 
1997; Stephanou et al., 1998] or limit ischaemia / reperfusion injury [Buerke et al., 2001; Vogt A et 
al., 1997; Stephanou et al., 1998]. 
 
Also, a key cardioprotective role for ERK-1 (ERK p42) was documented in opioid-induced 
cardioprotection in rats [Freyer et al., 2001]. This cascade was shown to be activated during 
ischaemia in the in vivo pig [Barancik et al., 1997; Araujo et al., 2001] and rat [Miyakawa et al., 
2001] models, in neonatal rat cardiomyocytes [Yue et al., 2000], as well as in human hearts [Talmor 
et al., 2000]. ERK activation was also observed during ischaemia and reperfusion in human, bovine, 
rat and guinea pig hearts by several [Talmor et al., 2000; Yue et al., 2000; Araujo et al., 2001], but 
not by all investigators [Clerk et al., 1998; Bogoyevitch et al., 1996].  
 
Numerous studies demonstrated the involvement of various MAPK cascades in the cardioprotective 
mechanisms of ischaemic preconditioning (IPC) [Cohen, Baines and Downey, 2000]. 
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In this context the ERK pathway was shown to be involved in IPC-mediated cardioprotection in pig 
myocardium, when inhibition of this pathway during the IPC caused inhibition of the infarct size 
limiting effect of IPC as well as inhibition of the ERK MAPK [Strohm et al., 2000]. Other studies 
also confirmed the cardioprotective role of ERKs in regulation of both the ‘classic’ early [Freyer et 
al., 2002] and late [Ping et al., 1999] phase of IPC-mediated cardioprotection. Essentially ERK 
MAPK forms part of the prosurvival kinases (PKB/Akt and ERK MAPK) also referred to as the 
Reperfusion Injury Salvage Kinases (RISK) pathway [Hausenloy and Yellon, 2004]. 
Pharmacological manipulation and up-regulation of these survival cascades recruited at the time of 
reperfusion in response to IPC, protect the myocardium from lethal reperfusion-induced cell death 
and may provide a novel strategy to salvage viable myocardium and limit infract [Hausenloy and 
Yellon, 2004].   
 
The p38 MAPK pathway belongs to the most investigated, but also the most controversial signaling 
pathway in the study of myocardial responses to ischaemia / reperfusion.  Many studies have shown 
that activation of p38 MAPK during ischaemia increases myocardial damage [Barancik et al., 2000] 
and inhibition this kinase proved to be cardioprotective [Pombo et al., 1994; Ma et al., 1999; 
Mackay and Mochly-Rosen, 1999; Martin et al., 2001]. However, studies of IPC suggest that p38 
MAPK confers myocardial protection [Zechner et al., 1997]. It is established that IPC activates p38 
MAPK in the isolated rat heart [Maulik et al., 1998; Alkhulaifi et al., 1997] and inhibition of this 
kinase with SB203580 during IPC abolished cardioprotection, suggesting that p38-MAPK activation 
contributes to its protective effects. The importance of P38 MAPK activation in IPC was further 
established when it was shown that raised p38 MAPK activity during ischaemia was associated with 
increased cardioprotection, which suggested a crucial role for p38-MAPK in IPC [Mocanu et al., 
2000]. 
 
These controversial results may be due to the fact that four isoforms of the kinase exists. Of the four 
isoforms, p38α MAPK and β are the most prevalent in the heart, and are similar in structure but have 
essential functional differences. Opposing functions of p38α and β isoforms were demonstrated in a 
study using adenoviral-mediated co-expression of p38α- and p38β MAPK in neonatal rat 
cadiomyocytes. In this study p38α MAPK was shown to have pro-apoptotic effects whereas 
overexpression of the β isoform results in hypertrophic effects [Wang et al., 1998], whereas others 
have reported a protective role for p38β MAPK [Saurin et al., 2000; Schulz et al., 2002; Martindale 
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et al., 2005]. In addition, blocking of the α, but not β isoform, led to an increase in cell viability and 
cardioprotection [Saurin et al., 2000]. Also in our laboratory, we demonstrated a down-regulation of 
p38 MAPK during a multi-cycle IPC protocol [Marais et al., 2001] with a subsequent further 
decrease of p38 MAPK activation during sustained ischaemia [Marais et al., 2001]. The evidence 
presented to date definitely supports the concept of differential activation of p38-MAPK isoforms by 
IPC [Saurin et al., 2000]. 
 
In contrast to the p38-MAPK pathway, the SAPK / JNK signaling pathway shows a different pattern 
of activation. Several studies showed that this kinase pathway is moderately or not activated during 
ischaemia, however, a stronger activation of JNKs was found during reperfusion after a brief 
ischaemic stimulus [Barancik et al., 1997; Knight and Buxton, 1996; Bogoyevitch et al., 1996]. The 
precise role of SAPK / JNK in pathophysiology of ischaemic injury remains unresolved. 
 
Recently, it was demonstrated in the in vivo rat model that SAPK/JNK activation is an important 
component of IPC- or opioid receptor-mediated reduction of infarct size [Fryer et al., 2001]. This is 
strengthened by the observation that IPC increased SAPK / JNKs activities [Ping P et al., 1999]. 
Moreover, pharmacological preconditioning with protein synthesis inhibitor anisomycin conferred 
the IPC-like anti-infarct protection in pigs [Barancik et al., 1999], rabbits [Weinbrenner et al., 1997; 
Nakano et al., 2000] and rats [Sato et al., 2000] and was found to be accompanied by an activation 
of SAPK/JNKs only [Barancik et al, 1999], or both SAPK/JNK and p38-MAPK cascades 
[Weinbrenner et al., 1997; Nakano et al., 2000]. Although the JNK pathway, similar to p38-MAPK 
pathway, is generally implicated in apoptotic processes, the effects of its activation could be 
isoenzyme specific and depend on the extent, intensity and timing of JNKs activation [Wang et al., 
1998].  
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1.17   Adenosine (Ado) 
  
Under normal conditions adenosine, an ubiquitous nucleoside, is continuously produced 
intracellularly and extracellularly and maintained at low intracellular levels (100-300 nM) by the 
enzymes adenosine kinase and adenosine deaminase. Adenosine is an intermediate metabolite with a 
short half-life (less than 1,5 seconds) [Honey, Ritchie and Thompson, 1930]. When released by 
metabolically active or stressed cells (oxygen depletion), the extracellular adenosine levels can rise 
up to 10 µM [Zetterstrom et al., 1982; Hagberg et al., 1987]. Adenosine was shown to play a major 
role in the cardiovascular system [Baines et al., 1999], the central nervous system [Fredholm et al., 
1995], the gastrointestinal tract [Linden, 1994; Marquardt, 1998], the immune system [Cronstein, 
1994], cell growth, proliferation and apoptosis [Burnstock, 2002; Abbracchio et al., 1997; Ohana et 
al., 2001] under basal conditions or in emergency situations. It also acts as an endogenous modulator 
of pain [Sawynok, 1998 and 1999]. 
 
In the heart, adenosine has potent electrophysiological effects [Drury and Szent-Gyorgi, 1929; 
Belardinelli, Linden J and Berne, 1989]: the transient, reversible slowing of heart rate (negative 
chronotropic effects), impairment of atrioventricular conduction (negative dromotropism) and 
antiarrhythmic effects of adenosine on mammalian hearts were first reported in 1929 by Drury and 
Szent-Gyorgi. Adenosine-mediated actions in the heart are essentially of two types, those that are 
cAMP independent (direct effects) and others that are cAMP dependent (indirect effects). The 
electrophysiological actions of adenosine was found to be directed at the activation of the inward 
rectifying potassium current, IKACH,Adenosine, referred  to as IKAdenosine, and is thought to underlie the 
direct effects of adenosine that are observed in the sinoatrial node (SA), atrium, and atrioventricular 
node (AV) [Belardinelli and Isenberg, 1983; Belardinelli, Giles and West, 1988]. Adenosine also 
causes a small (12-18%) inhibition of nonstimulated, basal inward current (Ica) in atrial myocytes 
[Cerbai et al., 1988; Visentin et al., 1990]. These events explain and form the basis of the 
antiarrhythmic properties of adenosine and were shown to 1) shorten the action potential in atrial 
cells [Belardinelli, Linden and Berne, 1989] 2) cause sinus slowing and hyperpolarize SA nodal 
cells to the potassium equilibrium potential [Belardinelli, Giles and West, 1988; West and 
Belardinelli, 1985] 3) depress the action potential in AV cells [Clemo and Belardinelli, 1986]. 
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Adenosine has an important role in regulating the myocardial oxygen supply – demand balance. 
This is achieved by increasing oxygen supply through coronary vasodilation and reducing oxygen 
demand by decreasing myocardial contractility, antagonizing the effects of catecholamines, and in 
so doing, depressing conduction within the sinoatrial (SA) and atrioventricular (AV) nodes, atrial 
contractility and ventricular automaticity, respectively [Belardinelli, Linden and Berne, 1989]. 
Adenosine also attenuates the release of norepinephrine from nerve terminals [Belardinelli, Linden 
and Berne, 1989; Pelleg, 1985], inhibits oxygen metabolite generation by activated neutrophils and 
stimulates glycolysis [Belardinelli, Linden and Berne, 1989; Pelleg, 1985]. Potassium conductance 
studies revealed that the cardiac actions of adenosine were remarkably similar to that of 
acetylcholine (ACh) [Belardinelli and Isenberg, 1983]. It appears therefore that ACh and adenosine, 
in addition to their direct effects, function in parallel to oppose the cardiac stimulatory actions of 
sympathetic stimulation.  
 
 
1.17.1   The pathways of normoxic and anoxic mediated intracellular and 
             extracellular adenosine production and transport  
 
Three pathways are involved in the production of adenosine, the first is from the breakdown of 
intracellular ATP to AMP and the subsequent dephosphorylation of AMP to adenosine by a 
cytosolic 5’-nucleotidase [Phillips and Newsholme, 1979] (Fig. 1.5). Adenosine is subsequently 
released from the cell by a nucleoside transporter [Meghii et al., 1985]. A second pathway involves 
an extracellular membrane bound 5’-nucleotidase that produces adenosine from extracellular 
sources of ATP / AMP [Bontemps et al., 1993]. Adenine nucleotides released from platelets and 
endothelial cells are potential sources of adenosine, while extracellular cyclic AMP (cAMP) may 
also be an important source of the nucleoside during β-adrenergic stimulation [Olsson et al., 1973]. 
A third means of adenosine formation is by the transmethylation pathway. This pathway converts 
methionine to cysteine and propionyl CoA. The first enzyme uses methionine as a substrate along 
with ATP. This is followed by the hydrolysis of S-adenosylhomocysteine by S-
adenosylhomocysteine hydrolase to produce adenosine and homocysteine as its end products. The 
relative contribution of each metabolic pathway to the formation of adenosine varies according the 
experimental condition. 
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For example, in normoxia a significant fraction of adenosine is derived from the transmethylation / 
SAH-pathway, whereas during hypoxia the ATP pathway is the main source of adenosine formation 
[Lloyd et al., 1988] (Fig. 1.5). However, during anoxia this enzyme is completely suppressed. 
Therefore, during anoxia the increase in adenosine is mainly due to a decreased recycling of 
adenosine rather than an increase in its formation [Bontemps F et al., 1983]. 
 
The elimination of intracellular adenosine occurs via the action of two enzymes (Fig. 1.5). 
Adenosine can be rephosphorylated into AMP by adenosine kinase, or catabolized by adenosine 
deaminase into inosine [Bontemps et al., 1993]. Inosine can be degraded to hypoxanthine, xanthine 
and uric acid or allontoin which can then be excreted out of the cell. Under normoxic conditions, 
adenosine is completely rephosphorylated to AMP by adenosine kinase and not converted to waste 
products. Inhibition of adenosine deaminase during anoxic stress also appears to be important in the 
accumulation of adenosine under these conditions [Phillis et al., 1988].  
 
Ischaemia increases cytosolic calcium levels [Roy and McCord, 1983], which activates Ca2+ 
dependent proteases and subsequently converts xanthine dehydrogenases to xanthine oxidase [Mc 
Cord, 1984]. On reperfusion, with the readmission of molecular oxygen, the presence of high 
concentrations of hypoxanthine, the other substrate of xanthine oxidase, may result in a burst of 
superoxide formation (O-) and other oxygen derived free radicals (Fig. 1.5).  
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Fig. 1.5: The pathways of normoxic and anoxic mediated intracellular / extracellular adenosine 
production and transport [lerman and Belardinelli, 1991; Buck and Shin 2003; Buck, 
2004] 
 
 
1.17.2   Adenosine receptors
 
 
It is now well established that adenosine acts as an important regulatory molecule through activation 
of cell surface receptors namely A1, A2A, A2B and A3 adenosine receptors (AdoRs), all of which 
belong to the G-protein-coupled superfamily of receptors [Stiles, 1992; Fredholm et al., 2001; Olah 
and Stiles 1995; Auchampach and Bolli, 1999]. Collectively, these receptors are widespread in 
virtually every organ and tissue and represent promising drugs targets for pharmacological 
interventions in many pathophysiological conditions that are associated with changes in adenosine 
levels such as asthma, neurodegenerative disorders, chronic inflammatory diseases and cancers 
[Pierce et al., 2002]. 
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While there is evidence that all of these receptors are expressed in different cell types of the heart 
and vessels, it should be noted that the A1 and A2A adenosine receptors are expressed in ventricular 
myocytes [Marala and Mustafa, 1998; Kilpatrick et al., 2002]. Also, the effects of the adenosine 
receptors on myocardial responses to ischaemia may not necessarily reflect direct myocyte 
responses but also indirect actions of other cell types [Peart and Headrick, 2007]. 
 
Initially, these receptors were pharmacologically categorized based on their effect on adenylate 
cyclase (AC) and on their selectivity for agonists and antagonists [Mubagwa and Flemming, 2001]. 
They have also been differentiated on the basis of amino acid sequences and molecular weights. 
Subtle interspecies differences exist in the primary structure of each receptor subtype [Linden, 1994; 
Ralevic and Burnstock, 1998]. 
 
The A1-AdoRs were shown to be coupled to Gi1,2,3 and Go [Freissmuth et al, 1991; Jockers et al., 
1994] , while the A3 receptors were shown to couple to Gi2,3 and possibly, Gq/11 [Palmer TM et al., 
1995]. The A2A-AdoRs are generally known to be coupled to the Gs protein, but recent reports [Kull 
B et al., 2000] show that these receptors can also be coupled to Go1f, G12/13 [Sexl et al., 1997] or 
G15/16 [Offermanns and Simon, 1995], depending on the tissue type. 
  
The A2A-AdoR, referred to as the low affinity receptor [Beukers et al., 2000] is generally coupled to 
the Gs protein but several other studies implicated signaling via Gq/11, mainly because of this 
receptor’s effects on inositolphosphate production and intracellular calcium, which were sensitive to 
inhibition by phospholipase C (PLC) blockers, but not to pertsussis toxin (PTX) [Yakel et al., 1993; 
Feoktistov et al., 1994].  
 
Adenosine receptor signaling can both enhance and inhibit proliferation of various cell types. The 
outcome of adenosine receptor stimulation with regard to mitogenicity and intracellular signaling 
may depend on the particular subtype present on the cell under investigation, the strength and 
duration of stimulation and many more. Indeed, all adenosine receptors are heterologously 
expressed in different cell types and were shown to interact with MAPK activation at various levels 
[Schulte and Fredholm, 2003].  
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1.17.2.1   A1-AdoR  
 
The A1-AdoRs are the most extensively studied and well characterized adenosine receptor subtype 
in relation to cardiac protection. However, there remain some controversies regarding the signaling 
cascades as well as the A1-AdoR mediated responses in the heart [Peart and Headrick, 2007]. 
Initially, it was thought that adenosine, via this receptor type induces myocardial protection through 
the preservation of ATP (and improved nucleotide repletion on reperfusion), stimulation of 
glycolysis and normalization of the oxygen supply / demand ratio [Ely and Berne, 1992; Mentzer et 
al., 1993].  
 
Subsequent investigations have identified essential protein kinase signaling cascades together with 
putative end-effectors facilitating cardioprotective phenomena such as preconditioning. For the most 
part, the transduction cascades induced by A1-AdoR agonism, follow those of several other GPCR 
systems [Gutkind, 1998; Marinissen and Gutkind, 2001]. 
 
As stated previously in (1.3.2), the A1 and A3 subtypes are coupled to G proteins (Go, Gi) mediating 
inhibition of AC- cAMP and its downstream targets. In the avian heart A1-AdoR stimulation causes 
a concomitant rise in phosphoinositides indicating that these receptors also activate phospholipase C 
[Mubagwa and Flameng, 2001]. Subsequent investigations identified signaling cascades, generally 
linking the A1-AdoR agonism to the PLC, DAG, IP3 cascade and to several kinase systems, 
including PKC, MAPKs, PI3-Kinase and PKB/Akt [Mubagwa and Flemming, 2001; Headrick et al., 
2003; Buck, 2004], which are shown in Fig. 1.6. 
 
The mitoKATP channel and PKC can contribute additively to acute adenosine receptor mediated 
protection [Peart et al., 2003; Peart and Headrick, 2003]. In the ischaemic myocardium PKC 
translocation was shown to be blocked by A1-AdoR antagonism [Borst et al., 1999] and on the other 
hand, PKC inhibitors indicated the involvement of this kinase in A1-AdoR mediated 
cardioprotection [Dana et al., 2000; Peart and Headrick, 2003]. Cardioprotection via this receptor 
subtype was shown to trigger both PKB/Akt and Erk p44/p42 MAPK activation [Germack et al., 
2004] and a p38 MAPK pathway has also been identified in the in vivo porcine myocardium 
[Yoshimura et al., 2004]. 
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These cardioprotective responses / signaling pathways converge on effectors such as the release of 
Ca2+ from the endoplasmic reticulum via an IP3-gated Ca2+ channel, mitochondrial targets such as 
the mitochondrial permeability pore (mPTP) [Pepe, 2000; Hausenloy et al., 2002; Murphy, 2004], 
mediating a reduction in heart rate, contractility and an attenuation of catecholamine stimulation in 
the heart [Huchinson and Scammells, 2004].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.6: The diagram summarizes possible pathways from the A1-AdoR to several kinase systems 
and possible end effectors of cardioprotection [Mubagwa and Flemming, 2001; Headrick 
et al., 2003; Buck, 2004; Pepe 2000; Hausenloy et al., 2002] 
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A1-AdoR-mediated cardioprotection 
 
Cardioprotection due to A1-AdoR agonism has been observed in all species examined [Reichelt et 
al., 2005; Morrison et al., 2006]. It is important to note that ischaemia itself can significantly inhibit 
A1-AdoR gene expression [Ashton et al., 2003] an effect which may impact on postischaemic 
outcomes. Involvement of this receptor subtype in IPC was demonstrated in the mouse A1-AdoR 
knockout model [Shulte et al., 2004]. Controversy still exists regarding the role of the A1-AdoR in 
different protective phenomena, including ischaemic preconditioning (IPC). For example 
Auchampach et al. (2004) indicated that A1-AdoR blockade does not modify protection with 
multiple cycle IPC in canine hearts although they previously demonstrated a role for these receptors 
with a single cycle IPC in dogs [Auchampach and Gross, 1993]. However, DPCPX, a highly 
selective A1-AdoR antagonist failed to abort IPC in the isolated rabbit heart [Liu et al., 1994], which 
suggested the involvement of another adenosine receptor subtype in the cardioprotective effects of 
IPC. 
 
The majority of current evidence suggests that the A1-AdoR mediated reduction in infarct size 
occurs via activation of PKC and possibly p38 MAPKs with subsequent phosphorylation of the 
mitochondrial KATP channel [Baines, Cohen and Downey, 1999; Miura et al., 2000]. However, 
adenosine can also elicit IPC without involvement of the KATP channel [for review see Downey et 
al., 2008] 
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1.17.2.2   A2A-AdoR 
 
Although, all the adenosine receptor subtypes appear to be expressed in cardiomyocytes 
[Auchampach and Boli, 1999], the A2A-AdoRs are known to be most prevalent in the coronary 
vessels. Generally, this receptor subtype is located on smooth muscle and endothelial cells of blood 
vessels mediating vascular effects of adenosine [Li and Fredholm, 1985].  However, A2A-AdoR 
mRNA and a functional coupling of this receptor to cAMP accumulation and positive inotropy have 
been demonstrated in cardiac myocytes [Xu, Stein and Liang, 1996]. 
 
The A2A-AdoRs are coupled to the AC- cAMP- PKA pathway via the stimulatory Gs protein. The 
catalytic subunit of PKA phosphorylates a range of substrates within the myocyte. In the heart, PKA 
functions to modulate contractilty (cardiac-excitation-contraction coupling - ECC) via 
phosphorylation of myocyte proteins including the voltage-gated L-type Ca2+ channel, the cardiac 
ryanodine receptor (RyR2), phospholamban and troponin I [Cannell et al., 1995; Lindemann et al., 
1983; Zhang R et al., 1995]. Signaling pathways leading from the adenosine A2A receptor to the 
positive modulation of ERK p44/p42 MAPK activation [Schulte and Fredholm, 2000; Klinger et al., 
2002] are summarized in Fig. 1.7. The pathway from the A2A-AdoR to ERK p44/p42 MAPK is Ras 
and MEK dependent and was reported to be independent of the Gs- cAMP- PKA -calcium and EGF 
transactivation pathway [Sexl et al., 1995] with coupling of the receptors to the G12/13 protein instead 
of Gs [Sexl et al., 1992].   
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Fig. 1.7: Summary of signaling pathways leading from the A2A-AdoR to the positive or negative 
modulation several kinase systems and possible end effectors of cardioprotection (Mancusi 
et al., 1997; Schulte and Fredholm 2000; Klinger et al., 2002) 
 
 
A2A-AdoRs in cardioprotection 
 
The A2A-AdoRs regulate inflammatory / immune responses in a variety of organs [Cronstein, 1994; 
Vinten-Johansen et al., 1999; Lukashev et al., 2004] and since inflammation is important in early 
and late aspects of tissue damage and remodeling with ischaemia and reperfusion, it seems likely 
that this receptor subtype exerts protective effects in this scenario [Peart and Headrick, 2007]. 
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Mechanisms implicated in A2A-AdoR dependent cardioprotection include inhibition of leukocyte-
dependent inflammatory processes [Visser et al., 2000; Sullivan et al., 2001] and direct inotropic 
actions [Dobson and Fenton, 1997].  
 
An A2A-AdoR-dependent reduction in ischaemia-reperfusion injury has been documented in vivo 
[Jordan et al., 1997; Lasley et al., 2001] which is consistent with evidence that the these receptors 
can limit the injurious effects of neutrophil activation [Zhao et al., 2001]. Furthermore, these 
receptors has also been implicated in the cardioprotective phenomenon of postconditioning [Kin et 
al., 2005], evident in both the presence and absence of blood cells [Zhao et al., 2003; Yang et al., 
2005]. Apart from modification of infarction and inflammation the A2A-AdoRs are also implicated 
in the process of angiogenesis, which may facilitate postischaemic recovery [Montesinos et al., 
2002]. 
 
Enhanced vasodilation during reperfusion induced by A2A-AdoR agonism in an experimental setting 
[Maddock et al., 2001; Peart et al., 2002] may be beneficial as was shown in guinea-pig, pig and 
murine hearts [Belardinelli et al., 1998; Lew and Kao 1999]. The A2A-AdoR was also indicated to be 
a key role player in vascular relaxation of porcine coronary smooth muscle, possibly via the p38 
MAPK pathway [Teng, Ansari and Mustafa, 2005]. Adenosine A2A and A2B receptor agonists was 
shown to enhance cGMP through NO generation in coronary endothelial cells [Olanrewaju and 
Mustafa, 2000]. 
 
A recent study highlights another form of receptor cross-talk [Lasley et al., 2006]. In this study the 
A2A-AdoRs and / or A2B-AdoRs appear to be essential for expression of cardioprotection with 
preischaemic adenosine A1 agonism. A2A-AdoR and / or A2B-AdoR antagonism during reperfusion 
blocks cardioprotection triggered by A1-AdoR agonist pretreatment. However, the basis for this 
cross-talk is still unclear [Lasley et al., 2006].  
 
A2A-AdoR stimulation during reperfusion in isolated rabbit heart has been shown to limit infarct size 
and this cardioprotection was linked to downstream kinase activation such as Erk p44/42 MAPK 
[Kis, Baxter and Yellon, 2003]. As previously mentioned, ERK p44/p42 MAPK forms part of the 
prosurvival kinases (PKB/Akt and ERK MAPK) [Hausenloy and Yellon, 2004] activated at the time 
of reperfusion in response to IPC and which protect the myocardium from lethal reperfusion-
induced cell death as previously described.  
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1.17.2.3   A2B-AdoRs 
 
A2B-AdoRs show a ubiquitous distribution, the highest levels being present in the colon, bladder, 
followed by blood vessels, lung, eye and mast cells [Puffinbarger et al., 1995; Ralevic and 
Burnstock, 1998]. The A2B receptor subtype has been implicated in the modulation of inflammatory 
processes involved in asthma, tumor growth, tissue injury, ischaemia and pain [Holgate, 2005; Abo-
Salem et al, 2004; Strohmeier et al., 1995].  However, controversy also exists regarding the presence 
and function of these receptors in mammalian cardiomyocytes, but functional evidence for their 
presence has been obtained in avian myocytes [Liang and Haltiwanger, 1995]. 
 
Adenosine A2A and A2B receptors were first identified and differentiated by their ability to stimulate 
cAMP production in brain slices at low (0.1-1uM) and high (>10 uM) adenosine concentrations, 
respectively [Schulte and Fredholm, 2003]. A2B-AdoRs were only stimulated at high adenosine 
concentrations and are therefore known as the low affinity adenosine receptor.  
 
A2B-AdoRs are thought to be coupled to AC via the stimulatory Gs protein and to the 
phosphoinositide metabolism via Gq [Yakel et al., 1993; Feoktistov et al., 1994; Feoktistov and 
Biaggioni, 1995; Feoktistov and Biaggioni, 1998]. Coupling of the this receptor type to the Gs 
protein was demonstrated in a study done on guinea pig coronary artery showing adenosine induced 
hyperpolarization. This effect is mediated through stimulation of AC, resulting in increased cAMP, 
activation of PKA, phosphorylation and increased KATP channel conductance [Mutafova-
Yambolieva and Keef, 1997], which in turn modulates contractility. 
 
The possible signaling pathways leading from the A2B-AdoR to activation of MAPKs are 
summarized in the schematic drawing in Fig. 1.8. The results were obtained with different cellular 
systems, such as receptor-transfected CHO cells [Schulte and Fredholm, 2000], HEK293 cells [Gao 
et al., 1999], human retinal endothelial cells [Grant et al., 2001] etc. The A2B-AdoRs are involved in 
proliferation in many cell types and activate all three families of MAPK: ERK p44/p42, p38, and 
JNK [Gao et al., 1999; Schulte and Fredholm, et al 2000; Schmitt and Stork, 2002]. The different 
kinetics of these protein phosphorylations, imply that they may be regulated by different upstream 
events. For example, the A2B-AdoRs in HEK293 cells were shown to activate MAPK ERK p44/p42 
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via PLC- Ras [Feig and Cooper, 1988] -MEK [Gao et al., 1999] signaling and the involvement of 
PKC was excluded because of the lack of effect of PKC inhibitors.  
 
In the human retinal endothelial cells studied, A2B-AdoR stimulation leads to a H89-sensitive 
increase in CREB phosphorylation [Grant et al., 2001]. Another recent study [Schulte and Fredholm, 
et al 2002] indicates that A2B-AdoRs expressed in CHO cells mediate ERK p44/p42 phosphorylation 
in a cAMP – dependent but PKA–independent manner involving signaling via PI3-K. On the other 
hand, both CREB and p38 phosphorylation, which are activated with similar potency as ERK 
p44/p42 phosphorylation, are dependent on cAMP and PKA but independent of PI3-K. This 
indicates that Gs-dependent activation of MAPK can occur via A2B-AdoRs as well [Gao et al., 1999; 
Feoktisov I, Goldstein and Biaggioni, 1999].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.8: The possible signaling pathways leading from A2B-AdoRs to MAPKs activation (Schulte 
and Fredholme, 2000; Gao et al., 1999; Grant 2001)  
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A2B-AdoRs in cardioprotection 
 
The A2B-AdoRs are even less well studied and understood than the A2A-AdoRs in the context of 
myocardial ischaemia-reperfusion. In addition, there is no direct evidence of the presence of A2B-
AdoRs in ventricular myocytes [Marala and Mustafa, 1998; Kilpatrick et al., 2002]. Proposed 
protective effects of this receptor type in ischaemic – reperfused hearts may stem from responses 
mediated by other cell types, e.g. the adenosine A2B subtype is known to activate angiogenic factors 
[Feoktistov et al., 2002] and trigger coronary endothelial growth [Dubey et al., 2002].  
 
Thus, this subtype may play a key role in modulation of vascular growth and tissue remodeling 
[Chen et al., 2004; Dubey et al., 2001] and consequently play a role in the progression of 
postischaemic changes, limiting potential fibrosis and facilitating angiogenic growth. Molecular 
targeting of the A2B-AdoRs impairs neovascularization in noncardiac tissue [Afzal et al., 2003].  
 
In terms of acute cardiac effects, the A2B-AdoRs have been implicated in the infarct limiting effects 
of postconditioning in rabbit myocardium [Philipp et al., 2006] with the protection based on the 
involvement of PKC. An important issue of the A2B-AdoR is its apparent low sensitivity to 
adenosine, which would limit its activation to periods of only excessive adenosine accumulation 
[Peart and Headrick, 2007]. Thus, based on this known sensitivity, significant A2B receptor 
activation will occur at times of excessive adenosine accumulation during and following ischaemia. 
The role of the A2B-AdoR at reperfusion following an IPC protocol was further established when 
blocking of this receptor at reperfusion abolishes IPC [Solenkova et al., 2005]. 
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1.17.2.4   A3-AdoR 
 
The A3-AdoRs are found in high levels in testes [Zhao et al., 1992], kidneys, lungs, heart 
[Carruthers and Fozard, 1993] and vascular smooth muscle cells [Zhao et al., 1997]. This subtype 
has almost uniformly been shown to mediate cardioprotective effects in multiple species and 
models, including man [Jacobson et al., 1998; Linden et al., 2001; Peart and Headrick, 2007; 
Armstrong and Genote, 1994; Auchampach et al., 1997; Tracey et al., 1997]. The role of the A3-
AdoRs in myocardial protection relates to the cellular location of the receptor [Headrick and Peart, 
2005]. On the other hand, prolonged and / or extreme levels of A3 agonism [Jacobson et al., 1998] 
has a paradoxical pro-death effect. 
 
Interestingly, the adenosine A1; A2A and A2B receptors bind to and are antagonized by 
methylxanthines, such as caffeine, theophylline or enprofyllin, whereas the adenosine A3 subtype is 
pharmacological distinct in being insensitive to xanthine based antagonists [Fredholm, 1995; 
Fredholm et al., 2001]. 
 
Although expression of the adenosine A3 subtype appears to be exceedingly low in the murine 
myocardium [Black et al., 2002] it was shown to be present in dog, rabbit and rat cardiac tissues 
[Auchampach et al., 1997; Takano et al., 2001]. Given that the adenosine A3 receptor itself has not 
been unequivocally isolated from cardiac tissues [Dixon et al., 1996], myocardial effects of 
stimulation this receptor may be indirect. The pronounced pharmacological heterogeneity of A3-
AdoR agonist and antagonists across species, complicates the interpretation of experimental findings 
[Muller, 2003]. Cellular location of the A3-AdoR raises another issue: A3 receptor mediated 
signaling in mast cells (non-cardiac cells) may be detrimental to the myocardium via pro-
inflammatory mechanisms [Linden, 1994; Salvatore et al., 2000; Tilley et al., 2000]. However, 
controversy remains regarding protective signaling coupled to A3-AdoR agonism. For this reason, 
the potential mechanisms of action were considered in the context of the varied protective responses, 
including early and delayed preconditioning and vascular protection [for review see Headrick and 
Peart, 2005].  
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Fig. 1.9: Summary of the signaling pathways leading from the A3-AdoR to the positive or negative 
modulation of  PKB/Akt and ERK p44/p42 MAPK activation (Fredholm, 1995; Schulte 
and Fredholm, 2000; Graham et al., 2001; Trincavelli et al., 2002) 
 
 
A3-AdoRs in cardioprotection 
 
Initial investigations of the A3-AdoRs indicated that acute treatment with agonists produced  
cardioprotection characterized by reduced infarct size [Auchampach et al., 1997; Maddock et al., 
2002] and apoptotic cell death [Maddock et al., 2002] associated with enhanced contractile function 
[Maddock et al., 2003; Gardner NM et al., 2004]. Some reports suggested that the A3-AdoRs 
mediated protection occurs post-ischaemia [Jordan et al., 1999; Maddock et al., 2002], while others 
indicate that pre-ischaemic agonism is required for cardioprotection [Thourani et al., 1999; Flood et 
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al., 2003]. However, it was also suggested that the anti-infarct response of A3-AdoR agonism was 
evident with either pre- or post–ischaemic treatment [Auchampach et al., 2003]. 
 
It was illustrated that selective A3-AdoR agonists could trigger a potent protective response in 
isolated cardiomyocytes [Armstrong and Genote, 1994; Lee et al., 2001; Chaudary et al., 2004; 
Germack et al., 2004]. The fact that these receptors could trigger a potent cardioprotective response, 
despite its low levels shows that this receptor must be efficiently coupled to powerful cell signaling 
pathways to generate different protected phenotypes observed after or during continuous or transient 
A3 receptor agonism [Headrick and Peart, 2005]. Liang et al. (1997) indicated in the avian heart that 
the A1-AdoRs and A3-AdoRs utilize different pathways to activate PKC. While both receptor 
subtypes induce an accumulation of diacylglycerol (DAG), this effect is more sustained after 
adenosine A3 receptor stimulation.  
 
Myocardial A3-AdoR overexpression generates a protected state similar to that observed following 
acute treatment with A3-AdoR agonists [Black et al., 2002]. From these studies, it has emerged that 
this receptor subtype enhance ischaemic tolerance and specifically overexpression of this receptor 
type significantly limits ATP depletion during ischaemia [Cross et al., 2002], which is consistent 
with adenosine-dependent enhancement of myocardial energy state [Fralix et al., 1993]. On the 
other hand, it has also been found that high levels of adenosine A3 receptors generate nodal 
dysfunction and brady-cardiomyopathy [Black et al., 2002] but still confers protection even in such 
hearts.  
 
A1-AdoR mediated cardioprotection appears to be dependent upon Gi-dependent phospholipase C 
(PLC) activation, whereas the A3-AdoR mediated protection involves preferentially 
phosphatidylethanolamine which converts phosphatidic acid into DAG [Lee et al., 2001; Parsons et 
al., 2000]. Thus, the A3-AdoR response is attributed to selective RhoA-dependent activation of 
phospholipase D (PLD) [Liang et al., 1997; Lee et al., 2001; Parsons et al., 2000]. However, this has 
only been confirmed in avian cells and the distal end-effectors have yet to be identified. Differential 
coupling may explain the different temporal profiles of the adenosine A1 and A3 receptor mediated 
protection. The A3-AdoR coupled phopholipase D / RhoA pathway mediates a less pronounced but a 
more sustained activation of downstream kinases relative to the A1-AdoR coupled phospholipase C 
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pathway [Lee et al., 2001; Parsons et al., 2000]. A3-AdoR mediated signaling cascades are 
summarized in Fig. 1.9.  
 
The A3-AdoRs can trigger ERK p44/p42 and PKB/Akt activation. However, as with the A1-AdoRs, 
the data supports the requirement of ERK p44/p42 but not PKB/Akt in its protective actions during 
hypoxia-reoxygenation [Germack et al., 2004; Germack and Dickenson, 2005]. The A3-AdoRs is 
also involved in the protection via grape-derived resveratrol [Das et al., 2005]. This response was 
shown to be associated with phosphorylation of PKB/Akt and cAMP response element binding 
protein (CREB). Inhibition of PI3-Kinase or MEK only partially limited CREB activation and 
protection, whereas simultaneous inhibition of these kinases and MEK completely blocked CREB 
activation and protection [Das et al., 2004]. In both adenosine A1 and A3 receptors mediated 
responses, there is evidence of convergence on common mediators / end-effectors such as the 
mitochondrial KATP channel [Tracy et al., 1998; Thourani et al., 1999a]. 
 
A3-AdoR mediated preconditioning differs from ischaemic preconditioning which appears to 
selectively limit necrosis but not stunning [Auchampach et al., 1997; De Jonge et al., 2002]. 
Although both adenosine A1 and A3 receptor activation protect against ischaemic injury, agonists of 
the A3-AdoR may be more promising as cardioprotective agents in the clinical setting due to lack of 
hemodynamic and anti-inflammatory effects, and a more sustained duration of protection than with 
A1-AdoR agonists [Liang and Jocobson, 1998; De Jonge et al., 2002]. The molecular basis for early 
/ acute preconditioning in response to A3-AdoR activation is not well delineated.  
 
However, early or classic preconditioning is thought to involve protein kinases converging on 
putative end-effectors such as the mitochondrial KATP channel, mitochondrial permeability transition 
pore (mPTP), voltage-dependent anion channel (a component of the mPTP), and apoptotic 
regulatory proteins Bcl-2 and Bad [Murphy, 2004; Cohen et al., 2000]. 
  
In addition to early preconditioning effects, the A3-AdoR mediates delayed preconditioning similar 
to the A1-AdoR [Tracey et al 1997; Takano et al., 2001]. It was also indicated that A3-AdoR 
agonism in mice 24 hours prior to ischaemia triggers delayed PKC-dependent protection which is 
reflected in reduced contractile dysfunction and necrosis [Zhao and Kukreja, 2003]. 
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Delayed preconditioning in response to receptor-dependent stimuli is thought to involve kinase-
dependent activation of transcription factors which, in turn, induces a range of protein mediators of 
protection including iNOS, cyclooxygenase-2, aldose reductase, superoxide dismutase and heat 
shock proteins [Bolli, 2000; Stein et al., 2004]. However, as with early preconditioning, pathways 
may vary for different stimuli, e.g. aldose reductase inhibition in early preconditioning generates 
cardioprotection which is thought to be additive to adenosine A3 receptor agonism [Tracey et al., 
2000]. 
 
The A3-AdoRs may also trigger a vasoprotective response. For example, Giannella et al. (1997) 
illustrated that A3 receptor agonists reduced the effects of hypoxic coronary hyperemia in guinea pig 
hearts. The powerful vasoprotective actions of the A3-AdoR was also illustrated in the ischaemic-
reperfused mouse hearts [Flood and Headrick, 2002]. Studies of vascular protection with 
preconditioning and adenosine support the signaling common to myocardial protection such as the 
active role of PKC and the mitoKATP channel [Maczewski and Beresewicz, 1998]. However, the 
exact mechanism(s) of this vasoprotection remains to be elucidated.  
 
 
1.17.2.5  Effect of species related differences and experimental models on the reactivity 
 of AdoRs  
 
The participation of adenosine in the cardioprotection of preconditioning was first demonstrated in 
rabbit hearts by Liu and coworkers in 1991: two chemically different non-selective adenosine 
receptor antagonists, 8-(p-sulfophenyl) theophylline (SPT) and PD115,199, infused shortly before 
the preconditioning cycle, successfully blocked IPC protection.  Conversely adenosine or a selective 
A1 agonist, rPIA, followed by washout prior to sustained ischaemia caused a significant reduction in 
infarct size in these animals. These observations in the rabbit were confirmed by many others (see 
for example Thornton et al 1992). Further studies focused on the involvement of specific adenosine 
receptors and subsequent studies by Liu (1994) and Auchampach and their respective coworkers 
(1997) suggested that both A1 and A3 receptors which couple to the Gi proteins could trigger 
preconditioning in rabbit hearts. 
 
These data in the rabbit heart were confirmed by others in various species using different 
approaches. For example, in dogs both PD115,199, a non-selective adenosine antagonist, and 
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DPCPX, a highly selective A1 receptor antagonist, administered prior to an IPC stimulus, prevented 
any reduction in infarct size (Auchampach et al., 1993). 
 
However in a later study Auchampach et al (2004) failed to abolish preconditioning in dog hearts 
using three different A1 receptor antagonists. As was found in rabbit hearts, these observations 
could implicate involvement of other adenosine receptor subtypes.  Involvement of adenosine in 
preconditioning of pig hearts has been shown by several workers (Schulz et al., 1995; Van Winkle et 
al., 1994). In addition, protection in both human atrial trabeculae and ventricular myocytes can be 
blocked with SPT or mimicked with either adenosine or PIA (Walker et al., 1995).  
 
Initial studies could not demonstrate a role for adenosine in preconditioning of the rat heart because 
adenosine receptor blockade failed to block protection (Liu & Downey, 1992).  Also in our own 
laboratory A1 receptor blockade could not abolish the protection elicited by 1x5 min ischaemia 
(Moolman & Lochner, unpublished data).  The study by Cave et al (1993) cast further doubt on the 
significance of adenosine in the preconditioning of the rat heart since they could not demonstrate a 
role for adenosine in the functional recovery of such hearts.  This observation has been confirmed in 
subsequent studies using more selective A1 antagonists, multiple cycle IPC protocols and by using 
infarct size as endpoint (for reviews see Cohen and Downey, 2008; Ganote & Armstrong, 2000). 
Despite intensive study the inability of adenosine to mimic preconditioning in the rat heart is still 
incompletely explained. A possible explanation may be the fact that adenosine activates 
MAPKAPK2 in the rat heart (Haq et al., 1998) and activation of p38MAPK during 
ischaemia/reperfusion has been shown to be detrimental in rat hearts (Moolman et al., 2006).  It is 
possible however that adenosine may contribute to a limited extent to IPC in rats since a study by 
Headrick (1996) showed that an adenosine antagonist could blunt cardioprotection. Interestingly the 
differences between rat and rabbit hearts with respect to the role of adenosine in preconditioning, 
were also observed in isolated cardiomyocytes: neither a A1 agonist nor adenosine protected rat 
cardiomyocytes in vitro, while in contrast, rabbit cardiomyocytes could be preconditioned by 
adenosine receptor activation (Kin et al., 2005; Kis et al., 2003). However, in a rabbit myocyte 
model, the A1-AdoR selective antagonist, DPCPX was unable to fully suppress the protective effect 
of IPC and had to be associated with an A3-AdoR antagonist (Liu GS et al., 1994) suggesting that 
the A1-AdoR subtype, as well as the A3-AdoRs are involved in IPC mediated cardioprotection. 
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Genetic manipulation of mice has permitted further evaluation of the role of adenosine in 
preconditioning. In A1 knockout mice Lankford and coworkers (2006) observed abrogation of any 
protective effect of IPC whereas Guo et al (2001) could precondition A3 knockout mice.  
However in a carefully conducted subsequent study Eckle and coworkers (2007) studied the ability 
of mice with deletion of either A1, A2A, A2B or A3 receptors to be preconditioned.  In contrast to 
Lankford, they. were able to protect A1, A2A as well as A3 knockout mice. In fact only in A2B 
knockout mice IPC protection was abolished. It is suggested that failure to block protection of 
preconditioning in the A1, A2A, and A3 knockout mice is the result of receptors of multiple 
agonists released during an IPC protocol which mask the effects of knockout of a particular gene. It 
is of course also possible that adenosine does not play a role in preconditioning the mouse heart. 
 
Reasons for differing outcomes with adenosine receptor blockade in varied models of IPC are not 
clear.  Evidence has been presented for substantial species differences in adenosine handling and 
receptor activation (Headrick, 1996), which may determine differing roles for adenosine and 
contribute to the differing abilities of antagonists to limit these responses.  Moreover the affinity and 
selectivity of adenosine receptor ligands vary across species. The differences between species may 
also be attributed to other agonists because of differences in their production during the 
preconditioning protocol. For example in the rat the opioid (or adrenergic?) receptor may be the 
principal one involved in IPC (Schultz et al., 1995) while in pigs bradykinin plays a major role 
(Schulz et al., 1995).   
 
In summary, discordant results of adenosine receptor subtype activation in cardioprotection and 
particularly in the phenomenon of IPC, can largely be attributed to the multiplicity of receptor 
subtypes in a given cell or tissue, species differences and experimental models [for review see 
Mubagwa and Flameng, 2001]. 
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1.18   Reactive oxygen species (ROS) 
 
Biological systems have substantial ability to tolerate ROS under normal conditions. However, in 
the setting of ischaemia and reperfusion, this well-balanced system becomes disturbed. Ischaemia 
reduces the cellular antioxidant defenses and new danger exists as elevated H2O2 becomes 
increasingly capable of generating the destructive hydroxyl radical (.OH) [Hess and Manson, 1984]. 
Hydroxyl radicals are extremely reactive and may cause lipid peroxidation and damage to 
membrane proteins and sulfhydryl bonds [Tappel et al., 1973; Ferrari et al., 1982]. Metal ions, 
particularly iron, may play a role in generating hydroxyl radicals, hence the rationale for metal 
chelation during oxidative stress [Hess and Manson, 1984; Hiraishi et al., 1994]. Additional oxygen-
related free radicals (nitric oxide, peroxinitrite, etc.) can also be produced causing important 
biological destructive or protective effects.     
 
A vast amount of experimental literature supports the concept of oxidative stress mediated  
reperfusion injury which occurs when oxygen is reintroduced  to ischaemic tissue [Hess and 
Manson, 1984; Park and Lucchesi 1999; Kilgore et a1., 1999; Zughaib et al., 1993; Opie, 1991; 
Ambrosio and Tritto, 1999; Weisfeldt et al., 1988]. This type of injury has been reported in the 
heart, kidney, liver, lung and intestine. Most of the data are derived from the indirect measurements 
of ROS and from the observations that free radical scavengers improve some aspects of reperfusion 
injury. For example, DMSO (free radical scavenger) added to the reperfusate of ischaemic rat hearts, 
decreased CPK release, diminished contraction band formation and preserved cellular morphology 
[Ganote, Simms and Safavi, 1982]. Superoxide dismutase and catalase administered during 
reperfusion in an occluded coronary artery canine model produced a reduction in infarct size (Jolly 
et al., 1984). 
 
At the isolated cellular level it was shown that although cell injury occurs during ischaemia, most of 
the loss of cell viability occurs during reperfusion [Bolli et al., 1989; Becker et al., 1999; Vanden 
Hoek et al., 1997; 1998 and 2000]. Consequently, the application of antioxidants at the time of 
reperfusion may significantly improve the cell survival. However, it cannot be ignored that oxygen 
radical scavengers might have other complimentary, pharmacological or haemodynamic effects, 
apart from reducing oxygen toxicity. Furthermore, it is not clear if their positive effects are 
permanent or merely a delay in the development of necrosis [Zweier et al., 1987]. 
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Despite the fact that ROS are produced primarily upon the reintroduction of oxygen following 
ischaemia, ROS generation during ischemia per se was also observed [Hess and Manson, 1984; 
Nohl and Jordan 1986; Becker et al., 1999; Kevin et al., 2003] and studies in cardiomyocytes 
showed the mitochondria to be the major source [Becker et al., 1999]. This concept is of major 
importance because these ischaemia-generated ROS appear to play an important signaling role 
[Carmody and Cotter, 2001] and to trigger the cardioprotective phenomenon of IPC [for review see 
Vanden Hoek et al., 1998]. 
 
 
1.18.1   Free radicals and oxidants also have protective effects 
 
As discussed above, living organisms have not only adapted to protect against ROS, they have 
developed mechanisms for the beneficial use of free radicals [Bai and Cederbaum, 2001; Droge, 
2002].  
 
Much of the insight of this concept stems from the work done in ischaemic preconditioning. The 
significance of free radical generation in cardioprotection was demonstrated by the finding that 
antioxidants abolished the protection of preconditioning [Vanden Hoek et al., 1998, 2000], 
illustrating a definitive role for these radicals in phenomenon. The signaling pathways that connect 
the triggering ROS to the induction of preconditioning protection have also been intensely 
investigated and a central role has been established for the opening of the mitochondrial ATP-
sensitive K+ channel during ischaemia and reperfusion [Tang et sl., 2002]. Following opening of the 
mitochondrial ATP-sensitive K channel, both NO and ROS appear to be generated in isolated 
cardiomyocytes which lead to the cardioprotected state [Garlid et al., 2003]. 
 
In contrast to the role of ROS in triggering the cardioprotection of ischaemic preconditioning, it 
should be kept in mind that direct exposure to ROS may lead to contractile dysfunction [Persad et 
al., 1998; Zeitz et al., 2002], due to a reduction in SERCA activity, Ca2+ uptake and sarcoplasmic 
Ca2+ overload [Xu et al., 1997]. Increased intracellular ROS can also increase sodium calcium 
exchanger (NCX) activity [Goldhaber, 1996] and when this increase is coupled with increased 
cytosolic sodium (Na+), it can lead to an increase in intracellular Ca2+ overloading.  
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1.19    Nitric oxide (NO) 
 
Nitric oxide (NO) is a lipophilic, highly reactive, free radical gas with diverse bio-messenger 
functions. The measured half-life of NO is only 5 seconds in a physiological milieu [Fujimoto et al., 
1998; Liu et al., 1998]. NO reacts with a wide range of substrates at a rapid rate and the most 
preferred chemical targets of NO include reactive oxygen species, other radicals, transition metals, 
thiols and molecular oxygen. The products of these reactions, for example, peroxy-nitrite (ONOO-), 
metal-nitrosyl adducts (M-NO), S-nitroso products and other derived species, contribute to the 
biological activity of arginine-derived NO. Under physiological conditions, peroxy-nitrite is 
sufficiently stable to diffuse some distance before reacting with target molecules such as membrane 
lipids, protein sulfhydryl groups [Gerschman et al., 1954; Chen et al., 2000], DNA [Zhang and 
Snyder, 1995] and cause cellular damage [Neuman et al., 2006]. 
 
Evidence also reveals the involvement of NO in a remarkable array of key physiological processes, 
including regulation of vascular tone [Ignarro et al., 1987; Palmer et al., 1988; Furchgott, 1988], 
platelet aggregation [Azuma et al., 1986], host defense [Hibbs et al., 1987], inflammation [Tiao et 
al., 1994; Harbrecht 1995], neurotransmission [Bredt et al., 1990], cell differentiation [Peunova and 
Enikolopov, 1995; Morbidelli 1996] and apoptosis [Sarih et al., 1993; Mannick et al., 1994]. 
 
 
1.19.1   Nitric oxide synthase (NOS) isoforms and NO synthesis 
 
Mammalian nitric oxide synthases have been characterized and found to comprise three distinct 
isoforms that are 50 – 60% homologous, and distinguished by their histological expression, 
susceptibility to arginine-based inhibitors, intracellular localization, NO output and mode of 
regulation.  These isoforms are products of distinct genes [Marsden et al., 1993; Xu et al., 1994] and 
are functionally categorized by whether their expression is constitutive or inducible.  
 
Type 1 (NOS I / nNOS) was first identified in central and peripheral neuronal tissue, although it is 
also found in other tissue [Papapetropoulos et al., 1999]. It is constitutively expressed, and its 
activation depends on elevated intracellular Ca2+, which promotes binding of calmodulin [Lincoln et 
al., 1997]. 
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Type 2 (NOS 2 / iNOS) is an inducible form of the enzyme, which acts independently of 
intracellular Ca2+ levels [Lincoln et al., 1997; Stuehr et al., 1991]. It still requires calmodulin for its 
activation, but it binds even in the presence of low Ca2+ levels. It is found in vascular smooth muscle 
cells (VSMCs) [Beasley et al., 1991], macrophages [Lincoln et al., 1997], and to a small extent in 
platelets [Mehta et al., 1995] and usually requires cytokines or lipopolysaccharide for its activation 
[Papapetropoulos et al., 1999]. 
 
Type 3 (NOS 3 / eNOS), like NOS 1, is constitutively expressed and its activation is dependent upon 
the binding of calmodulin via increased Ca2+ [Forstermann et al., 1991]. However, NOS 3 can also 
be activated independently of Ca2+ elevation, by phosphorylation of various serine residues by a 
number of protein kinases [Dimmeler et al., 1999; Butt et al., 2000]. This isoform was first 
identified and cloned from vascular endothelial cells (Lamas et al., 1992; Pollock et al., 1991) and is 
also found in cardiac myocytes [Balligand et al., 1993] and platelets [Sase and Michel, 1995].  
 
Cardiac myocytes express all three isoforms of NO synthase. NOS 1 and 3 are constitutively 
expressed and produce low amounts of NO, while NOS 2 is not usually expressed in cardiac 
myocytes but its expression is induced during the inflammatory response, common in heart failure 
patients [Ziolo et al., 2001]. All three NOS isoforms catalyze a five-electron oxidation of one of the 
equivalent guanido nitrogens of L-arginine to yield 1 mol each of nitric oxide and L-citrulline, at the 
expense of 1.5 mols nicotinamide adenine dinucleotide phosphate (NADPH) and 2 mols dioxygen 
[Lane and Gross, 1999]. The reaction involves two successive mono-oxygenation reactions, with 
Nw-hy-droxy-L-arginine produced as an intermediate. All NOS isoforms contain four prosthetic 
groups:  flavin adenine dinucleotide (FAD), flavin adenine mononucleotide (FMN), iron 
protoporphyrin IX (heme) and tetrahydrobiopterin (BH4). The flavins are involved in electron 
storage and delivery, accepting two electrons from NADPH and then delivering single electrons to 
the heme group within the active site. 
 
1.19.2   The involvement of NO in preconditioning-induced cardioprotection 
 
NO has beneficial as well as detrimental actions on the heart. For example, in a study of ischaemia / 
reperfusion damage, it was observed that peroxynitrite (ONOO-) and  the hydroxyl radical (.OH) 
were formed as result of NO interaction with superoxide (.O-2) during early reperfusion and that 
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inhibition of this pathway leads to improved recovery of  myocardial function [Naseem et al., 1995; 
Wang and Zweier, 1996]. It was found that NOS is activated by ischaemia and this activation was 
rapid during the whole ischaemic episode (particularly in the cytosolic fraction) and decreased 
significantly / disappears during reperfusion [Depre et al., 1996]. On the other hand, it was shown 
that if xanthine oxidoreductase (XOR) is presented with inorganic nitrite (NO-2) as an alternative 
substrate, the generation of NO from NO-2 protects the myocardium from ischaemia / reperfusion 
damage [Webb et al., 2004]. In addition, it was illustrated that NO donors decreased myocardial 
necrosis and decreased the reperfusion-induced endothelial dysfunction [Siegfried et al., 1992]. 
 
Pharmacological mimicking with NO donors can bring about the same cardioprotection as elicited 
by IPC. This can be abolished by administration of L-NAME during the IPC protocol [Lochner et 
al., 2000]. It also appears that endogenous NO production during an IPC protocol is sufficient to 
elicit protection [Prendes et al., 2007; Cohen, Yang and Downey, 2006]. Generation of NO also 
occurs in the cAMP / PKA signaling pathway: β2-AR stimulation is associated with increased NOS 
3 serine phosphorylation levels in endothelial cells [Ferro et al., 1999; Yao et al., 2003]. However, a 
PKA-independent component of β2-AR-mediated NOS stimulation also brings about 
cardioprotection via activation of the ERK p44/p42 MAPK [Daaka et al., 1997; Shizukuda and 
Buttrick, 2002] as well as the PI3-K-Akt pathway [Chesley et al., 2000; Zhu et al., 2001].  
 
β3-AR stimulated activation of NO was shown to be accompanied by decreased contractility in 
humans [Gauthier et al., 2000] and various other experimental models [Cheng et al., 2001; Tavernier 
G et al., 2003; Barbier J et al., 2007]. The negative inotropic effects β3-AR stimulation oppose those 
of the β1-AR or β2-AR, at high catecholamine concentrations, serving as a safety mechanism against 
increased sympathetic drive [Moens et al., 2010]. This negative inotropic effect was shown to be 
inhibited by non-selective NOS inhibitors. Immunohistochemical staining of ventricular biopsies 
showed the expression of NOS 3 but not NOS 2, suggesting an interaction between NOS 3 and the 
β3-AR [Barouch et al., 2002]. 
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1.20   The involvement of the KATP channel in cardioprotection 
 
The sarcolemmal KATP channel was first described in cardiac ventricular myocytes [Noma, 1983]. 
This channel is a complex of two different proteins [Inagaki et al., 1995; 1996]. One subunit is an 
inwardly-rectifying potassium channel (Kir) subunit and it is thought that four of these subunits 
combine to form the channel pore. The sulfonylurea (SUR) subunit is the protein which confers a 
regulatory role as well as sensitivity of the channel to pharmacological agents and ATP [Ashcroft, 
1996]. SUR 1 is highly expressed in pancreatic β-cells, while SUR 2 is highly expressed in cardiac 
and skeletal muscle cells. It is unknown in how many ways these different Kirs and SURs can 
interact but data suggest different combinations in different tissue types. Currently it is thought that 
Kir6.2 and SUR 2 form the cardiac sarcoKATP channel [Inagaki et al., 1996].  
 
KATP channels are of intermediate conductance and are inhibited by physiological concentrations of 
ATP. They were originally termed ATP-dependent potassium channels because ATP was the first 
modulator studied. However, other endogenous modulators have since been identified and are now 
generally referred to as the ATP-sensitive channel. KATP channels (sarcKATP and mitoKATP 
channel) have also been found to be modulated by pH, fatty acids, NO, SH-redox state, various 
nucleotides, G-proteins and ligands (adenosine, acetylcholine, benzopyrans, cyanoguanidines, and 
more) [Edwards and Weston, 1993; Ming, Parent and Lavallee, 1997]. These channels are expressed 
in numerous tissue types including skeletal muscle, brain, kidney, heart, pancreatic β-cells and 
smooth cells [Noma, 1983; Edwards and Weston, 1993; Spruce et al., 1985; Treherne and Ashford, 
1991], where they serve as metabolic energy sensors.  
 
1.20.1   Properties of the mitochondrial KATP channel (mitoKATP) 
 
The mitoKATP channel was first identified in 1991 from single-channel recordings of the inner 
mitochondrial membrane [Inoue et al., 1991]. Two components of the channel have been identified, 
a 55kD channel protein and a 63 kD sulfonylurea receptor (SUR), based on its labelling with 
bodipy-glyburide [Grover and Garlid et al., 2000]. It appears that the mitoKATP channel has a 
heteromultimeric structure similar to that of the sarcolemmal KATP channel. Neither subunit has yet 
been cloned.  
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The main function of the mitochondrial potassium cycle is to regulate matrix volume [Garlid, 1998]. 
The mitochondrial potassium cycle consists of eletrophoretic K+ uptake and electroneutral K+ efflux 
across the inner membrane. The K+ efflux is mediated by the K+ / H+ antiporter [Mitchell, 1961, 
1966; Garlid, 1980], while the K+ influx is mediated by the mitochondrial the KATP channel and by 
an inward K+ leak due to diffusion caused by the high electrochemical gradient favouring inward 
flux [Garlid, 1980, 1998]. The K+ / H+ antiporter cannot sense changes in either of its substrates and 
it is regulated indirectly by the matrix Mg2+ and H+ to sense changes in matrix volume and 
consequently, volume must change before the K+ / H+ antiporter adjusts to equal the rate of K+ 
influx. This will cause transient swelling and results in a higher steady-state volume for as long 
mitoKATP channel remains open. 
 
Despite extensive pharmacological evidence that mitoKATP channels are crucial for IPC 
[Auchampach et al., 1992; Fryer et al., 2000; Hide and Thiemermann, 1996] the question still 
remains as to how the opening of the mitoKATP channels might protect myocytes against ischaemic 
damage. It was proposed that inner membrane depolarization produced by the increased K+ 
conductance may reduce mitochondrial Ca2+ entry through the calcium uniport, which in turns 
blunts mitochondrial Ca2+ overload.  
 
KATP channel openers reverse inhibition of mitoKATP by ATP, ADP and palmitoyl CoA with K1/2 
values that are well within the ranges observed for plasma membrane KATP channels from various 
tissues [Cook and Quast, 1990]. Thus, the K1/2 values are 1 µM and 0.4 µM for cromakalim and 
diazoxide, respectively [Garlid et al., 1996]. A new understanding of the pharmacology of mitoKATP 
inhibitors revealed that glyburide and 5-HD are ineffective in intact, respiring mitochondria [Beavis, 
Lu and Garlid, 1993] and it was suggested that this was probably dependent on the experimental 
model and conditions [Grover and Garlid, 2000].  
 
1.20.2   The role of KATP in ischaemic preconditioning  
  
While all investigators agree on the profound protection of IPC, there is less agreement on the 
molecular mechanism of protection. Initially it has been proposed that the KATP channel is the end-
effector [Garlid et al., 1997]. The role of the KATP channels in cardioprotection has been complicated 
by the presence of these channels in both the cell membrane and the mitochondria. 
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Studies showing KATP openers to mimic IPC, are consistent with the notion that these channels are 
crucial to IPC, but do not prove it. Further proof required the use of pharmacological blockers of this 
channel. This was first illustrated in a canine model when the sarcolemmal KATP channel blocker, 
glyburide (glybenclamide) abolished IPC [Gross and Auchampach, 1992]. This blocker also 
abolished IPC in man [Tomai et al., 1994]. It is now generally accepted that the mitoKATP channel 
plays an important role in triggering IPC. These channels are not the end effectors of protection, but 
rather their opening before ischemia generates ROS that trigger entrance into a preconditioning state 
and activation of PKC [Pain et al., 2000].  
 
It is evident that some degree of selectivity exists for KATP channel blockers. The mitoKATP blocker 
5-HD efficiently abolishes the cardioprotective effects of all KATP channel openers tested, but has 
little effect on cardiac sarcolemmal KATP channel [Garlid et al., 1997; McCullough et al., 1991]. It 
is also of interest that 5-HD is incapable of blocking the vasodilator effects of KATP channel openers. 
 
Interestingly, blockers of A1-AdoR and KATP channel completely abolished IPC in similar animal 
models when administered alone. In neonatal rat cardiac myocytes it was found that A1-AdoR 
activation also activated the KATP channel through a Gi coupled pathway [Kirsch et al., 1990]. It was 
also found that the A1-AdoR agonist, R-PIA reduced infarct size in dogs and this effect was 
completely abolished by glyburide, suggesting adenosine receptor activation to be upstream of KATP 
channel
 
activation [Grover, Sleph and Dzwonczyk, 1992; Van Winkle et al., 1994]. This pathway 
was also shown to be operative in man [Cleveland et al., 1997]. 
 
If it is assumed that adenosine receptor activation is upstream of KATP channel activation during IPC, 
then it becomes important to determine the signaling pathway linking the two systems. Adenosine 
A1 receptor activation inhibits PKA and activates PKC, both of which are known to be involved 
with the KATP channel. PKC has been shown to be involved with activation of sarcolemmal KATP 
channel in patch clamp studies and its activation protects the myocardium in a glyburide-reversible 
manner [Hu et al., 1996; Speechly-Dick, Grover and Yellon, 1995]. Some studies also proved that 
IPC is associated with action potential duration shortening [Yao & Gross, 1994]. 
 
Convincing evidence also exists for a role of the mitoKATP channels as mentioned above. However, 
in the intact rabbit heart opening of mitoKATP channel failed while opening of sarcolemmal KATP 
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channel reduced infarct size [Haruna et al., 1998]. Diazoxide, which had been believed to be a 
mitoKATP-specific channel opener, failed to protect the heart in kir6.2−/− mice, which lacked surface 
KATP but preserved mitoKATP channels [Suzuki et al., 2003]. It could be possible that both the 
sarcolemmal KATP and mito KATP channels are necessary for IPC. Their protective functions could 
be complementary, but their importance may vary in different animal species or different 
experimental conditions. 
 
 
1.21   Motivation and aims of study 
 
As described previously, transient β-AR activation with ligands such as isoproterenol and 
dobutamine can mimick ischaemic preconditioning and elicit protection against a subsequent period 
of sustained ischaemia [Asimakis et al., 1994; Miyawaki and Ashraf, 1997; Nasa and Takeo, 1997; 
Lochner et al., 1999; Frances et al., 2003; Robinet, Hoizey and Millart, 2005]. As in the case of IPC, 
the exact mechanisms whereby activation of the β-AR signal transduction pathway and generation 
of cAMP during the triggering phase [Lochner et al., 1999], lead to cardioprotection, still need to be 
elucidated. In addition, it is not clear which of the three currently known β-AR receptors (β1-, β2- or 
β3-AR) present in heart muscle, is involved in β-AR preconditioning.   
 
A possible mechanism whereby transient β-AR activation elicits a cardioprotective response is via a 
process of demand ischaemia with associated raised adenosine levels. The role of adenosine in the 
process of IPC has been thoroughly investigated and the possibility exists that β-PC elicits 
protection in a similar manner as IPC. 
 
In addition, β-adrenergic stimulation increases both NO [Balligand et al., 1999] and reactive oxygen 
species generation [Opie et al., 1979], which should be considered as possible mechanisms whereby 
β-PC mediates a cardioprotective response. As previously outlined, the main source of ROS appears 
to be the mitochondria where the mitoKATP channels play an essential role [Costa et al., 2005; Costa 
and Garlid, 2008] and it is possible that opening of the mitoKATP channel may act as a signal 
transduction element also in β-PC [Pain et al., 2000]. With the exception of p38 MAPK [Marais et 
al., 2001], relatively little is known about the role of the MAPK family in β-PC. In this study 
attention was focused on the role of ERK p44/p42 MAPK in association with PKB/Akt activation 
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(RISK pathway) during reperfusion. In addition, whether β-AR is associated with activation of the 
RISK pathway, as in IPC, still needs to be determined. Although the contribution of JNK to IPC has 
been investigated [Fryer et al., 2001; Ping P et al., 1999], no information is at present available 
regarding its role in β-PC and is a subject for future studies. 
 
In view of this, the aims of this study were therefore to unravel the mechanisms involved in the 
cardioprotective response of β-PC and the following aspects were investigated: 
 
1. The role of β1-, β2- and β3-adrenergic receptor subtypes in β-PC, using appropriate agonists and 
antagonists as well as the contribution of Gi protein and PKA to β-adrenergic preconditioning,  
 
2. The role of the prosurvival kinases, PKB/Akt and ERK 44/p42 MAPKinase in β-drenergic 
preconditioning  
 
3. Adenosine release and the relative contributions of the A1-, A2-, A3-adenosine receptor subtypes 
and associated PI3-K / PKB /Akt and ERK activation during the triggering and mediatory phases 
of β-PC with isoproterenol 
 
4. Involvement of the mitoKATP channel in the cardioprotection of β-PC, using the specific inhibitor 
5-HD 
 
5. The role of ROS in β-PC using the ROS scavenger N-acetyl-cysteine  
 
6. The contribution of NOS activation and NO release to β-PC, using the NOS inhibitors, L-NAME 
and L-NNA 
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Chapter 2 
 
 
Materials and Methods 
 
 
 
2.1   Animals 
 
Male Wistar rats weighing 250 to 350 g were used in this study. Rats were housed in an AAALAC 
(Association for Assessment and Accreditation of Laboratory Animal Care) facility and their 
handling of laboratory animals was in accordance to institutional ethical guidelines. The rats had 
free access to food and water prior to anesthesia (30 mg pentobarbital / rat) by intraperitoneal 
injection. 
 
 
2.2   Perfusion Technique (Fig. 2.1) 
 
The hearts were rapidly excised and arrested in ice cold Krebs-Henseleit buffer, containing in 
mM/L: NaCl 119; NaHCO3 24.9; KCl 4.74; KH2PO4 1.19; MgSO4 0.6; NaSO4 0.59; CaCl2 
1.25; glucose 10. The buffer was gassed with 95 % O2 and 5 % CO2 prior to and during the 
perfusion protocol. 
 
The hearts were mounted on the aortic cannula of the Neely-Morgan perfusion system and 
retrogradely perfused at 100 cm H2O for 15 minutes during which time the left atrium was 
cannulated to allow atrial perfusion at a preload of 15 cm H2O. Subsequent to the stabilization 
period, the mode of perfusion was changed to working heart mode for 15 minutes, the left 
ventricle ejecting against a hydrostatic pressure of 100 cm H2O (afterload). This was followed 
by a retrograde perfusion episode of 30 minutes, prior to 35 minutes regional ischemia and a 30 
minutes reperfusion period. The myocardial temperature was monitored by insertion of a 
temperature probe in the left atrium and controlled throughout the experiment. Drugs were 
applied via a side-arm into the aortic cannula, while the hearts were retrogradely perfused at a 
pressure of 100 cm H2O. 
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2.3   Regional ischaemia 
 
Regional ischaemia was applied by inserting a silk suture underneath and around the proximal 
LAD. Tightening of the suture resulted in occlusion of the coronary artery, cessation of regional 
myocardial perfusion and a 33 % reduction in total coronary flow.  
Regional cyanosis of the area of the occluded vessel was also used as an indicator of effective 
occlusion of the vessel. Coronary artery occlusion was maintained for 35 minutes at 36.5 oC. 
 
Fig. 2.1:  Basic perfusion Protocol  
 
 
 
2.4   End - points of ischaemic damage 
 
2.4.1   Myocardial Function 
 
Coronary (Qe) and aortic (Qa) flow rates in ml/minute were measured manually. The aortic 
pressure (mm Hg) was obtained through a side branch of the aortic cannula which was 
connected to a Viggo-spectramed pressure transducer. The peak systolic pressure (PSP) and 
heart rate (HR) were obtained from the recordings made. The following parameters were 
calculated:  
• Cardiacoutput (CO) (ml/min) = (Qa + Qe) 
• Stroke volume (SV) (ml/min) = (CO / HR) 
The mean external power produced by the left ventricle (TW) in mWatts according to 
Kannengieser and co-workers, 1979: 
 TW = 0.002222(PAO-11.25)(CO) 
             Where  
                          PAO = aortic pressure  and  CO = cardiac output 
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION  
1250 60 9515 30
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Measurements were made before and after ischaemia, during reperfusion. Functional recovery 
of hearts was determined by expressing post-ischaemic aortic output as a percentage of pre-
ischaemic aortic output. 
 
2.4.2   Determination of infarct size 
 
Comprehensive studies on the effect of reperfusion time on infarct size were done on three 
different occasions and it was found in all series that infarct sizes (expressed as a percentage of 
the area at risk) were similar in hearts reperfused for 30 and 120 min after 35 min regional 
ischaemia (2h reperfusion : NPC:36.8±2.21 n=6; PC: 15.94±1.83 n=6; 30 min reperfusion: 
NPC: 37.82±1.54 n=15; PC: 16.80±2.08 n=13).  Thus in this study hearts were routinely 
reperfused for 30 min before determination of infarct size.   
 
At the completion of regional ischaemia and reperfusion, the silk suture around the LAD was 
permanently tied and a 0.25% Evan’s blue solution infused into the heart to outline viable 
tissues. Hearts were removed, frozen, cut into 2 mm thick transverse tissue segments and 
incubated in 1 % triphenyl tetrazolium chloride (TTC) in phosphate buffer, pH 7.4 for 10 
minutes. Damaged tissues take on a deep red coloration. Infarcted tissue areas are not stained 
and have a white colour. The reaction with TTC was stopped by placing the tissue segments in 
10 % formalin. Tissue segments were placed between two glass plates and traced to outline the 
infarcted as well as the area at risk in each ventricular section. The left ventricle area at risk (R) 
and the area of infarct (I) tissue were determined using computerised planimetry (UTHSCSA 
Image Tool program, developed at the University of Texas Health Science Center at San 
Antonio, Texas).  The infarct size was expressed as a percentage of the risk zone (I/R%). 
 
 
2.4.3   Western Immunoblot analysis 
 
Hearts were snap-frozen at the time intervals indicated in the results section. Immunoblotting 
and detection of total – and phospho - ERK p44 / p42 MAPKinase and PKB / Akt were 
performed using appropriate antibodies from Cell Signalling Technology. Immunoreactive 
bands obtained were analysed using densitometry. 
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2.4.3.1   Preparation of lysates 
 
The lysis or protein extraction buffer contained the following: 20 mM Tris-HCl, 1 mM EGTA, 1 
mM EDTA, 150 mM NaCl, 1 mM β-glycerolphosphate, 1 mM NaVO3, 50 µg/ml PMSF, 10 
µg/ml Leupeptin, 10 µg/ml Aprotinin, 1 % Triton. NaVO3 was prepared weekly; PMSF 
(phenylmethylsulfonyl fluoride) was added last to the buffer. Approximately 30 mg tissue was 
homogenized in 900 µl lysis buffer using a polytron homogenizer (2x4 seconds). After 
incubation on ice for 20 min, samples were centrifuged at 14500 rpm for 10 min to obtain the 
cytosolic fraction. The protein content of each sample was determined using the Bradford 
method (Bradford, 1975]. The protein concentration of all samples were adjusted and equalized 
to 20 µg / 9 µl with sample and lysis buffer after which samples were boiled for 5 min and 
stored at – 20oC. 
 
 
2.4.3.2   Western Immunoblot analysis 
 
Samples were subjected to electrophoresis on a 12 % polyacrylamide gel (SDS –PAGE) using 
the standard BIO-RAD Mini Protean III system. The separated proteins were transferred to a 
Immobilon membrane (Millipore). Proper protein transfer and equal loading were routinely 
assessed using Ponceau-s staining and corrections were made if necessary. Non-specific binding 
sites on the membrane were blocked with 5% fat free milk in TBST (Tris-buffered saline + 0.1 
% Tween 20) for 1-2 hours at room temperature and incubated overnight in the primary 
antibodies (Cell Signaling Technology, Massachusettes, USA) that recognize total or 
phosphorylated proteins: total ERK p44/p42 and phospho-ERK p44/p42 (Tyr-204 / Thr-202); 
total PKB / Akt and phospho-PKB / Akt (Ser-473). The membranes were washed with TBST 
(5x5 min) and then incubated with a diluted horseradish peroxidase-labelled secondary antibody 
(Amersham Life Science, Buckinghamshire, UK).   
 
After thorough washing with TBST, membranes were covered with ECL detective reagents and 
briefly exposed to a autoradiography film (Amersham Hyperfilm ECL) to detect light emission 
via a non-radioactive method. Films were analysed using densitometry (UN-SCAN-IT, Silk 
Scientific Inc, USA). 
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2.5   Statistical analysis 
  
Results were expressed as mean ± standard error of the mean (SEM). For multiple comparisons 
one-way analysis of variance (ANOVA) was utilised (GraphPad software. PrizmPlus Version 
4.0). Post-hoc testing for differences between selected groups was done using Bonferroni’s 
method. In view of the fact that Bonferroni is a strict post-hoc test which carries the risk of type 
II error, results were also analyzed using the Tukey or Newman-Keuls tests. Similar results were 
obtained. A minimum of 6 animals were used per experimental group and not more than 4 
groups were included in each comparison. A p-value of <0.05 was considered significant. 
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Chapter 3 
 
Role of β-adrenergic receptors in β-adrenergic preconditioning (β-PC) 
 
The protection against ischaemia elicited by ischaemic preconditioning is associated with a 
reduction in infarct size and decreased reperfusion arrhythmias, diminished apoptosis and 
improved functional recovery upon reperfusion [Cohen et al., 2000; Downey and Cohen, 2006].  
The protective effects of this phenomenon have been demonstrated to be mediated by G-protein 
coupled receptors and their associated signal transduction pathways [Das and Das, 2008; Gross 
and Gross, 2008].  Amongst others, the beta-adrenergic receptors (β-ARs) have been shown to 
be involved in ischaemic preconditioning [Asimakis et al., 1994; Tong et al., 2005].  In fact, 
transient β-AR activation with ligands such as isoproterenol and dobutamine mimicked 
ischaemic preconditioning and elicited protection against a subsequent period of sustained 
ischaemia – the so-called phenomenon of β-adrenergic preconditioning (β-PC) [Asimakis et al., 
1994; Lochner et al., 1999; Miyawaki and Ashraf, 1997].  However, as in the case of ischaemic 
preconditioning, the exact mechanisms whereby activation of the β-adrenergic signal 
transduction pathway and generation of cAMP during the triggering phase [Lochner et al., 
1999], lead to cardioprotection, still need to be elucidated.  
 
It is also not clear which of the three β-AR receptors (β1-, β2- or β3-AR) present in heart muscle, 
is involved in β-AR preconditioning.  The β1-AR predominates in heart muscle, the β1/β2 ratio 
being ~80:20 [Bristow et al., 1986], while the expression of β3-AR is very low in the rat heart 
[Rozec and Gauthier, 2006].  The β1-subtype couples primarily to the Gs protein, while the β2- 
and β3- subtypes couple to the Gi protein [Rozec and Gauthier, 2006]. Coupling to Gs may exert 
a proapoptotic effect, while Gi coupling is anti-apoptotic [Rozec and Gauthier, 2006; Zheng, 
Hau and Xiao, 2004].  It has also been shown that selective β3-AR agonists exert negative 
inotropic effects in human ventricular muscle [Gauthier et al., 1996] and caused activation of the 
NO pathway and an increase in cGMP [Gauthier et al., 1998]. 
 
A number of studies point to a role for β1-AR activation as trigger in β-AR preconditioning: (i) 
propranolol (a non-selective β-blocker) and atenolol (a more selective β1-blocker) abolished 
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isoproterenol-induced protection, while the selective β2-blocker IC1-118551 was without effect 
[Frances et al., 2003];  
(ii) the specific β1-adrenergic agonist xamoterol could elicit protection against ischaemia, which 
was abolished by atenolol and PKA inhibition [Robinet, Hoizey and Millart, 2005]; (iii) hypoxic 
preconditioning was attenuated by a β1-selective blocker, metoprolol [Mallet et al., 2006]; (iv) 
desflurane and sevoflurane preconditioning was shown to be dependent on β1-AR activation, 
since it could be blocked by esmolol and H89, a PKA inhibitor [Lange et al., 2006].  However, a 
major role for β1-AR activation as trigger in β-PC cardioprotection may be questioned, in view 
of its well-established effects on necrosis and apoptosis. The fact that most membrane receptors 
coupled to the Gi protein are able to elicit cardioprotection, suggests that the β2-AR may also be 
a strong candidate for triggering β-PC. Indeed, Tong and coworkers, 2005 found that 
preconditioning could not be elicited by isoproterenol in transgenic β2-AR knock out mice.  
Furthermore, it was found that the Gi inhibitor pertussis toxin blocked isoproterenol-induced 
improvement in postischaemic function and reduction in infarct size [Tong et al., 2005].  As far 
as we know no information is available regarding a role for the β3-AR in β-AR preconditioning. 
 
In view of the above, the aim of the present study was to evaluate the respective roles of the β1-, 
β2- and β3-AR receptors in β-AR preconditioning by using selective agonists and antagonists. 
Infarct size and functional recovery during reperfusion were used as endpoints.  In addition, the 
contribution of the Gi protein and PKA to the mechanism of isoproterenol-induced 
cardioprotection was investigated. 
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REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION  
NPC
Infarct size
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION 
β-PC
5 MIN  Isoproterenol
5 MIN WASH OUT Infarct size
3.1   Methods 
 
3.1.1   Investigating the effect of β-adrenergic preconditioning on  
           haemodynamic parameters  and  myocardial  infarct size 
           (Fig. 3.1) 
 
Hearts were subjected to the β-adrenergic preconditioning protocol in the following manner: 
hearts were subjected to a stabilization period of 15 minute retrograde perfusion which was 
followed by 15 minutes perfusion in the work heart mode at the end of which haemodynamic 
parameters were recorded. This was followed by a 20 minute retrograde perfusion, exposure to 
an appropriate β-AR agonist for 5 minutes and a 5 minute washout episode prior to 35 minutes 
regional ischaemia and 30 minutes reperfusion at the end of which haemodynamic parameters 
were recorded. Non preconditioned hearts were subjected to exactly the same perfusion protocol 
except that the β-AR agonist was not administered prior to regional ischaemia. 
  
Experimental protocol: (Fig. 3.1) 
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STABILIZATION    
0 3015 50 55 60
5 MIN  ISO / Formoterol / BRL37344 (Work Heart mode)
5 MIN  KREBS (Work Heart mode)
3.1.2   Investigating the effectiveness of the 5 minutes washout episode after 
          β-AR stimulation (Fig. 3.2) 
 
The effectiveness of the 5 minute washout period applied after transient β-AR stimulation with 
the β1/β2-AR agonist, isoproterenol (ISO) (0.1 µM) / β2-AR agonist, formoterol (1 nM) / β3-AR 
agonist, BRL 37344 (1 µM) was investigated, to ensure that beta-adrenergic stimulation was 
effectively stopped and that all haemodynamic parameters returned to baseline prior to regional 
ischaemia. Subsequent to the 15 minutes stabilization period, the mode of perfusion was changed 
to working heart mode for 15 minutes (haemodynamic parameters recorded). This was followed 
by a retrograde perfusion episode of 20 minutes. β-adrenergic stimulation with isoproterenol / 
formoterol / BRL 37344 was applied when the heart was perfused in work heart mode for 5 
minutes and haemodynamic parameters recorded. This was followed by a 5 minute washout 
episode, at the end of which haemodynamic parameters were again recorded.  
 
 
Experimental protocol: (Fig. 3.2) 
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STABILIZATION    
5 MIN  WASH OUT
10 MIN Antagonist 5 MIN ISO (Work Heart mode)
0 3015 50 60 65 70
3.1.3   To test the effectiveness of the 5 minute washout episode after the 
            application of β-adrenergic antagonists on haemodynamic 
            parameters (Fig. 3.3) 
 
It was important to test the effectiveness of the 5 minute washout period applied after the 
application of various β-AR antagonists, to ensure complete removal and that all haemodynamic 
parameters returned to baseline prior to regional ischaemia. The β-AR antagonists were 
dissolved in DMSO and added to the Krebs-Henseleit buffer (final DMSO concentration 0.00023 
% v/v). Subsequent to the 15 minutes stabilization period, the mode of perfusion was changed to 
working heart mode for 15 minutes and the haemodynamic parameters recorded. This was 
followed by a retrograde perfusion episode of 20 minutes. The β-AR antagonist was then applied 
for 10 minutes (CGP-20712A; β1-ARs antagonist, 300 nM; ICI 118,551; β2-ARs antagonist, 50 
nM; SR 59230A; β3-ARs antagonist, 100 nM). This was followed by a 5 minute washout period 
in retrograde mode, followed by a 5 minute episode of β-AR stimulation with isoproterenol 
(working heart) and recording of the haemodynamic parameters. 
 
 
Experimental protocol: (Fig. 3.3) 
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3.1.4    Exploring the β-adrenergic receptor subtype involved in β-  
             adrenergic preconditioning (β-PC) (Fig. 3.4) 
 
Non-preconditioned hearts (NPC) were subjected to a 15 minutes stabilization period after 
which the mode of perfusion was changed to working heart mode for 15 minutes 
(haemodynamic parameters recorded). This was followed by a 30 minute retrograde perfusion, 
35 minutes regional ischaemia and 30 minutes reperfusion. In addition, non- preconditioned 
hearts were also exposed to the following β-adrenergic antagonists for 10 minutes followed by a 
5 minute washout episode prior to regional ischaemia and reperfusion: 
β1-ARs antagonist (CGP-20712A) (300 nM), β2- ARs antagonist (ICI 118,551) (50 nM) and β3-
ARs antagonist (SR 59230A) (100 nM). Haemodynamic parameters were recorded at the end of 
the 15 minute working heart mode prior to regional ischaemia and compared with 
haemodynamic parameters and infarct size at the end of reperfusion. 
 
β-PC hearts were subjected to a stabilization period of 15 minute retrograde perfusion which 
was followed by 15 minutes perfusion in the work heart mode at the end of which 
haemodynamic parameters were recorded. This was followed by a 15 minute retrograde 
perfusion, isoproterenol 0.1 µM (β1/β2-PC) / formoterol 1 nM (β2-PC) / BRL 37344 1 µM (β3-
PC) for 5 minutes and a 5 minute washout episode prior to 35 minutes regional ischaemia and 
30 minutes reperfusion. The following β-adrenergic antagonists / agonists were applied prior to 
isoproterenol for 5 minutes as well as during isoproterenol administration: β1-AR antagonist 
(CGP-20712A) (300 nM), β2-AR antagonist (ICI 118,551) (50 nM), β2- AR agonist (formoterol 
hemifumarate) (1 nM), β3-AR antagonist (SR 59230A) (100 nM), β3-AR agonists (BRL 37344) 
(1µM). After a 5 min washout episode, hearts were subjected to 35 min regional ischaemia 
during which time the temperature was carefully controlled and maintained at 36.5oC. Hearts 
were retrogadely reperfused for 10 minutes, followed by 20 minutes perfusion in the work heart 
mode. The haemodynamic parameters recorded at the end of the 15 minute working heart 
perfusion prior to regional ischaemia were compared with those obtained during reperfusion. 
Infarct size was measured at the end of reperfusion following regional ischaemia.  
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REGIONAL ISCHAEMIASTABILIZATION  
NPC
REPERFUSION
REGIONAL ISCHAEMIASTABILIZATION    
NPC + CGP-20712A / ICI 118,551 / SR 59230A 
REPERFUSION
5 MIN WASH OUT
10 MIN  ANTAGONIST
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ISO + β2 / β3 agonists or antagonists
5 MIN WASH OUT
5 MIN   ISO + AGONIST OR ANTAGONIST
5 MIN   AGONIST OR ANTAGONIST
REPERFUSIONSTABILIZATION    REGIONAL ISCHEMIA
β-PC 5 MIN  β-AR Agonists (ISO / Formoterol / BRL 37344)
REPERFUSIONSTABILIZATION REGIONAL ISCHEMIA
Experimental protocol: (Fig. 3.4) 
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REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION 
NPC + CGP-20712A  +  Formoterol applied prior to RI
10 MIN   ANTAGONIST + AGONIST
5 MIN WASH OUT Infarct size
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3.1.5    Investigating the specificity of the β1-AR antagonist (CGP- 
              20712A) and its effects on β2-AR stimulation with formoterol  
            (Fig. 3.5) 
 
To investigate the relevance of β1-ARs in β2- AR mediated cardioprotection, β1-AR inhibition 
was applied in combination with the β2- AR agonist. Hearts were subjected to a 15 minute 
retrograde perfusion which was followed by 15 minutes work heart mode. This was followed by 
another 15 minute retrograde perfusion after which the β1-ARs antagonist, CGP-20712A (300 
nM) and β2- ARs agonist, formoterol (1nM) were applied for 10 minutes. This was followed by 
a 5 minute washout episode, 35 minutes regional ischaemia and 30 minutes reperfusion. 
Haemodynamic parameters were recorded at the end of the 15 minute working heart mode prior 
to regional ischaemia and compared with those obtained at the end of reperfusion following 
regional ischaemia. Infarct size was measured at the end of reperfusion. 
 
 
Experimental protocol: (Fig. 3.5) 
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5 MIN  ISO 
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION    
5 MIN  WASH OUT
30 µg kg-1 Ptx, i.p. 48 hr prior to Exp Infarct size
1250 5545 60 9515 30
3.1.6    Investigating the involvement of guanine nucleotide regulatory  
              proteins (Gαi/o) in β-adrenergic preconditioning (Fig. 3.6) 
 
Bordetella pertussis toxin (PTX), which catalyzes ADP-ribosylation of guanine nucleotide 
regulatory proteins and specifically, Gαi/o, thus functionally uncoupling this binding protein 
from its associated receptors, was examined to determine its involvement in the protective effect 
of β-adrenergic preconditioning. Pertussis toxin (Sigma-Aldrich) was diluted in normal saline 
and injected intra-peritoneally at a concentration of 30 µg/kg BW 48 hours before 
experimentation. Control animals were injected with an equivalent volume of the vehicle (saline 
solution). Hearts were preconditioned with ISO, 0.1 µM for 5 minutes followed by a 5 min 
washout episode, 35 min regional ischemia, 30 minutes reperfusion and the determination of 
infarct size at the end of reperfusion. Haemodynamic parameters were recorded at the end of the 
15 minute working heart perfusion prior to regional ischaemia and compared with those obtained 
at the end of reperfusion. 
 
 
Experimental protocol: (Fig. 3.6) 
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STABILIZATION    
5 MIN Carbachol (Work Heart Mode)
30 µg kg-1 Ptx, i.p. 48 hr prior to Exp
0 2515 30
3.1.7   Investigating the effectiveness of Gαi/o inhibition with carbachol  
          (Fig 3.7) 
 
Parasympathetic stimulation of the heart acts through muscarinic receptors, which mediates its 
signaling actions via pertussis toxin-sensitive Gαi/o proteins and affects the chronotropic and 
inotropic status of the heart. Effectiveness of Gαi/o inhibition with PTX was assessed by 
determining its ability to block the bradycardia response associated with carbachol, a muscarinic 
/ cholinergic receptor agonist. After treatment with PTX (as described in 3.1.6), hearts were 
subjected to a 15 minute retrograde perfusion which was followed by 10 minutes perfusion in 
the working mode at the end of which the haemodynamic parameters were recorded. Carbachol 
(1 µM) was administered for 5 minutes and the haemodynamic parameters recorded at the end of 
this period.  
 
 
Experimental protocol: (Fig. 3.7) 
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STABILIZATION    
30 µg kg-1 Ptx, i.p. 48 hr prior to Exp
5 MIN Formoterol (Work Heart Mode)
3.1.8   Investigating the involvement of Gαi/o protein in β2 –adrenergic 
           receptor stimulation with formoterol (Fig. 3.8) 
 
The β2-AR couple to Gαs- and Gαi/o-protein, and evidence has accumulated that β2-AR agonists 
can differentially activate either Gαs or Gαi/o-protein. The involvement of the Gαi/o regulatory 
protein in the specific actions of the selective β2-ARs agonist, formoterol hemifumarate (1 nM) 
was assessed after treatment with PTX (30 µg/kg BW, ip.) as described in (3.1.6). Hearts were 
subjected to a 15 minute retrograde perfusion which was followed by 10 minutes perfusion in 
the working mode at the end of which haemodynamic parameters were recorded. Formoterol 
was administered for 5 minutes in work heart mode and haemodynamic parameters recorded at 
the end of this period.  
 
Experimental protocol: (Fig. 3.8) 
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ISO + Rp-8CPT-cAMPS applied at the onset of reperfusion
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION    
5 MIN Rp5 MIN ISO
ISO + Rp-8CPT-cAMPS applied prior to index ischaemia
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION    
5 MIN Rp
5 MIN ISO + Rp
5 MIN  WASH OUT Infarct size
Infarct size
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3.1.9   Investigating the involvement of PKA in β-PC (Fig. 3.9) 
 
The specific PKA inhibitor (Rp-8-CPT-cAMP) was dissolved in distilled water and added to the 
Krebs-Henseleit buffer (final concentration 16 µM) for 5 minutes prior to and during the 5 
minute isoproterenol (0.1 µM) administration, followed by a 5 minute washout episode. Hearts 
were subsequently subjected to 35 minutes regional ischaemia and 30 minutes reperfusion, 
followed by the determination of infarct size at the end of reperfusion. In a separate group of 
experiments the PKA inhibitor (Rp-8-CPT-cAMP) was applied at the onset of reperfusion 
following regional ischemia. Haemodynamic parameters were recorded at the end of the 15 
minute working heart perfusion prior to regional ischaemia and compared with those obtained at 
the end of reperfusion. Infarct size was determined at the end of reperfusion. 
 
 
Experimental protocol: (Fig. 3.9) 
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3.2   Results 
 
3.2.1   The effectiveness of the 5 minute washout episode after β-
 
ARs  
          stimulation (Table 3.1)  
 
Before determining the efficacy of the β-AR agonists used to elicit cardioprotection, it was 
necessary to determine whether the 5 minute washout period was sufficient to eliminate all traces 
of the  β-AR agonists studied.  
 
During administration of isoproterenol, haemodynamic parameters such CF, AO and total work 
significantly increased after 1 minute. CF remained elevated, while the AO and total work were 
significantly reduced after 5 minutes. All haemodynamic parameters returned to baseline values 
after 5 minutes washout (Table 3.1).  
 
Compared to isoproterenol, the application of the β2-AR agonist formoterol had no effect any of 
the haemodynamic parameters during the 5 minute period of administration nor did any of the 
parameters differ significantly from baseline after a 5 minute washout episode (Table 3.2). 
 
Administration of the β3-AR agonist BRL 37344 for a period of 5 minutes had no effect on CF 
while AO and total work were significantly reduced throughout the treatment period. These 
parameters were shown to return to baseline values after 5 minutes washout (Table 3.3). 
 
In summary, the results obtained with all three β-AR agonists showed that a washout period of 5 
minutes was sufficient to remove all traces of the drugs before the onset of regional ischaemia. 
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Table 3.1:  The haemodynamic parameters of isolated rat hearts before, and after 1, 3 and  
                    5 min β-AR stimulation with isoproterenol as well as after 5 min washout  
 
β-AR agonist: Isoproterenol (0.1 µM) (n=6) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
 15 min WH 16.67±0.42 40.00±0.42 57.00±2.33 260.00±15.2 97.33±1.49 12.33±0.71 
       
1 min WH+ ISO 
 
23.67±1.66 
∗ 
53.50±3.69¥ 77.17±4.91¥ 303.00±7.33 101.20±2.01 17.55±1.41 
∗ 
       
3 min WH+ ISO 22.17±0.90 
∗ 
34.00±3.01 
ϕ 
56.17±3.63 311±11.00 95.83±1.49 11.91±0.89 
δ 
       
5 min WH+ ISO 20.00± 0.85 
¥ 
24.00±2.30 
∗ϕ 
43.00± 2.76 299.00±9.15 93.50±1.47 8.42±0.67 
ϕ 
 
5 min Washout 17.00±0.44 39.67±2.49 56.33±3.07 244.00±3.41 95.50±1.72 12.06±0.79 
 
¥ p<0.05 vs 15 min WH          ∗ p<0.01 vs 15 min WH          δ p<0.01 vs   1min WH+ISO 
 
ϕ p<0.001 vs 1min WH+ISO  
 
 
 
Table 3.2:  The haemodynamic parameters of isolated rat hearts before and after 1, 3 and 
                   5 min β2-AR stimulation with formoterol as well as after 5 min washout  
 
β2-AR agonist: formoterol (1 nM) (n=6) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
15 min WH 16.67± 0.42 42.83±2.10 59.90±2.39 231.0±0.42 98.33±1.97 13.08±0.70 
       
1 min WH+ 
Formoterol 
17.67±1.20 44.50±3.38 62.50±4.30 232.00±5.00 
 
98.83±1.85 13.77±1.17 
       
3 min WH+ 
Formoterol 
19.00±1.23 45.67±2.94 64.33±3.87 245.00±5.00  98.67±2.15 14.15±1.08 
       
5 minWH+ 
Formoterol 
19.00±1.25 44.50±2.87 63.50±3.66 240.00±6.00  98.00±1.63 13.89±0.96 
 
5 min 
washout 
17.33±0.42 41.67±1.58 59.00±1.95 231.00±12.47 96.00±2.42 12.77±0.68 
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Table 3.3:  The haemodynamic parameters of isolated rat hearts before and after 1, 3 and 5  
                    min β3-AR stimulation with BRL 37344  
 
 
β3-AR agonist: BRL 37344 (1 µM) (n=6) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
15 min WH 16.00±0.0 36.33±1.33 53.33±1.33 221.00±1.76 92.00±1.73 10.72±0.19 
       
1 min WH+ 
BRL 37344 
16.00±0.0 22.00±3.05 
∗ 
38.00±3.05 
∗ 
262.00±3.51 
∗ 
89.33±2.84 7.54±0.54 
∗ 
       
3 min WH+ 
BRL 37344 
15.17±0.83 18.67±3.52 
∗ 
34.67±3.52 
∗ 
260.00±6.48 
∗ 
90.00±2.88 7.16±0.68 
¥ 
       
5 minWH+ 
BRL 37344 
15.17±0.83 18.00±3.42 
∗ 
33.17±3.56 
¥ 
266.00±7.89 
∗ 
89.33±0.88 6.47±0.55 
¥ 
 
 
5 min 
washout 
16.00±0.0 32.00±1.02 47.33±1.76 212.00±4.35 87.00±0.0 9.22±0.34 
 
∗p<0.05vs15 min WH 
 
¥p<0.01vs15 min WH 
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3.2.2 a   The effect of β-adrenergic preconditioning with isoproterenol,   
                 formoterol or BRL 37344 on mechanical recovery during  
               reperfusion following regional ischaemia (Table 3.4) 
 
The basal coronary flow (CF), aortic output (AO), cardiac output (CO), heart rate (HR), peak 
systolic pressure (PSP), and total work during stabilisation prior to regional ischaemia were 
similar in  NPC as well as β-PC groups. The values were pooled for comparison purposes. 
Similarly, the aortic output, cardiac output and total work measured during reperfusion after RI 
were significantly reduced in all groups when compared to the baseline values. Hearts 
preconditioned with either isoproterenol (β1/β2-PC) or the β2-AR agonist formoterol (β2-PC) 
exhibited significant increases in AO, CO and total work during reperfusion after RI, when 
compared with NPC hearts. However, hearts preconditioned with combination of isoproterenol 
and formoterol (β1/β2-PC + β2-AR agonist) showed no significant change of haemodynamic 
parameters measured after RI, illustrating no cumulative effects.  
 
In contrast to isoproterenol and formoterol, the β3-AR agonist BRL 37344 (β3-PC) did not 
improve post-ischaemic functional recovery and the values obtained were similar to those of 
untreated NPC hearts. Interestingly, preconditioning with a combination of   isoproterenol and 
BRL 37344 (β1/β2-PC + β3-AR agonist) resulted in functional recovery similar to β1/β2-PC 
alone. 
 
In summary, preconditioning with isoproterenol or the specific β2-AR agonist, formoterol, 
resulted in a significant improvement in functional recovery, while the β3-AR agonist BRL 
37344 was without effect. 
 
 
 
 
 
 
 98 
 
Table 3.4:   Effect of β-adrenergic receptor stimulation on mechanical recovery during  
                    reperfusion after 35 min coronary artery ligation 
 
 
(A)  β-AR agonist: isoproterenol (0.1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC  
Before RI  
(n=18) 
15.56±0.34 41.50±1.06 56.84±1.18 254±5.22 100.7±1.70 12.70±0.33 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
#  
235±15.30 86.80±2.13 3.61±0.22  
#  
β1/β2-PC  
Before RI  
(n=18) 
15.85±022 40.24±1.02 56.24±1.06 263±5.68 101.2±1.87 12.90±0.42 
β1/β2-PC  
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
# P< 0.05 vs β-PC After RI  
 
 
(B)  β2-AR agonist: formoterol hemifumarate (formoterol) (1nM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+β2 
 agonist 
After RI  (n=6) 
15.58±0.40 
 
29.00±3.09 
 
45.00±3.23 
 
251±7.40 92.17±2.07 9.637±0.52 
 
       
βPC+β2  
agonist  
After RI  (n=6) 
16.00±0.0 
 
21.38±3.85 
 
37.38±3.85 
 
268.3±15.41 92.75±3.01 7.60±1.01 
 
 
p<0.001 vs NPC After RI 
 
 
(C)  β3-AR agonist: BRL 37344 (1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+β3  
agonist 
 After RI (n=6) 
9.5±2.56 13.60±4.66 23.00±7.09 189±47.44 72.19±18.07 4.84±1.38 
       
βPC+β3  
agonist 
After RI  (n=6) 
12.30±0.73 21.20±1.20 
 
33.50±1.25 
 
265±8.58 92.88±1.97 6.74±0.39 
 
 
p<0.001 vs NPC After RI 
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3.2.2 b   The effect of β-AR preconditioning with isoproterenol,  
               formoterol or BRL 37344 on infarct size (Fig. 3.10 A and B)  
 
The area at risk zone (54.42±0.65%), expressed as a percentage of the left ventricular volume was 
similar in NPC and β-PC groups, as well as in all other experimental groups in which various 
pharmaceutical agents were applied. This implied that all results obtained were comparable.  
 
The cardioprotective effect of β1/β2-PC with isoproterenol was clearly illustrated when 
comparing the reduced IS of β1/β2-PC, 22.01±0.65% to the large IS of untreated NPC hearts, 
41.72±1.65%, p<0.001. Similarly, NPC hearts treated with formoterol significantly reduced IS 
(20.74±1.43%, p<0.001 vs NPC). The β2-AR agonist, formoterol applied prior to and during 
β1/β2-PC, did not add to the cardioprotective effect of β1/β2-PC, since the application of this 
agonist did not further reduce the IS of β1/β2-PC. The β3-AR agonist, BRL 37344, applied in the 
same setting, had no effect on the IS of NPC hearts but significantly increased the IS of hearts 
exposed to β1/β2-PC, 35.68±1.61%, p<0.001 vs β1/β2-PC. 
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Fig. 3.10:  The effect of preconditioning with the β1/β2-AR agonist (isoproterenol) (A), the  
                  β2-AR agonist (formoterol) (A) or β3-AR agonist (BRL 37344) (B) on infarct size
(B) 
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3.2.3   The effect of the 5 minute washout episode after application of β-  
           adrenergic antagonists on haemodynamic parameters (Table  3.5 A, 
           B and C) 
 
Before the effects of β-AR antagonists on the response of the heart to β-adrenergic 
preconditioning could be evaluated, it was essential to establish (i) whether the antagonist could 
counteract the effects of isoproterenol and (ii) whether a 5 minute washout period was sufficient 
to remove both isoproterenol and its antagonists before the onset of regional ischaemia. 
 
The effects of β-AR stimulation with ISO after β1-AR, β2-AR or β3-AR blockade with CGP-
20712A, ICI 118,551 or SR 59230A respectively, abolished the significant increase in CF, AO, 
CO and total work seen with isoproterenol after 1 minute (Table 3.1). These haemodynamic 
parameters returned to baseline values after 5 washout. 
 
 
Table 3.5 A:   The haemodynamic parameters of isolated rat hearts before and after 5 min  
                        β1-AR inhibition followed by β-AR stimulation with isoproterenol (0.1 µM) 
 
β1-AR antagonist: CGP-20712A (300 nM) (n=4) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
15 min WH 
before 
β1antagonist 
16.00± 0.00 37.00±1.00 53.00±1.00 256.00±11.92 94.50±1.19 11.26±0.43 
       
1 min WH+ISO 
after 
β1antagonist 
18.00±0.81 37.50±2.75 56.00±3.16 273.50 ±21.57 98.00±4.14 12.33±1.27 
       
3 min WH+ISO 
after 
β1antagonist 
17.50±1.25 33.00±3.41 51.00±4.65 283.00±17.55 95.50±3.37 10.91±1.33 
       
5 min WH+ISO 
after 
β1antagonist 
17.50±1.23  27.00±2.51 44.50±2.51 286.00±17.38 93.00±1.47 9.27±0.91 
 
5 min Washout 16.00±0.00 36.25±1.49 51.75±1.18 291.00±12.22 93.25±1.28 10.89±0.45 
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Table  3.5 B:   The haemodynamic parameters of isolated rat hearts before and after β2-AR 
                         inhibition followed by β-AR stimulation with isoproterenol (0.1 µM) 
 
 
β2-AR antagonist: ICI 118,551 (50 nM) (n=4) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
15 min WH 
before 
β2antagonist 
16.67±0.66 36.00±2.30 53.33±1.33 276.00±29.05 94.00±3.51 11.17±0.35 
       
1 min WH+ISO 
after 
β2antagonist 
20.67±0.66 40.00±0.00 60.67±0.66 312.00±6.43 101.30±2.18 13.30±0.27 
       
3 min WH+ISO 
after 
β2antagonist 
21.33±0.66 
∗ 
28.00±2.30 
¥ 
49.33±1.76 
δ 
354.00±39.01 93.00±1.52 10.11±0.66 
¥ 
 
       
5 min WH+ISO 
after 
β2antagonist 
22.00±15 
∗ 
21.33±2.66 
€ ϕ 
42.00±3.05 
∗δ 
322.00±44.51 91.33±2.33 8.56±0.80 
ϕ 
   
5 min Washout 17.33±0.66 36.00±2.30 53.33±2.90 300.00±7.21 91.33±0.66 10.87±0.59 
 
∗ p<0.05 vs 15 min WH before β2 antagonist 
 
€ p<0.01 vs 15 min WH before β2 antagonist 
 
 
¥ p<0.05  vs 1 min WH+ISO after β2 antagonist 
 
ϕ p<0.01  vs 1 min WH+ISO after β2 antagonist 
 
δ p<0.001 vs 1 min WH+ISO after β2 antagonist 
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Table 3.5 C:   The haemodynamic parameters of isolated rat hearts before and after β3-AR  
                        inhibition followed by β-AR stimulation with isoproterenol (0.1 µM) 
 
 
β3-AR antagonist: SR 59230A (100 nM) (n=4) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
15 min WH 
before 
β3antagonist 
16.67± 0.66 36.00±2.00 53.33±1.33 270.00±27.47 93.67±1.20 11.14±0.28 
€ 
       
1 min WH+ISO 
after β3antagonist 
18.67±0.66 40.00±2.30 58.67±2.40 313.00±16.80 100.00±1.55 13.04±0.49 
 
       
3 min WH+ISO 
after β3antagonist 
18.00±1.55 28.00±0.00 
ϕ ∗ 
46.67±0.66 
ϕ 
317.00±33.50 94.00±1.00 9.74±0.24 
¥ 
       
5 min WH+ISO 
after β3antagonist 
18.00±15 25.00±0.00¥ 
∗ 
41.33 ±0.66 
¥ δ 
372.00±20.30 90.00±0.57 8.26±0.10 
¥ δ 
 
5 min Washout 16.67±0.66 31.33±3.17 48.00±4.83 317.00±22.08  91.67±0.88 10.06±0.73 
 
 
∗ p<0.05 vs 15 min WH before β3 antagonist 
 
δ p<0.01 vs 15 min WH before β3 antagonist 
 
 
€ p<0.05  vs 1 min WH + ISO after β3 antagonist 
 
ϕ p<0.01 vs 1 min WH + ISO after β3 antagonist 
 
¥ p<0.001 vs 1 min WH + ISO after β3 antagonist 
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3.2.4 a   The effect of β1-AR (CGP-20712A), β2-AR (ICI 118,551) or β3-AR  
              antagonists (SR 59230A) on mechanical recovery during reperfusion  
              following regional ischaemia (Table 3.6) 
 
The aortic output, cardiac output, and total work after regional ischaemia (RI) were significantly 
lowered in the β1/β2-PC+β1 antagonist group (p<0.05) when compared with the β1/β2-PC 
group. The coronary flow, heart rate and peak systolic pressure remained unaffected. 
Pretreatment of β1/β2-PC hearts with the β2-AR antagonist ICI 118,551 caused a significant 
reduction in the aortic output in comparison with the β1/β2-PC group after RI, while the 
coronary flow, cardiac output, heart rate and peak systolic pressure and total work unchanged. 
Interestingly, treatment of NPC hearts with the β3-AR antagonist resulted in a significant 
increase in aortic output during reperfusion compared to the NPC hearts. Furthermore, β3-AR 
blockade combined with β1/β2-PC, caused a significant increase in AO, compared with β1/β2-
PC alone (25.33±1.33 vs 18.00±2.78, p<0.05). In fact, administration of the β3-AR antagonist 
elicits cardioprotection, similar to β1/β2-PC alone. 
 
 
Table 3.6:   Effect of β-adrenergic receptor antagonists on mechanical recovery during  
                  reperfusion of β-adrenergic receptor preconditioned hearts 
 
 
(A)  β-AR agonist: isoproterenol (0.1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC  
Before RI (n=18) 
15.37±0.29 40.74±0.55 55.97±0.57 264±6.34 100.70±1.40 12.78±0.19 
NPC 
After RI 
8.95±1.17 
 
8.13±1.61 
# 
17.08±2.04 
# 
199±5.95 89.71±2.83 3.63±0.59 
#  
β1/β2-PC  
Before RI (n=18) 
16.09±0.14 40.70±0.71 56.96±0.81 264±5.27 104.00±1.43 13.14±0.27 
β1/β2-PC  
After RI 
13.27±0.68 19.43±1.73 
 
32.70±2.20 237±11.7 82.43±2.63 6.67±0.40 
 
# P< 0.05 vs β1/β2-PC After RI 
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(B)  β1-AR antagonist: CGP-20712A (300 nM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+β1 
antagonist  
After RI (n=6) 
7.30±3.10 5.60±3.42 12.90±5.28 138.±56.75 89.33±2.02 3.85±1.43 
       
β1/β2-PC+β1 
antagonist  
After RI (n=6) 
7.20±2.93 7.00±3.02 
ჶ 
14.20±5.83 
ჶ 
161±66.0 55.40±22.83 3.024±1.29
ჶ 
 
ჶP< 0.05 vs β1/β2-PC After RI 
 
 
 
(C)  β2-AR antagonist: ICI 118,551 (50 nM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+β2 
antagonist   
After RI (n=6) 
6.37±3.69 3.12±2.02 9.62±5.71 148 ± 86 45.06± 52.04
  
1.88±1.12 
 
       
β1/β2-PC +β2 
antagonist  
After RI (n=6) 
13.42±0.59 9.75±1.97 
 
23.42±1.86 255±11.04 88.43±1.85 5.122±0.24 
 
 P< 0.05 vs β1/β2-PC After RI 
 
 
 
(D)  β3-AR antagonist: SR 59230A (100 nM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+β3 
antagonist After 
RI  (n=6) 
11.38±1.32 
₤ 
18.50±2.75 
₤ 
29.88±4.06  
₤ 
247±17.64 88.87±3.19 6.32±1.23 
₤ 
       
β1/β2-PC +β3 
antagonist After 
RI  (n=6) 
13.08±0.35 25.33±1.33 
 
39.75±1.91 
 
272±13.01 92.35±1.30 8.00±0.44 
  
 
₤ p<0.05 vs NPC After RI 
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3.2.4 b   Effect of β1-AR (CGP-20712A), β2- AR (ICI 118,551) or β3-AR  
                 antagonists (SR 59230A) on infarct size after β1/β2-AR 
               preconditioning with isoproterenol (Fig. 3.11 A; B and C) 
 
The IS of NPC hearts averaged at 41.60±1.89%, compared to the significantly reduced IS of 
hearts exposed to β1/β2-PC, 22.26±1.46%, p<0.001 vs NPC. Antagonists to β1-ARs (CGP-
20712A, 300nM) or β2-ARs (ICI 118,551, 50 nM) applied prior to and during β-adrenergic 
preconditioning, followed by a washout episode prior to regional ischemia, significantly 
increased infarct size (41.60±1.89% and 44.25±1.28%, p<0.001 vs β1/β2-PC, respectively) and 
abolished the protective effect of β1/β2-PC. In contrast, the β3-AR (SR59230A, 100 nM) 
antagonist applied in the same manner, had no effect on the reduction in infarct size elicited by 
β1/β2-PC. 
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Fig. 3.11:   Effect of β1-AR (CGP-20712A) (A), β2- AR (ICI 118,551)  (B) or β3-AR  
                   antagonists (SR 59230A) (C) on IS in β1/β2-PC 
(B) 
(C) 
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3.2.5 a   The effect of the β1-AR  antagonist (CGP-20712A) on β2-AR stimulation  
                 with formoterol on mechanical recovery during reperfusion after  
              regional  ischaemia (Table 3.7) 
 
The β2-specific agonist formoterol, caused a significant increase in CF, AO and CO during 
reperfusion, when compared with the functional performance of NPC hearts. However, the β1-
AR antagonist, CGP-20712A (300 nM) and β2- ARs agonist, formoterol (1 nM) when applied in 
combination to hearts prior to regional ischaemia had no significant effect on any of the 
haemodynamic parameters during reperfusion, when compared with formoterol alone.  
 
 
Table 3.7:   Effect of β1-AR inhibition (CGP-20712A) and β2-AR stimulation (formoterol)  
                    on mechanical recovery during reperfusion after 35 min coronary artery  
                    ligation 
 
 
 β1-AR antagonist: CGP-20712A + β2-AR agonist: formoterol  
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC   
Before RI  (n=18) 
15.56±0.23 43.78±0.87 59.90±0.91 266±6.28 97.24±1.30 12.88±0.23 
NPC 
After RI 
10.25±0.90 
# 
7.250±1.01 
#  
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
# 
 
      # P< 0.001 vs NPC before RI 
 
 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+Formoterol 
After RI  (n=6) 
15.58±0.40 
 
29.00±3.09 
 
45.00±3.23 
 
251±7.40 92.17±2.07 9.637±0.52 
 
       
NPC+ 
CGP-20712A +  
formoterol 
After RI  (n=6) 
14.34±2.66 20.00±4.12 34.33±6.74 227±47.51 76.50±15.48 7.10±1.47 
 
p<0.001 vs NPC After RI 
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3.2.5 b   The effect of the β1-AR  antagonist (CGP-20712A) on infarct size after  
                 preconditioning with formoterol (Fig. 3.12) 
 
Preconditioning with formoterol (β2-PC), significantly reduced the IS of NPC hearts 
(20.74±1.43%, p<0.001 vs NPC). The application of the β1-ARs antagonist, CGP-20712A in 
combination with formoterol prior to RI, caused a slight but significant increase in IS, thus 
negatively affecting the β2-AR mediated cardioprotective effects (32.55±0.92%, p<0.01 vs 
formoterol). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.12:   The effect of the β1-AR antagonist (CGP-20712A) and β2-AR stimulation 
                    with formoterol on infarct size 
Infarct size
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3.2.6   The role of PTX sensitive Gαi/o proteins in β-adrenergic 
           preconditioning  
 
3.2.6 a   The effectiveness of Gαi/o inhibition (Table  3.10 A and B) 
 
Effectiveness of Gαi/o inhibition with PTX (30 µg kg-1) was assessed by determining its ability 
to block the bradycardia response associated with carbachol, a muscarinic / cholinergic receptor 
agonist. Administration of carbachol (1 µM) for 5 min caused a 51-52 % reduction in CF, AO, 
CO and heart rate of untreated control hearts. PTX treatment significantly decreased the 
negative inotropic and chronotropic effects of carbachol (% change: AO 22; CO 19; heart rate 
21), with no change in PSP and total work.   
 
 
Table 3.8 A:  The haemodynamic parameters before and 5 min after application of 
                       carbamylcholine chloride / carbachol to isolated rat hearts 
 
 
 
Muscarinic / cholinergic receptor agonist: carbachol (1 µM) (n=3) 
 
Total perfusion 
time (min) 
CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
15 min WH 17.33±0.66 40.67±4.05 58.00±4.61 232.00±22.85 98.33±2.96 12.63±1.12 
       
20 min WH+ 
Carbachol 
8.50±0.50 
∗ 
20.00±2.30¥ 28.50±2.75 
¥ 
112.00±2.88 
δ 
114.3±2.33 
δ 
7.45±0.63 
δ 
 (51 %) (51 %) (51 %) (52 %)   
25 min WH+ 
washout 
16.67±0.66 40.00±3.46 56.67±4.05 203.00±12.74 100.00±3.00 12.69±1.23 
 
∗ p<0.001 vs 15 min WH as well as 25 WH+washout 
 
¥ p<0.01 vs 15 min WH as well as 25 WH+washout 
 
δ p<0.05 vs 15 min WH as well as 25 WH+washout 
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Table 3.8 B:  The hemodynamic parameters before and 5 min after the application of  
                       carbachol to isolated hearts taken from rats pretreated with PTX                      
 
Muscarinic / cholinergic receptor agonist: carbachol (n=4) 
  
Total perfusion 
time (min) 
CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
PTX+15 min WH 16.50± 0.50 34.00±0.81 50.50±0.95 241.00±9.00 95.00±1.05 10.69±0.29 
       
PTX+20 min 
WH+ Carbachol 
14.88±0.65 26.50±0.95 40.88±1.32 190.00±10.91 97.00±1.78 9.06±0.32 
  (22 %) (19 %) (21 %)   
PTX+25 min 
WH+ washout 
16.00±0.00 24.00±4.89 40.00±4.89 222.00±20.00 94.50±3.06 8.79±0.91 
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3.2.6 b   The involvement of the Gαi/o protein in β2-PC with formoterol  
               (Table  3.9) 
 
The involvement of the Gαi/o regulatory protein in the specific actions of the selective β2-ARs 
agonist, formoterol was assessed 48 hours after PTX (30 µg kg-1) pretreatment. Results show 
that haemodynamic parameters recorded after the application of formoterol for 5 minutes did 
not differ significantly from values recorded prior to, or after formoterol treatment (compare 
Table 3.2). 
 
 
Table 3.9:  The haemodynamic parameters of isolated hearts taken from rats pretreated  
                  with PTX (30 µg kg-1) before and after 1, 3 and 5 min β2-AR stimulation with 
                  formoterol  
 
 
β2-AR agonist: formoterol (n=4) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
PTX+5 min 
WH 
16.67±0.66 37.33±1.33 54.00±2.00 261.00±13.80 95.33±1.45 11.43±0.30 
       
PTX+1 min 
WH+ 
Formoterol 
18.67±0.66 41.33±1.33 60.00±2.00 241.00±29.36 98.67±1.20 13.22±0.35 
       
PTX+3 min 
WH+ 
Formoterol 
20.67±1.76 42.67±1.33 63.33±2.90 264.00±11.67 99.00±1.15 13.96±0.59 
       
PTX+5 min 
WH+ 
Formoterol 
21.33±1.33 42.67±1.33  64.00±2.30 261.00±5.66 98.00±1.73 13.90±0.41 
 
PTX+5 min 
WH+ 
Washout 
17.33±0.67 36.00±0.00 53.33±0.66 263.00±17.04 94.33±1.85 11.03±0.10 
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3.2.7 a   The role of PTX sensitive Gαi/o protein in β1/β2-PC and β2-PC 
              (Table  3.10) 
 
 
Experimental protocols were applied 48 hours after treatment with pertussis toxin. 
Haemodynamic parameters were recorded at the end of the 15 minute working heart mode prior 
to regional ischaemia and compared with haemodynamic parameters and infarct size at the end 
of reperfusion. As shown previously, the AO, CO and total work of NPC hearts after regional 
ischaemia and 30 minutes reperfusion were significantly lower than those from hearts exposed to 
β1/β2-PC. PTX pretreatment had no affect on any of the haemodynamic parameters of NPC 
hearts or hearts exposed to β1/β2-PC. In contrast, PTX pretreatment significantly reduced AO, 
CO and total work of hearts exposed to β2-AR stimulation with formoterol (β2-PC), suggesting a 
role for the Gαi/o protein in β2-AR-induced cardioprotection. 
 
 
 
Table 3.10:   The effect of PTX sensitive Gαi/o protein inhibition on mechanical recovery of  
                       hearts exposed to β1/β2-PC (ISO) or β2-PC (formoterol) 
 
  
β1/β2-PC: Isoproterenol 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC   
Before RI  (n=18) 
15.56±0.23 43.78±0.87 59.90±0.91 266±6.28 97.24±1.30 12.88±0.23 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
# 
β1/β2-PC   
Before RI  (n=18) 
15.97±0.15 40.39±1.19 56.11±1.33 252±8.01 98.25±1.28 12.40±0.34 
β1/β2-PC   
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
# P< 0.05 vs β1/β2-PC After RI 
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Table 3.10:   (continued) 
 
 
PTX (30 ug/kg, i.p., 48 hrs prior to isolation) + β1/β2-PC (Isoproterenol) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+PTX  
After RI  (n=6) 
11.33±2.46 11.25±3.06 
 
23.25±5.23 
 
224±47.57 69.90±13.9 4.70±1.17 
       
β1/β2-PC+PTX  
After RI  (n=6) 
14.75±0.55 20.92±2.59 
 
35.67±3.03 261±11.42 88.17±1.36 6.99±0.66 
 
 
 
β2-PC: Formoterol  
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
β2-PC After RI  
(n=6) 
15.58±0.40 
 
29.00±3.09 
 
45.00±3.23 
 
251±7.40 92.17±2.07 9.637±0.52 
 
 
p<0.001 vs NPC After RI 
 
 
PTX (30 ug/kg, i.p., 48 hrs prior to isolation) + β2-PC (Formoterol)  
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+PTX  
After RI  (n=6) 
11.33±2.46 11.25±3.06 
 
23.25±5.23 
 
224±47.57 69.90±13.9 4.70±1.17 
       
NPC+PTX + β2-PC       
After RI  (n=6) 
13.83±0.83 15.00±2.13 
¥ 
28.93±2.48 
¥ 
250±3.76 88.35±2.02 6.30±0.45 
ε 
 
¥p<0.01 vs β2-PC After RI 
 
ε p<0.001 vs β2-PC After RI 
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30 µg kg-1 Ptx, i.p. 48 hr prior to Exp Infarct size
3.2.7 b  The effect of PTX sensitive Gαi/o protein inhibition on infarct size of  
              hearts exposed to β1/β2-PC and β2-PC (Fig. 3.13) 
  
NPC hearts show the characteristic large IS (40.24±2.36%), whereas the IS of hearts exposed to 
β1/β2-PC was significantly reduced (23.20±1.29%, p<0.001 vs NPC). The IS of NPC hearts 
treated with the β2-AR agonist, formoterol (β2-PC) was significantly reduced (20.65±0.82% 
p<0.001 vs NPC) compared to those of NPC hearts. PTX had no effect on the IS of NPC hearts 
(PTX+NPC group), NPC hearts treated with formoterol (PTX+NPC+Formoterol group) or 
β1/β2-PC hearts (PTX+ β1/β2-PC group).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.13:  The effect of PTX sensitive Gαi/o protein inhibition on infarct size of  
                  hearts exposed to β1/β2-PC and β2-PC  
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3.2.8 a   The involvement of PKA in β-adrenergic preconditioning 
              (Table 3.11) 
 
The role of PKA activation in the cardioprotection elicited by β1/β2-PC with isoproterenol, was 
evaluated by using the specific PKA inhibitor, Rp-8-CPT-cAMP (16 µM). Rp-8-CPT-cAMP, 
when applied either prior to (trigger phase) or after regional ischemia / at the onset of 
reperfusion, had no effect on mechanical performance of NPC hearts, while it significantly 
reduced the AO, CO and total work of β1/β2-PC hearts. 
 
 
Table 3.11:  Effects of PKA inhibition prior to RI or during reperfusion on mechanical  
                   recovery of hearts exposed to β1/β2-PC  
 
 
(A)  β1/β2-PC: Isoproterenol (0.1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC   
Before RI  
( n=12) 
15.20±0.38 42.40±0.67 56.35±0.68 270±3.85 102.5±1.53 13.00±0.34 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
# 
β1/β2-PC     
Before RI 
( n=12) 
15.96±0.21 40.00±1.06 56.15±1.07 260±8.45 102.90±1.92 13.09±0.44 
β1/β2-PC     
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
 # P< 0.05 vs β1/β2-PC After RI 
 
 
(B)  PKA inhibitor: Rp-8-CPT-cAMPS (Trigger) (16 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+Rp-8CPT   
After RI  (n=6) 
7.75±2.52 10.13±3.58 17.75±6.02 177±56.67 61.75±19.42 3.84±1.35 
       
β1/β2-PC + Rp-
8CPT  
After RI  (n=6) 
7.25±2.33 6.16±2.85 
Փ 
14.51±5.03 
Փ 
209±68.04 61.00±19.67 2.89±1.18 
Փ 
 
Փ P< 0.05 vs β1/β2-PC After RI 
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Table 3.11:  (continued) 
 
 
(C) PKA inhibitor: Rp-8-CPT-cAMPS (Reperfusion) (16 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+Rp-8CPT  
After RI  (n=6) 
9.50±1.96 7.66±2.23 17.17±3.87 215±43.54 74.80±15.27 3.47±0.77 
       
β1/β2-PC + Rp-
8CPT  
After RI  (n=6) 
8.667±1.90 6.75±3.34 
€ 
15.42±4.76 
€ 
254±53.61 72.10±14.51 2.61±1.10 
€ 
 
€ P< 0.05 vs β1/β2-PC After RI 
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3.2.8 b   The effect of PKA inhibition on infarct size of hearts exposed to  
                 β1/β2-PC (Fig. 3.14) 
 
β1/β2-PC significantly decreased IS (22.75±1.23%, p<0.001) compared to NPC hearts 
(42.04±1.63). The PKA inhibitor, RP-8-CPT-cAMP applied prior to regional ischaemia in the 
βPC+RP group (35.74±1.40%, p<0.001 vs β1/β2-PC) or at the onset of reperfusion, the β1/β2-
PC + RP R10 group (32.55±2.92%, p<0.01 vs β1/β2-PC) significantly increased IS and 
consequently decreased the protective effect of β1/β2-PC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.14:  The effect of the
 
PKA inbibitor (RP-8-CPT-cAMP) on infarct size in β1/β2-PC 
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3.3   Discussion 
 
The most significant observations made in this section were the following: (i) β-PC can be elicited 
via stimulation of either β1- or β2-, but not β3-AR receptors; (ii) β-PC can be blocked by either β1- or 
β2-AR blockade; (iii) β3-AR blockade appears to be cardioprotective, while a combination of β1/β2-
PC and β3-AR blockade augments protection and (iv) demand ischaemia is not involved in the 
reduction of necrosis, but in attenuating stuning. 
 
3.3.1   The role of β-adrenergic receptors in the cardioprotective effects of  
            β-adrenergic  preconditioning (β-PC) 
 
It is well established that in the heart, β-AR stimulation by catecholamines (norepinephrine and 
epinephrine) serves as a powerful regulatory mechanism to maintain excitation contraction coupling 
(ECC) in normal functioning hearts and to enhance cardiac performance in response to stress, injury 
or exercise [Lohse et al., 2003; Hata et al., 2004]. Stimulation of β2-AR but not β1-AR activates Gi 
proteins in adult rat cardiomyocytes [Zheng et al., 2004], while both β-AR subtypes are able to 
stimulate the classic / traditional Gs-AC-cAMP-PKA signaling pathway [Xiao et al., 1995; Daaka et 
al., 1997; Kilts et al., 2000]. β1-AR activated stimulation of the Gs-adenylyl cyclase-cAMP-PKA 
pathway, can be disseminated throughout the cell, whereas β2-AR-evoked cAMP signaling is 
spatially and functionally compartmentalized, due its attachment to Gi protein [Xiao and Lakatta, 
1993; Kuschel et al., 1999; Xiao, 2001]. Thus, Gi coupling can qualitatively and quantitatively 
modify the outcome of Gs signaling.  
 
While recognizing the significance of long-term or chronic β1-AR and β2-AR stimulation and the 
concomitant signaling pathways, in the development of various aetiologies of heart failure, it is 
reasonable to believe that the selective down-regulation of β1-ARs and the up-regulation of β2-AR-
Gi signaling in the failing heart, elicit opposing effects on survival of cardiomyocytes and may 
represent cardiac adaptive mechanisms to protect myocytes against apoptosis and consequent 
contractile dysfunction. The results obtained in the present study demonstrated how transient 
activation of either β1-AR or β2-AR elicits cardioprotection against a long subsequent period of 
sustained ischaemia, similar to that induced by ischaemic preconditioning. 
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In an attempt to determine the trigger of cardioprotection elicited by β-AR stimulation, it was argued 
that isoproterenol, a potent β1/β2-AR agonist, causes demand or supply ischaemia and that its 
mechanism is, in fact, similar to that of ischaemic preconditioning. Within the first min of 
isoproterenol, CF, AO and HR were significantly increased, while stroke volume remained 
unchanged. During the remainder of administration period, a progressive decline in stoke volume 
occurred, despite unchanged coronary flow (Table 3.3). The significance of these events is 
supported by the fact that the combination of isoproterenol and the β3-AR agonist, BRL 37244, 
which abolished the positive inotropic effect of isoproterenol alone, led to an increase in infarct size.  
 
However, β3-AR per se reduced AO and CO, without cardioprotection. In addition, transient 
stimulation of the β2-AR with formoterol was equally effective in eliciting cardioprotection, while 
having no effect on the contractile behaviour of the heart during the 5 min period of administration 
(Table 3.2). It therefore appears unlikely that transient changes in contractile behaviour of the heart 
during administration of the β-adrenergic receptor agonist and possible development of ischaemia 
trigger the process. Unfortunately tissue high energy phosphates were not measured at the end of 5 
minute isoproterenol administration. The significant activation of PKB/Akt and ERK p44/p42 
MAPK seen at this stage as reported recently (Fig. 4.4 A and B) also confirm the absence of 
ischaemia, since it is well-established that activation of these kinases does not occur during an 
ischaemic episode.  
 
Thus far, several studies indicated the involvement of the β1-AR in cardioprotection: (i) propanolol 
(non-selective β-blocker) abolished protection, while the selective β2-AR blocker ICI 118551 had no 
effect [Frances et al., 2003]; (ii) the specific β1-adrenergic agonist xamoterol could elicit protection 
against  ischaemia, which was abolished by atenolol [Robinet et al., 2005]; (iii) hypoxic 
preconditioning was attenuated by a selective β1-selective blocker, metoprolol [Mallet et al., 2006]; 
(iv) pharmacological preconditioning with desflurane and sevoflurane was shown to be dependent 
on β1-AR activation, since it could be blocked by esmolol and H-89, a blocker of PKA [Lange, 
2006]. Although the role of β1-AR in cardioprotection may be questioned, in view of its well- 
established effects on necrosis and apoptosis, the period of administration during a β-AR 
preconditioning protocol is probably too short to elicit such harmful effects. 
 
β1-AR induces hypertrophy and apoptosis via the time dependent β1-AR signaling switch from PKA 
to Ca2+ / calmodulin-dependent kinase II (CAMK II) dominant pathway which is independent of 
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the classic cAMP-PKA pathway [Communal et al., 1999; Zaugg et al., 2000]. The CaMK II 
pathway may be clinically relevant, since inhibition thereof is a potential target to prevent adverse 
cardiac remodeling, particularly myocyte hypertrophy and apoptosis in the context of enhanced β1-
AR signaling. The results obtained in the present study suggest a role for PKA both during the 
triggering and mediating phases (Fig. 3.14), but the involvement of CAMK II still needs to be 
determined. On the other hand, the β2-AR promotes cell survival via the PKA-dependent β2-AR 
phosphorylation switch from Gs to Gi protein coupling [Daaka et al., 1997; Zou et al., 1999], which 
minimizes the receptor mediated inotropic response while enhancing the cardioprotective effects 
mediated by a signaling pathway involving Gi, Gβγ, PI3K and PKB/Akt [Zhu et al., 2001]. 
 
The results obtained using either isoproterenol plus β2-AR blockade or the specific β2-AR agonist, 
formoterol hemifumarate suggest a definite role for the β2-AR in β-AR cardioprotection, since the 
selective β2-AR antagonist ICI-18851 completely abolished isoproterenol-induced cardioprotection 
(Fig. 3.11 B). This drug has a high degree of specificity and selectivity for the β2-AR (Ki 2.0±0.4 
nM, β2/1 selectivity ratio 123:1) [Bristow et al., 1986] and was used at a concentration of 50 nM in 
the present study, similar to that used by several others [Communal et al., 1999; Kaumann, et al., 
1996].   
 
The significance of the β2-AR in β-AR preconditioning was confirmed by using the potent, selective 
and long-acting β2-AR agonist formoterol hemifumarate which has a 330 fold selectivity for β2- over 
β1- receptors [Anderson, 1993; Naline, 1994]: transient administration of this drug elicited the same 
reduction in infarct size as isoproterenol, while significantly improving mechanical performance 
during reperfusion (AO during RI (ml/min) isoproterenol: 18.00±2.78; formoterol: 29.00±3.09) 
when compared to isoproterenol (Table 3.4 and Fig 3.10 A). A role for the β2-AR in preconditioning 
was further confirmed by the finding that hearts of β2-receptor knockout mice could not be 
preconditioned [Tong, 2005]. 
 
Interestingly, simultaneous administration of isoproterenol and formoterol hemifumarate did not 
have additive effects, suggesting a similar mode of action.  Despite using a high-specificity β2-AR 
agonist, formoterol hemifumarate, simultaneous administration of the β1-AR antagonist CGP-
20712A, partially attenuated the beneficial effects of formoterol on infarct size (Fig. 3.12), but not 
on functional recovery (Table 3.7). 
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This is probably due to the presence of endogenous catecholamines in our preparation and should be 
investigated further. Previous studies on the role of β1- and β2-AR subtypes in preconditioning were 
done on reserpinized animals or after treatment with β-hydroxydopamine to eliminate the effects of 
the endogenous catecholamines [Frances et al., 2003; Robinet et al., 2005]. 
 
3.3.2   Role of the Gi proteins in β-AR preconditioning 
 
Contrary to expectations, our results showed that the cardioprotective actions of isoproterenol 
(β1/β2-PC) were not mediated via the PTX sensitive Gi regulatory protein (Table 3.10 and Fig. 
3.13). It is well established that the β1-AR exerts its effects via the Gs protein. In view of the 
preponderance of this receptor subtype compared to the β2-AR, it is possible that stimulation of the 
β1-AR by isoproterenol overrides the effects of Gi inhibition and still causing cardioprotection. 
 
In the case of formoterol (β2-PC), pretreatment with PTX yielded interesting results namely that 
although the infarct size remained unchanged, the parameters of functional recovery were 
significantly reduced, suggesting that the Gi protein does contribute to β2-AR preconditioning 
(Table 3.9 and Fig. 3.13). Another possibility is that the Gi protein is not involved in tissue necrosis, 
but does affect stunning during reperfusion. The dosage of PTX was proven to be sufficient, since it 
could significantly attenuate the effects of carbachol in our model (Table 3.8). 
  
Results reported on the effects of the Gi proteins in cardioprotection are contradictory. Many studies 
support a role for this regulatory protein in cardioprotection, for example (i) it was shown in the 
isolated rat heart that pretreatment with PTX completely abolished the cardioprotective effects of 
ischaemic preconditioning [Schultz et al., 1998]. 
(ii) the Gi/o protein is a crucial component in the cardioprotection of hypoxic preconditioning in 
neonatal rat cardiomyocytes [Chen and Xia, 2000]. 
(iii) β2-AR preconditioning, could be blocked by PTX pretreatment [Oldenberg et al., 2002; Tong et 
al., 2004]. It was also reported that PKA inhibition blocked the protection of preconditioning and 
isoproterenol, consistent with the role of PKA in the switching of β2-AR coupling from Gs to Gi 
[Tong et al., 2005]. 
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However, in contrast to the above, it has also been reported that ischaemic preconditioning in the rat 
heart does not to involve the PTX sensitive regulatory Gi protein [Downey et al., 1993; Piacentini et 
al., 1995]. Furthermore, Frances and coworkers (2003) could not show involvement of the β2-AR in 
β-PC, since they found that β2-AR blockade did not abolish isoproterenol-induced preconditioning. 
These controversial findings are probably due to differences in the protocols since they used a much 
higher ICI-18851 concentration than us (2 µM vs 50 nM) combined with a lower isoproterenol 
concentration (20 nM) in reserpinised animals.  Clearly more work is required to solve these 
controversies. 
 
It should be borne in mind that the type and duration of the β-AR stimulation ultimately determines 
the signaling cascade and cardioprotective response obtained, i.e. acute β-AR stimulation such as β-
PC will differ markedly from chronic β-AR stimulation which eventually enhance and develop into 
CHF. In the scenario of β-AR preconditioning, stimulation of the receptor (β1- or β2-AR) is short 
lived and transient and the signaling patterns will differ from those of chronic β-AR stimulation. 
 
Finally, although the results obtained are strongly suggestive of major involvement of the β2-AR, 
subsequent studies using specific β1-AR agonists, denopamine and xamoterol hemifumarate showed 
that specific activation of the latter receptor is equally effective in producing cardioprotection [Salie 
and Lochner, unpublished observations]. In view of these observations, it was decided to use 
isoproterenol as agonist in all subsequent studies in which the mechanism of protection was 
investigated. Studies evaluating the mechanism of β2-AR stimulation are currently in progress. 
 
 
3.3.3   What happens downstream of the β-AR ?  A role for PKA  
 
PKA has been implicated to be an important role player in agonist-induced receptor desensitization 
and down-regulation [Benovic et al., 1988]. PKA-dependent β1-AR phosphorylation promotes 
receptor desensitization, whereas PKA-dependent β2-AR phosphorylation switches the receptor G 
protein coupling from Gs to Gi [Daaka et al., 1997] which reduces the receptor-mediated intropic 
response while enhancing its cardioprotective effect during chronic β-AR stimulation. 
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Previous studies from our laboratory showed that ischaemic preconditioning as well as treatment 
with forskolin or isoproterenol rapidly and transiently increase tissue levels of cAMP and PKA 
activation prior to sustained ischemia [Lochner et al., 1999; Makaula and Lochner, 2005]. This in 
turn leads to desensitization of the β-AR and subsequent protection against ischaemic damage 
[Lochner et al., 1999]. In the present study, it was illustrated that the selective PKA blocker, Rp-8-
CPT-cAMP administered prior to sustained ischemia or at the onset of reperfusion completely 
abolished the cardioprotective effect of β1/β2-PC, in both instances, suggesting that PKA is an 
essential component in β1/β2-PC induced cardioprotection (Table 3.11 and Fig. 3.14). Unfortunately 
the effect of PKA inhibition was not studied in the case of β2-PC, which does not allow for 
distinction of the role of this kinase in each receptor subtype.  
 
It is also possible that the rapid activation of PKA which occurs during a preconditioning protocol, 
causes a Gs to Gi switch in the case of the β2-agonist formoterol, explaining the lack of a positive 
inotropic response observed with this drug (Table 3.11). 
 
The mechanism whereby PKA activation during a preconditioning protocol elicits protection as well 
as downstream events remains to be established.  Possible mechanisms of PKA action include (i) 
calpain inhibition, resulting in reduced hydrolysis of structural proteins, reduced sarcolemmal 
fragility and less cell death [Inserte et al., 2004] (ii) increased HSP27 activation [Marais et al., 2005] 
(iii) phospholamban phosphorylation, causing increased SR Ca2+ uptake and a reduction in cytosolic 
Ca2+ [Sichelschmidt et al., 2003] (iv) inhibition of the small GTPase RhoA and its downstream Rho-
kinase.  The latter kinase is known to enhance cardiac damage in acute ischaemia [Sanada et al., 
2004; Dong, Leung and Manser, 1998; Shimokawa, 2002] and Sanada and coworkers (2004) 
suggested that transient pre-ischaemic activation of PKA reduces infarct size through Rho-kinase 
inhibition.  It is also possible that, both in the case of β1-and β2-AR preconditioning, PKA activation 
leads to switching their coupling from Gs to Gi and activation of ERKp42/p44, as has been 
demonstrated by Martin and coworkers [Martin et al., 2004].  
 
Interestingly administration of the inhibitor during the first 10 min of reperfusion of β1/β2-AR 
preconditioned hearts also abolished the beneficial effects of prior preconditioning, while having no 
effect on the NPC hearts (Fig. 3.14).  As far as we know, this is the first demonstration of the 
significance of PKA activation during reperfusion of β-AR preconditioned hearts, the mechanism of 
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which remains to be determined. It may occur via its cross-talk with PKB/Akt contributing to 
activation of the RISK pathway, which is also characteristic of β-AR preconditioning (see chapter 
5). It is also possible that PKA activation during reperfusion elicits protection by inhibition of GSK-
3beta which, in turn, limits the induction of mitochondrial permeability transition [Juhaszova et al., 
2004]. The finding that short-term PKA inhibition during reperfusion has no effect on infarct size of 
NPC hearts is in contrast to the findings in rabbits using H89 [Lange et al., 2009]. 
 
3.3.4   Cardioprotection of β-PC does not involve β3-AR  
 
The role of the β3-AR in the cardiovascular system remains controversial. However, increasing 
evidence suggest that it acts as a brake in sympathetic overstimulation [Moens et al., 2010]. Unlike 
the stimulation of β1-AR and β2-AR subtypes, the activation of β3-AR leads to negative regulation of 
cardiac contractility via the Gi-coupled signaling [Gauthier et al., 1996], increased NO production 
and an increase in intracellular cGMP levels [Moens et al., 2010]. β3-AR - induced NO production 
was initially linked to eNOS [Gauthier et al., 1998], but recent data indicate that these receptors can 
also modulate NO production via nNOS and iNOS [Maffei A et al., 2007]. 
 
To delineate the contribution of the β3-AR to isoproterenol - induced cardioprotection, use was made 
of the β3-AR antagonist SR 59230A and agonist BRL 37344, respectively. This study illustrated that 
the selective β3-AR agonist, BRL 37344 significantly reduced haemodynamic parameters after 1 to 
5 minutes application, which returned to baseline values after 5 minutes washout (Table 3.3), 
demonstrating the presence and negative inotropic nature of the β3-AR in the rat myocardium. This 
agonist was capable of completely reversing the immediate positive inotropic and chronotropic 
effects of isoproterenol (Table 3.4 C) and explains why BRL 37344 abolished the cardioprotective 
effects of isoproterenol, as shown by the significant increased infarct size (Fig. 3.10 B). 
 
As expected, the results showed that the selective β3-AR antagonist, SR 59230A, applied prior to 
sustained ischaemia, had no effect on haemodynamic parameters or the infarct limiting capabilities 
of β1/β2-PC (Table 3.6 D and Fig. 3.11 C), suggesting that this receptor is not involved in 
isoproterenol – induced cardioprotection. Interestingly, NPC hearts exposed to SR 59230A per se 
displayed similar contractile recovery as β-PC hearts, as well as a significant reduction in infarct 
size (Table 3.6 D and Fig. 3.11 C). However, the exact mechanism whereby this is accomplished 
needs to be determined. It is known that the β3-AR functions as a negative inotrope which is 
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activated only after extended periods of exposure to higher levels of catcholamines [Lafontan et al., 
1994]. Activation of this receptor during transient stimulation of the β1-AR and β2-AR as occurs 
during a preconditioning protocol is therefore unlikely to occur. In summary, the results presented in 
this chapter indicate roles for the β1- as well as the β2-AR in cardioprotection, while β3-AR is not 
involved. 
 
 
3.3.5   The correlation between measured endpoints:  infarct size and  
 
           functional recovery  
 
The results obtained stress the significance of the endpoint used in the interpretation of the data and 
suggest that use of one endpoint only could yield misleading interpretations. Reduction in infarct 
size is regarded by many researchers as the “gold standard” for evaluation of the effects of 
preconditioning, but this is not always associated by improvement in mechanical recovery during 
reperfusion due to concomitant stunning [Cohen et al., 1999; Lochner et al., 2003].  
 
In the present study the reduction in infarct size β1/β2-AR preconditioned hearts was associated 
with a significant increase in functional recovery. This could be an indication of the efficacy of β-
adrenergic preconditioning, demonstrating that the protection afforded by this intervention was 
sufficient to override the effects of stunning (Table 3.1; 3.2 and 3.3).  However the opposite was 
also observed namely that a reduction in postischaemic function was not necessarily associated with 
an increase in infarct size (Tables 3.5 and 3.10). A possible explanation is that measurement of 
infarct size is perhaps not sensitive enough to pick up relatively small changes in infarct size or that 
the intervention used (e.g. pertussis toxin pretreatment) was without effect on necrosis, while 
attenuating the beneficial effects of the intervention on stunning, leading to a further reduction in 
functional recovery. Nevertheless, the data suggest that care should be exercised when final 
conclusions regarding the effects of interventions are based on results obtained from one endpoint 
only. 
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Chapter 4 
 
Investigating the role of the prosurvival kinases, PKB/Akt and ERK p44/p42 
MAPKinase in β-adrenergic preconditioning  
 
However, it is well established that the (PI3K) PKB/Akt and ERK p44/p42 MAPK signaling 
cascades are activated in response to the stimulation of a wide range of receptors, including 
those for growth factors (RTK) and GPCRs [Widmann et al., 1999]. Activation of these 
signaling cascades prior to lethal ischaemia has been shown to be associated with ischaemic 
preconditioning induced cardioprotection [Tong et al., 2000; Fryer et al., 2001]. In addition, it 
has also been shown that ischaemic preconditioning protects the heart by phosphorylating the 
prosurvival kinases PKB/Akt and ERK p44/p42 MAPK, during early reperfusion [Hausenloy et 
al., 2004]. Pharmacological manipulation and up-regulation of these pro-survival kinases, which 
are also referred to as the Reperfusion Injury salvage Kinases (RISK), as an adjunct to 
reperfusion may protect the myocardium from reperfusion-induced cell death and provide a 
novel approach to salvage viable myocardium and limit infarct size [Hausenloy and Yellon, 
2004].  
 
The involvement of these prosurvival kinases in β-adrenergic preconditioning has not yet been 
studied. Thus the aim of this study was to establish the involvement of these kinases prior to 
sustained ischaemia as well as at the onset of reperfusion in the context of β-adrenergic 
preconditioning. The PI3K inhibitor, wortmannin and the MEK inhibitor, PD 98,059 were used 
to achieve these objectives. 
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4.1   Methods 
 
4.1.1   Investigation of the expression of total and phosphorylated PKB/Akt 
            and ERK p44/p42 MAPKinase during β1/β2-PC (Fig. 4.1) 
 
To establish the involvement of PKB/Akt and ERK p44/p42 MAPKinase during the 
preconditioning protocol prior to sustained ischaemia, β1/β2-PC hearts were freeze-clamped 
immediately after 5 min application of isoproterenol (0.1 µM). In another group, β1/β2-PC 
hearts were freeze-clamped after 1.5 min, 3 min and 5 min of washout prior to sustained 
ischaemia and analysed using Western blot analysis for total and phosphorylated PKB/Akt and 
ERK p44/p42 MAPKinase. 
 
 
Experimental protocol: (Fig. 4.1) 
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4.1.2   The effect of PI3-Kinase / PKB/Akt and ERK p44/p42 MAPKinase on 
            functional recovery and infarct size in β1/β2-PC (Fig. 4.2 A and B) 
 
Non-preconditioned hearts were subjected to a 30 minute stabilization period followed by a 30 
minute perfusion in the working heart mode, 35 min regional ischaemia and reperfusion. After 
50 min of stabilization, β1/β2-PC hearts were preconditioned with isoproterenol (0.1 µM) for 5 
minutes followed by a washout episode of 5 min, 35 min regional ischaemia and reperfusion (as 
described in chapter 2).  
 
The PI3-Kinase inhibitor, wortmannin (final concentration 100 nM) or the MEK inhibitor, PD 
98,059 (final concentration 10 µM) was dissolved in DMSO, the concentration of which was 
less than 0.00023 % vol/vol in the Krebs-Henseleit buffer. These inhibitors were applied in 
Krebs-Henseleit buffer to the NPC hearts for 10 minutes, followed by a 5 min washout episode 
prior to 35 min regional ischaemia and reperfusion (Fig. 4.2 A). 
 
In the case of β1/β2-PC hearts, the inhibitors were administered for 10 min while isoproterenol 
(0.1 µM) was added to the perfusate for the last 5 min. This was followed by a 5 min washout 
episode, 35 min regional ischaemia and reperfusion (Fig. 4.2 A). In a separate group of 
experiments, wortmannin or PD 98,059 was applied at the onset of reperfusion for a period of 5 
min. Haemodynamic parameters were recorded at the end of the 15 minute working heart mode 
prior to regional ischaemia and compared with haemodynamic parameters and infarct size at the 
end of reperfusion (Fig. 4.2 B). 
 
Experimental protocol: (Fig. 4.2 A) 
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Experimental protocol: (Fig. 4.2 A) (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental protocol: (Fig. 4.2 B) 
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4.1.3   Investigation of the expression of total and phophorylated PKB/Akt  
            and ERK p44/p42 MAPKinase in β1/β2-PC during early reperfusion  
            using Western blot analysis (Fig. 4.3) 
 
Non-preconditioned hearts were subjected to a 30 minute stabilization period followed by a 30 
minute retrograde perfusion, 25 minutes global ischaemia, followed by freeze- clamping after 5 
minutes reperfusion. β1/β2-PC hearts were preconditioned with isoproterenol (0.1 µM) for 5 
minutes followed by a washout episode of 5 min, 25 min global ischaemia and freeze-clamping 
after 5 min reperfusion. Freeze-clamped hearts were analysed using Western blot analysis for 
total and phosphorylated PKB/Akt and ERK p44/p42 MAPKinase. In addition, hearts were 
treated with wortmannin or PD 98,059, as outlined in 4.1.2, freeze-clamped after 5 min 
reperfusion and processed as described above. 
 
Experimental protocol: (Fig. 4.3)              
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4.2   Results 
 
4.2.1   Western blot analysis of total and phosphorylated PKB/Akt and ERK 
           p44 / p42 MAPKinase after β1/β2-PC and during the washout episode  
           (WO)  (Fig. 4.4 A and B) 
 
Expression of total PKB/Akt was similar at all time intervals studied. Western blot analysis for 
phosphorylated PKB/Akt of hearts subjected to β1/β2-PC illustrated a significant increase of 
this kinase at the end of 5 min administration of isoproterenol (0.1 µM) (fold increase: 
3.47±1.12, p<0.001 vs negative control). The activation of PKB/Akt remained significantly 
elevated at 1.5 min (4.45±0.25), 3 min (3.94±0.15) as well as after 5 min (3.93±0.36) washout 
prior to global ischaemia (Fig. 4.4 A), i.e. until the onset of sustained ischaemia. 
 
Similarly, Western blot analysis for phosphorylated ERK p44/p42 MAPKinase of hearts 
exposed to β1/β2-PC illustrated a significant increase in phosphorylated ERK p44 MAPKinase 
(2.46±0.17, p<0.001 vs negative control). Phosphorylated ERK p44 MAPKinase remained 
elevated at 1.5 min and 3 min washout, and increased even further after 5 min washout (fold 
increase: 3.50±0.20, p< 0.001 vs 1.5 min and 3 min washout, respectively) (Fig. 4.4 B). 
 
Even though, ERK p42 MAPKinase was less activated compared to p44 MAPKinase, the p42 
MAPKinase followed a similar trend after 5 min washout (fold increase: 2.77±0.08, p<0.01 vs 
1.5 min washout, p<0.05 vs 3 min washout, respectively) (Fig. 4.4 B). Expression of total ERK 
p44/p42 MAPKinase after β1/β2-PC, at 1.5 min, after 3 min as well as after 5 min washout did 
not differ significantly from negative control values, respectively (Fig. 4.4 B). 
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Fig. 4.4 A:   PKB/Akt activation after β1/β2-PC, as well as after 1.5 min, 3 min and 
                     5 min washout following β-adrenergic stimulation    
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Fig. 4.4 B:  ERK p44/p42 MAPKinase activation after β1/β2-PC, as well as after 1.5  
                    min, 3 min and 5 min washout following β-adrenergic stimulation 
Total ERK 
-Ve C BPC BPC 1.5 min     
WO
5min 
WO
3min  
WO
Co
ntr
ol
B1
/B2
-
PC
B1
/B2
-
PC
+1
.
5 W
O
B1
/B2
-
PC
+3
 
WO
B1
/B2
-
PC
+5
 
WO
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
 p<0.001 vs BPC
p44
p42
p<0.01 vs BPC


ϕ
ϕp<0.001 vs Control
ϕ
ϕ
ER
K 
Ac
tiv
at
io
n
 
(F
ol
d 
In
cr
ea
se
)
1.5; 3; 5 MIN  WASH OUT
5 MIN  ISO
Western blot analysis
 
Phospho-ERK p44 / p42 
 135 
 
4.2.2   The role of PKB/Akt and ERK p44 / p42 MAPKinase activation  
             on functional recovery of hearts exposed to β1/β2-PC 
           (Table 4.1 A and B) 
 
As was demonstrated in Chapter 3, preconditioning of hearts with isoproterenol (0.1 µM), 
caused a significant increase in AO, CO and total work during reperfusion, when compared 
with those of NPC hearts. The PI3-Kinase inhibitor, wortmannin (100 nM) applied prior to 
regional ischaemia (trigger phase) or at the onset of reperfusion of hearts exposed to β1/β2-PC, 
significantly reduced haemodynamic parameters such as CF, AO, CO and total work, 
illustrating a definite role for PI3-Kinase-PKB/Akt in the cardioprotective effects of β1/β2-PC 
during both the preconditioning protocol as well as early reperfusion (Table 4.1 A). In the same 
experimental setting, the MEK (ERK p44/p42 MAPK) antagonist, PD 98,059 applied prior to 
regional ischaemia (trigger phase) or at the onset of reperfusion of hearts exposed to β1/β2-PC, 
had no significant effect on any of the parameters of functional recovery during reperfusion of 
β1/β2-PC hearts (Table 4.1 B). 
 
 
Table 4.1 A:  Effects of PI3-K - PKB/Akt inhibition with wortmannin on mechanical  
                       recovery during reperfusion of β1/β2-PC hearts 
 
 
β-AR agonist: Isoproterenol (0.1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI  
14.67±0.55 42.00±0.77 55.30±1.41 270±5.41 104.1±2.10 13.27±0.49 
NPC 
After RI (n=6) 
10.25±0.90 
€ 
7.250±1.01 
* # 
19.01±1.02 
* # 
235±15.30 
€ 
86.80±2.13 
* 
3.61±0.22 
* #  
β1/β2-PC 
Before RI 
15.83±0.47 39.33±2.73 55.25±1.30 253±9.07 101.8±2.64 12.95±1.30 
β1/β2-PC 
After RI (n=6)                          
13.58±1.11 18.00±2.78 
 
31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
€p< 0.05 vs NPC Before RI 
*p< 0.001 vs NPC Before RI 
# p< 0.05 vs β1/β2-PC After RI 
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Table 4.1 A:  (continued) 
 
 
PKB/Akt inhibitor: Wortmannin (Trigger) (100 nM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI  
16.20±0.12 37.00±1.54 53.10±1.63 274.00±12.95 98.83±2.88 11.89±0.67 
NPC 
After RI (n=6) 
6.00±2.55 
* 
7.50±3.10 
* 
13.40± 5.63 
* 
144.00±60.69
* 
62.60±21.54
*  
3.62±1.12 
* 
β1/β2-PC 
Before RI 
16.10±0.12 40.00±1.67   56.00±1.67 254.00±16.23 102.20±2.51 12.79±0.47 
β1/β2-PC 
After RI (n=6) 
6.12±2.51 
# 
4.40±2.07 
€ 
10.40±4.28 
¥ 
129.00±54.64 37.07±19.09 2.51±1.04 
¥ 
 
*p< 0.001 vs NPC before RI 
 
# p< 0.05 vs β1/β2-PC After RI 
 
€ p< 0.001 vs β1/β2-PC After RI 
 
¥ p< 0.01 vs β1/β2-PC After RI 
 
 
PKB/Akt inhibitor: Wortmannin (Reperfusion) (100 nM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI  
15.40±0.24 41.00±0.63 55.20±0.58 282.00±13.41 101.00±2.33 12.64±0.27 
NPC 
After RI (n=6) 
5.40±2.35 
* 
3.20±1.94 
* 
8.50± 3.71 
* 
154.00±65.90
* 
48.19±19.79
*  
1.52±0.67 
* 
β1/β2-PC 
Before RI 
16.10±1.00 38.40±0.97 54.40±0.97 261.00±18.04 98.76±3.10 12.30±0.11 
β1/β2-PC 
After RI (n=6) 
6.30±2.70 
# 
4.30±2.26 
€ 
10.60±4.87 
¥ 
149.00±61.60 50.56±20.71 2.02±0.95 
¥ 
 
*p< 0.001 vs NPC before RI 
 
# p< 0.05 vs β1/β2-PC After RI                
 
€ p< 0.001 vs β1/β2-PC After RI 
 
¥ p< 0.01 vs β1/β2-PC After RI 
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Table 4.1 B:   Effects of MEK (ERK p44/p42 MAPK) inhibition with PD 98,059 on  
                        mechanical recovery during reperfusion of β1/β2-PC hearts 
 
β-AR agonist: Isoproterenol (0.1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI  
14.67±0.55 42.00±0.77 55.30±1.41 270±5.41 104.1±2.10 13.27±0.49 
NPC 
After RI (n=6) 
10.25±0.90 
€ 
7.250±1.01 
* # 
19.01±1.02 
* # 
235±15.30 
€ 
86.80±2.13 
* 
3.61±0.22 
* #  
β1/β2-PC 
Before RI 
15.83±0.47 39.33±2.73 55.25±1.30 253±9.07 101.8±2.64 12.95±1.30 
β1/β2-PC 
After RI (n=6)                          
13.58±1.11 18.00±2.78 
 
31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
€p< 0.05 vs NPC Before RI     *p< 0.001 vs NPC Before RI      # p< 0.05 vs β1/β2-PC After RI 
  
 
MEK (ERK p44/p42 MAPK) inhibitor: PD 98,059 (Trigger) (10 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI (n=6) 
16.80±0.20 38.60±2.08 54.50±2.09 268.00±14.05 101.40±6.07 12.35±1.13 
NPC 
After RI 
8.50±2.70 
* 
6.82±2.16 
* 
14.34±4.74 
* 
179.00±57.17
* 
59.34±18.79
* 
3.74±0.90 
* 
β1/β2-PC 
Before RI (n=6) 
16.60±0.36 36.40±0.97 52.80±1.35 268.00±26.30  106.60±2.16 12.68±0.47 
β1/β2-PC 
After RI 
10.50±3.05 12.60±3.95 22.10±6.92 223.00±56.35 70.26±17.67 5.11±1.36 
 
*p< 0.001 vs NPC Before RI 
 
 
MEK (ERK p44/p42 MAPK) inhibitor: PD 98,059 (Reperfusion) (10 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI (n=6) 
16.60±0.60 
 
39.80±1.14 
 
56.40±1.28 
 
295.00±10.82 103.10±3.55 13.29±0.57 
NPC 
After RI 
8.70±2.29 
* 
7.90±3.11 
* 
16.50±5.14 
* 
205.00±52.46
* 
88.47±1.61 
 
3.30±1.03 
* 
β1/β2-PC 
Before RI (n=6) 
16.00±0.72 43.60±2.85 60.10±3.13 282.00±12.07 101.10±5.52 13.35±1.12 
β1/β2-PC 
After RI 
12.30±0.48  15.90±3.42 28.20±3.81 226.00±9.14  78.39±1.85 5.97±0.77 
 
*p< 0.001 vs NPC Before RI 
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4.2.3   The effect of PI3-Kinase - PKB/Akt and ERK p44 / p42 MAPKinase  
           inhibition on infarct size (IS) in β1/β2-PC (Fig. 4.5 A and B) 
 
As shown previously, β1/β2-PC with isoproterenol (0.1 µM) caused a significant reduction in 
infarct size, when compared with NPC hearts (41.76±1.48%, p<0.001 vs βPC). The PI3-Kinase 
inhibitor, wortmannin (100 nM) applied prior to regional ischaemia (trigger phase) or at the 
onset of reperfusion of hearts exposed to in β-adrenergic preconditioning, significantly 
increased IS and abolished the cardioprotective effects of β-preconditioning in both 
experimental settings (33.61±0.44% and 34.08±0.61%, p<0.001 vs 19.55±1.19 % of β1/β2-PC, 
respectively) (Fig. 4.5 A). Similarly, the MEK (ERK p44/p42 MAPK) antagonist, PD 98,059 
applied prior to regional ischaemia (trigger phase) or at the onset of reperfusion of hearts 
exposed to β1/β2-PC, significantly increased IS (44.56±1.70% and 40.36±1.65%, p<0.001 vs 
β1/β2-PC, respectively) (Fig. 4.5 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
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Fig.  4.5:  The effect of PI3-Kinase - PKB/Akt inhibition (wortmannin) (A) and 
                 MEK- ERK p44 / p42 MAPKinase inhibition (PD 98,059) (B) on infarct 
                         size in β1/β2-PC  
 
(B) 
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4.2.5   Western blot analysis of total and phosphorylated PKB/Akt and  
             ERK p44 / p42 MAPKinase in β1/β2-PC at early reperfusion  
             (Fig. 4.6 A, B, C and D) 
 
Western blot analysis for phosphorylated PKB/Akt of hearts subjected to β1/β2-PC illustrated a 
significant fold increase of phosphorylated PKB/Akt (2.24±0.17, p<0.05 vs NPC) which was 
significantly suppressed with the application of wortmannin prior to global ischaemia in the β-
PC+ group (1.18±0.15, p<0.001 vs β1/β2-PC) (Fig. 4.6 A).  
 
Similarly, Western blot analysis for phosphorylated ERK p44/p42 MAPKinase of hearts 
subjected to β1/β2-PC illustrated a significant fold increase of ERK p44 (2.49±0.06, p<0.001 vs 
NPC) and ERK p42 (2.29±0.05, p<0.01 vs NPC). The application of wortmannin prior to global 
ischaemia (β-PC+) significantly suppressed the activation of ERK p44 (1.86±0.09, p<0.01 vs 
β1/β2-PC) as well as ERK p42 during reperfusion (1.35±0.13, p<0.001 vs β1/β2-PC) (Fig. 4.6 
B). 
 
The application of PD 98,059 (β-PC+) in the same experimental setting had no effect on the 
activation of PKB/Akt (Fig. 4.6 C). However, PD 98,059 significantly reduced the activation of 
ERK p44 (1.46±0.17, p<0.001 vs β1/β2-PC) as well as ERK p42 (1.23±1.33, p<0.001 vs β1/β2-
PC) (Fig. 4.6 D). In all experimental conditions, the expression of total PKB/Akt, ERK p44 as 
well as ERK p42 MAPKinase was unaltered, compared to the negative controls. 
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Fig. 4.6 A:   The effect of PI3-K inhibition with wortmannin on PKB/Akt expression 
                     during early reperfusion  
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Fig. 4.6 B:  The effect of PI3-K inhibition with wortmannin on ERK p44/p42 MAPKinase 
                    expression during early reperfusion  
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Fig 4.6 C:  The effect of MEK (ERK p44/p42 MAPKinase) inhibition with PD 98,059 on  
                   PKB/Akt expression during early reperfusion  
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Fig. 4.6 D:   The effect of MEK (ERK p44/p42 MAPKinase) inhibition with PD 98,059 on  
                     ERK p44/p42 MAPKinase expression during early reperfusion  
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4.3    Discussion 
 
In this study, the cardioprotection of β1/β2-PC was shown to be dependent on the activation of 
PI3K-PKB/Akt and ERK p44/p42 MAPK during the administration of isoproterenol as well as 
during the washout episode prior to sustained ischaemia (Fig. 4.4 A and B), suggesting that 
these two kinases play an important role in triggering protection. This was substantiated by the 
fact that inhibition of these kinases during this phase, abolished protection, in this regard, it 
was shown in this study that inhibition of PI3K-PKB/Akt (with Wortmannin) or inhibition of 
ERK p44/p42 MAPK (with PD 098,059) prior to sustained ischaemia also significantly 
reduced their activation at reperfusion (Fig. 4.6 A and C). As far as we know, this is the first 
demonstration that activation of these two survival kinases is a prerequisite for eliciting β-AR 
cardioprotection. As expected, activation of these two kinases during early reperfusion, is also 
a required for the protective action of β1/β2-PC. The significantly increased infarct size and 
reduced cardioprotective effects (Fig. 4.5 A and B) associated with inhibition of these kinases, 
emphasize the significance of activation of the RISK pathway during reperfusion in 
cardioprotection.   
 
Although both kinases are associated with cardioprotection, it was shown in this study that they 
have a interdependent relationship to achieve the cardioprotective response seen in β1/β2-PC, 
since inhibition of PI3K-PKB/Akt (with Wortmannin) during the triggering phase not only 
caused significant inhibition of PI3K-PKB/Akt but  also of  ERK p44/p42 MAPK activation 
(Fig. 4.6 A and B), whereas inhibition of ERK p44/p42 MAPK (with PD 098,059) significantly 
reduced ERK p44/p42 MAPK but had no significant effect PI3K-PKB/Akt activation (Fig. 4.6 
C and D), indicating that ERK p44/p42 MAPK activation depends largely on PI3K-PKB/Akt 
activation and not vice versa. These observations suggest that ERK p44/p42 MAPK activation 
during early reperfusion is perhaps more significant in β1/β2-PC induced cardioprotection, 
since abolishment of cardioprotection could be obtained in the presence of  PI3K-PKB/Akt 
activation, as was shown with the administration of PD 098,059 during the β1/β2-PC 
preconditioning protocol (see Fig. 4.6 C). 
 
The results obtained in our study are in agreement with the activation of the RISK pathway 
observed in ischaemic preconditioning. These kinases are known to be activated prior to lethal 
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ischaemia [Tong et al., 2000; Fryer et al., 2001] as well as at the time of reperfusion 
[Hausenloy et al., 2004] and suggested to mediate ischaemic preconditioning induced 
cardioprotection.  
 
Activation of the anti-apoptotic pro-survival kinase signaling cascades, (PI3K) PKB/Akt and 
ERK p44/p42 MAPK, has been implicated in cellular survival through their recruitment of 
anti-apoptotic pathways of protection [Gross et al., 2000]. These include the phosphorylation 
and inactivation of a diverse array of substrates, responsible for mediating cardioprotection, 
including GSK-3β [Michael et al., 2004], proapoptotic  proteins such as BAD [Datta et al., 
1997], the mitochondrial permeability transition pore [Shanmuganathan et al., 2005], BAX 
[Tsuruta et al., 2002; Weston et al., 2003], BIM [Weston et al., 2003], p53 and caspases 
[Cardone et al., 1998; Erhardt et al., 1999], GLUT4, transcription factors (IKK-α), P70S6K 
[Chung, et al., 1994; Lehman and Gomez-Cambronero, 2002], NOS [Dimmeler et al., 1999] 
and PKC [Le Good et al., 1998].  
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Chapter 5 
 
The function of adenosine, its receptors (A1, A2A, A2B and A3) 
and downstream targets in the cardioprotective phenomemon of   
                
β-adrenergic preconditioning 
 
Having established the involvement of the β-adrenergic receptor subtypes and subsequent 
signaling in triggering the cardioprotection of β-adrenergic preconditioning, the next aim was to 
further elucidate the mechanism of β-adrenergic receptor mediated cardioprotection. 
 
β-adrenergic receptor stimulation per se causes an increased workload on the heart and could 
conceivably elicit demand ischaemia with concomitant adenosine production. Indeed, 
stimulation with isoproterenol has been shown to cause adenosine release, due to an imbalance 
between oxygen supply and demand [Duessen and Schrader, 1991]. The relative importance of 
adrenergic stimulation and demand ischaemia as important preconditioning stimuli remains 
unclarified, however it was shown that demand ischaemia can precondition the myocardium 
while increased demand alone without ischaemia had marginal preconditioning effects. This 
may be of clinical relevance to patients with severe stenosis exposed to stressful stimuli before 
the development of myocardial infarction [Sharaf et al., 2000].  
 
In the heart, adenosine has potent electrophysiological effects [Drury, and Szent-Gyorgi, 1929; 
Belardinelli, Linden and Berne, 1989] and the transient, reversible slowing of the heart rate 
(negative chronotropic effects) and impairment of atrioventricular conduction (negative 
dromotropism), antagonize the effects of catecholamines (anti-adrenergic) [Schrader, Baumann 
and Gerlach, 1977]. The role of adenosine as a trigger of ischaemic preconditioning has been 
intensely studied and reviewed by several authors [Cohen and Downey, 2008; Headrick and 
Peart, 2005; Lasley et al., 2007]. Unlike bradykinin and opioids, the other two autacoids 
involved in this process, adenosine is not dependent on opening of the mitochondrial KATP 
channel or release of ROS, but activates phopholipase C and / or PKC directly [Cohen and 
Downey, 2008]. 
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Adenosine exerts its effects almost exclusively via four currently defined G-protein-coupled 
receptors (GPCRs): A1, A2A, A2B and A3 [Fredholm et al., 2001]. However, the effect of 
adenosine itself on the ischaemic responses may be more complex than modulation of these 
receptors above [Ashton et al., 2007], since it has been shown that adenosine can modulate 
cardiac tolerance to ischaemia or hypoxia via non-receptor-mediated metabolic or substrate 
actions [Bolling et al., 1994; Peart and Headrick, 2003]. 
 
The A1-AdoRs and A3-AdoRs participate in the intracellular signaling that triggers ischaemic 
preconditioning [Dougherty et al., 1998; Miura and Tsuchida, 1999]. Conversely, participation 
of the A2A-AdoRs and A2B-AdoRs has been identified in the protective phenomenon of 
postconditioning [Zhao et al., 2003; Kin et al., 2005; Yang et al., 2005]. During reperfusion 
activation of PKC initiates the activation of the low sensitivity A2B receptor, making it 
responsive to adenosine which accumulated during sustained ischaemia. This would limit its 
activation only to periods of excessive adenosine accumulation (Peart and Headrick, 2007). In 
addition, role of the A2B receptor in reperfusion has been demonstrated by the fact that A2B 
agonists infused at reperfusion mimics preconditioning [Eckle et al., 2007].  
 
In this chapter the role of adenosine release and the relative contribution of the A1, A2A, A2B and 
A3 receptors during the triggering and mediatory phases of β1/β2-PC were investigated. In 
addition, the involvement of PI3-K and ERK signal transduction pathways in the mechanism of 
β-adrenergic receptor mediated cardioprotection were further elucidated. 
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5.1   Methods 
 
5.1.1   Investigating the role of adenosine and the adenosine A1, A2A, A2B  
            and A3  receptors in β1/β2-PC (Fig. 5.1 A and B) 
 
Non-preconditioned hearts as well as β1/β2-PC hearts were exposed to administration of the 
following drugs: adenosine deaminase (0.3 U/ml); A1-AdoR antagonist (DPCPX) (1µM); A3-
AdoR
 
antagonist (MRS 1191) (1µM); A2A-AdoR antagonist (ZM241385) (1 µM); A2B-AdoR 
antagonist (MRS1754) (1µM). In the NPC hearts, drugs were administered for 10 minutes 
followed by a 5 minute washout episode prior to 35 minutes regional ischaemia and reperfusion. 
In the case of the β1/β2-PC hearts, isoproterenol (0.1 µM) administration was initiated 5 min 
after the antagonists and co-administered for a further 5 min. The rest of the protocol was similar 
for the two groups.   
 
In separate groups of experiments adenosine deaminase or antagonists of the adenosine A1, A2A, 
A2B or A3 receptor were applied during the first 10 min of reperfusion after regional ischemia. 
Haemodynamic parameters were recorded at the end of the 15 minute working heart mode prior 
to regional ischaemia and compared with those measured at the end of reperfusion following 
regional ischaemia. Adenosine deaminase was dissolved in distilled water whereas the adenosine 
antagonists were dissolved in DMSO and applied in Krebs-Henseleit buffer, respectively. The 
concentration of DMSO in the Krebs-Henseleit buffer was less than 0.00023 % vol/vol. To 
ensure that DMSO had no effect on the pharmacological agents used, DMSO (0.00023 %) alone 
was applied in the same experimental setting.   
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REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION
NPC + DMSO / ADA / DPCPX / ZM 241385 / MRS 1754 / MRS 1191 applied prior to index ischaemia
5 MIN WASH OUT
10 MIN  ANTAGONIST
5 MIN WASH OUT
5 MIN ISO + ANTAGONIST
5 MIN ANTAGONIST
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION 
β1/β2-PC + DMSO / ADA / DPCPX / ZM 241385 / MRS 1754 / MRS 1191 applied prior to index ischaemia
Infarct size
Infarct size
1250 5550 60 9515 30 45
Experimental protocol: (Fig. 5.1 A) 
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ADA / DPCPX / ZM 241385 / MRS 1754 / MRS 1191 applied at the onset of reperfusion  
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION 
5 MIN  ISO
β1/β2-PC +
Infarct size
REGIONAL ISCHAEMIA REPERFUSIONSTABILIZATION 
NPC
Infarct size
ADA / DPCPX / ZM 241385 / MRS 1754 / MRS 1191 applied at the onset of reperfusion  
10  MIN ANTAGONIST
1250 5550 60 9515 30 100
10  MIN ANTAGONIST
Experimental protocol: (Fig. 5.1 B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.2    To investigate whether adenosine and adenosine A1, A2A,  A2B and  
                A3 receptors affect PKB and ERKp42/p44 MAPKinase  activation  
            in β1/β2-PC (Fig. 5.2 A and B) 
 
The adenosine A1 (DPCPX) (1µM), A2A (ZM241385) (1 µM), A2B (MRS1754) (1µM) or the A3 
(MRS 1191) (1µM) receptor antagonist was administered prior to global ischaemia to NPC and 
β1/β2-PC hearts as indicated in Fig. 5.2 A. These hearts were freeze-clamped at 5 min 
reperfusion after 25 min global ischaemia and analysed using Western blot analysis to 
investigate the expression of total and phosphorylated PKB/Akt as well as total and 
phosphorylated ERK p44/p42 MAPK. 
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5 MIN WASH OUT
5 MIN ISO + ANTAGONIST
5 MIN ANTAGONIST
GLOBAL ISCHAEMIA REPERFUSIONSTABILIZATION
β1/β2-PC + DPCPX / ZM 241385 / MRS 1754 / MRS 1191 applied prior to index ischaemia
Western blot analysis
5 MIN WASH OUT
10 MIN ANTAGONIST
GLOBAL ISCHAEMIA REPERFUSIONSTABILIZATION  
NPC + DPCPX / ZM 241385 / MRS 1754 / MRS 1191 applied prior to index ischaemia
Western blot analysis
5550 60 8515 30 45 900
In separate groups of experiments the A2A (ZM241385) (1 µM) or A2B (MRS1754) (1µM) 
receptor antagonist was applied at the onset of reperfusion for 5 minutes, after which hearts 
were freeze-clamped and analysed using Western blot analysis for total and phosphorylated 
PKB/Akt and ERK p44/p42 MAPKinase (Fig 5.2 B). 
 
 
Experimental protocol: (Fig. 5.2 A) 
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5 MIN WASH OUT
5 MIN ISO
5 MIN ANTAGONIST
GLOBAL  ISCHAEMIA REPERFUSIONSTABILIZATION  
β1/β2-PC + ZM 241385 / MRS 1754 applied at onset of reperfusion
Western blot analysis
5 MIN ANTAGONIST
GLOBAL  ISCHAEMIA REPERFUSIONSTABILIZATION
NPC + ZM 241385 / MRS 1754 applied at onset of reperfusion
Western blot analysis
5550 60 8515 30 900
Experimental protocol: (Fig. 5.2 B) 
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5.2   Results 
 
 
5.2.1 a   The involvement of adenosine in β1/β2-PC (Table 5.1) 
 
To assess the involvement of adenosine in β-PC, a preliminary study was done using adenosine 
deaminase (at one concentration only). Adenosine deaminase (ADA) (0.3 U/ml) applied prior to 
RI (trigger phase) of NPC or hearts exposed to β1/β2-PC (0.1 µM) had no significant effect on 
any of the haemodynamic parameters at the end of reperfusion and hearts subjected to β1/β2-
PC still showed significant increases in AO, CO and total work in the presence of adenosine 
deaminase. 
 
 
Table 5.1:   Effect adenosine deaminase on mechanical recovery of β1/β2-PC hearts 
 
 
β-AR agonist: Isoproterenol 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI (n=18) 
16.28±0.36 39.78±0.85 55.94±0.84 269±4.00 107.0±1.38 13.39±0.27 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
# 
β1/β2-PC 
Before RI (n=18) 
16.61±0.25 40.25±1.01 56.78±1.18 252±3.57 107.5±1.66 13.99±0.45 
β1/β2-PC 
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
# P< 0.05 vs β1/β2-PC After RI 
 
 
 
Adenosine deaminase  
  
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+ADA   
After RI  (n=6) 
8.00±3.62 5.23±2.64 13.58±6.23 126±57.75 44.93±20.16 2.72±1.23 
       
β1/β2-PC+ADA 
After RI  (n=6) 
15.17±1.50 14.17±2.54 29.33±3.34 245±5.63 88.78±1.58 5.89±0.82 
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5.2.1 b   The effect of adenosine deaminase on IS in β1/β2-PC (Fig. 5.3) 
 
Adenosine deaminase (0.3 U/ml) applied to NPC hearts did not show significant change of IS. 
However, the application of adenosine deaminase (0.3 U/ml) in the same experimental setting 
prior to regional ischemia of β1/β2-PC hearts, illustrated a significantly increased infarct size 
(β1/β2-PC: 16.39±0.72% vs 27.24±1.30%, p<0.01), which clearly illustrates the involvement of 
adenosine in β-adrenergic preconditioning, despite the fact that mechanical recovery of these 
hearts were not affected.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3:  The effect of adenosine deaminase on infarct size in β1/β2-PC 
Infarct size
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5.2.1 c   The effect of adenosine inhibition on PKB/Akt and ERK p44 / p42  
                 MAPKinase (Fig. 5.4 A and B) 
 
Western blot analysis for phosphorylated PKB/Akt of hearts subjected to β1/β2-PC showed a 
significant increase (fold increase: 2.36±0.12, p<0.001 vs control), after 5 min reperfusion, 
which was not affected by the application of adenosine deaminase prior to global ischaemia 
(Fig. 5.4 A).  
 
Similarly, Western blot analysis for phosphorylated ERK p44/p42 MAPKinase of hearts 
subjected to β1/β2-PC exhibited significant increase in ERK p44 (fold increase: 2.78±0.24, 
p<0.001 vs control ) and p42 (2.53±0.26, p<0.001 vs control), after 5 min reperfusion, which 
was not significantly altered by the application of adenosine deaminase prior to global 
ischaemia (Fig. 5.4 B). Total PKB/Akt and ERK p44/p42 MAPKinase were similar in all 
groups studied. 
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Fig. 5.4 A:   The effect of adenosine deaminase on PKB/Akt expression during early 
                     reperfusion  
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Fig. 5.4 B:   The effect adenosine deaminase on ERK p44 / p42 MAPKinase expression  
                     during early reperfusion  
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5.2.2 a   The involvement of A1-AdoR  in β1/β2-PC (Table 5.2) 
 
The A1-AdoR antagonist, DPCPX (1µM), applied prior to RI (trigger phase) or during 
reperfusion of NPC or hearts exposed to β1/β2-PC (0.1 µM) had no significant effect on any of 
the haemodynamic parameters at the end of reperfusion.  
 
 
Table 5.2:  Effect of A1-AdoR antagonist, DPCPX on mechanical recovery during 
                 reperfusion of β1/β2-PC hearts 
 
β-AR agonist: Isoproterenol 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI (n=18) 
15.08±0.37 39.17±1.09 53.88±1.05 269±4.04 102.0±4.04 12.46±0.35 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
# 
β1/β2-PC  
Before RI (n=18) 
15.89±0.21 39.33±0.51 55.17±0.68 274±7.41 104.70±1.27 13.25±0.24 
β1/β2-PC  
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
# P< 0.05 vs β1/β2-PC After RI 
 
 
A1-AdoR antagonist: DPCPX (Trigger) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+DPCPX  
After RI (n=6) 
14.85±0.95 4.66±1.28 19.25±1.83 273±7.86 84.52±1.45 4.15± 0.20 
       
β1/β2-PC 
+DPCPX After RI 
(n=6) 
13.50±0.01 14.90±2.86 26.50±3.14 270±10.27   88.30±1.51 5.67±0.63 
 
 
A1-AdoR antagonist: DPCPX (Reperfusion) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+DPCPX  
After RI (n=6) 
11.50±1.38 9.58±1.77 20.92±2.83 240±9.65 85.36±2.87 4.10± 0.63 
       
β1/β2-PC 
+DPCPX After RI 
(n=6) 
13.33±1.07 12.33±1.99 25.58±2.67 260±19.53 89.08±1.95 5.18±0.25 
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5.2.2 b   The effect of DPCPX on infarct size in β1/β2-PC (Fig. 5.5) 
 
A1-AdoR inhibition with DPCPX (1µM), applied to NPC or β1/β2-PC hearts, prior to RI or at 
the onset of reperfusion did not show significant changes in IS, in both instances. This indicated 
clearly that this receptor subtype is not involved in the protective effect of β1/β2-PC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Fig. 5.5:  The effect of A1-AdoR inhibition with DPCPX on infarct size in β1/β2-PC  
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5.2.2 c   The effect of A1-AdoR inhibition with DPCPX on PKB/Akt and 
                    ERK p44 / p42 MAPKinase  (Fig 5.6 A and B) 
 
Western blot analysis for phosphorylated PKB/Akt of hearts subjected to β1/β2-PC exhibited a 
significant increase (fold increase: 2.18±0.21, p<0.001 vs control) during early reperfusion, 
which was not affected by the application DPCPX (2.29±0.23) prior to global ischaemia (Fig. 
5.6 A). 
  
Similarly, Western blot analysis for phosphorylated ERK p44/p42 MAPKinase of hearts 
subjected to β1/β2-PC showed a significant fold increase of ERK p44 (fold increase: 2.49±0.10, 
p<0.001 vs control ) and p42 (2.13±0.04, p<0.001 vs control), which was not altered by the 
administration of DPCPX prior to global ischaemia (Fig. 5.6 B). 
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Fig. 5.6 A:  The effect of DPCPX on PKB/Akt expression during early reperfusion  
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Western blot analysis
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Fig. 5.6 B:  The effect of DPCPX on ERK p44 / p42 MAPKinase expression during  
                    early reperfusion  
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5.2.3 a   The involvement of A2A-AdoR in β1/β2-PC (Table 5.3) 
 
The A2A-AdoR antagonist, ZM 241385 (1 µM), applied prior to regional ischaemia (trigger 
phase) or at the onset of reperfusion of hearts exposed to β1/β2-PC (0.1 µM) had no significant 
effect on haemodynamic parameters as measured during reperfusion. However, the CF, AO, 
CO and total work of hearts receiving ZM 241385 at the onset of reperfusion were significantly 
lower than those treated with the drug during the trigger phase of β1/β2-PC. 
 
Table 5.3:   Effect of A2A-AdoR antagonist, ZM 241385 on mechanical recovery during  
                  reperfusion of β1/β2-PC hearts 
 
β-AR agonist: Isoproterenol 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI (n=18) 
15.33±0.33 40.83±0.63 55.79±0.55 263±7.65 100.80±1.52 12.79±0.29 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
# 
β1/β2-PC  
Before RI (n=18) 
16.17±0.16 41.67±0.82 57.77±0.85 258±5.12 100.0±2.64 13.67±0.31 
β1/β2-PC  
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.53±0.70 
 
# P< 0.05 vs β1/β2-PC After RI 
 
A2A-AdoR antagonist: ZM 241385 (Trigger)  (1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+ZM  
After RI (n=6) 
13.90±0.90 11.70±2.21 25.50±1.48 261±9.87 85.29±1.44 4.87±0.36 
       
β1/β2-PC +ZM 
After RI (n=6) 
15.17±0.52 22.33±2.27 37.50±2.27 257±12.69 93.84 ±0.92 7.98±0.22 
 
 
A2A-AdoR antagonist: ZM 241385 (Reperfusion)  (1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+ZM  
After RI (n=6) 
10.92±2.49 8.41±2.14 19.83±4.47 235±49.33 74.38±15.07 3.81±0.83 
       
β1/β2-PC +ZM 
After RI (n=6) 
10.25±2.17 
¥ 
10.92±2.27
¥ 
20.83±4.29 
¥ 
229±47.49 75.00±15.29 4.25±0.88 
¥ 
 
¥ P<0.05 vs β1/β2-PC After RI  
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5.2.3 b   The effect of ZM 241385 on IS in β1/β2-PC (Fig. 5.7) 
 
A2A-AdoR inhibition with ZM 241385 (1 µM), prior to regional ischaemia of hearts exposed to 
β1/β2-PC, did not increase infarct size (22.10±0.68%) but when applied at the onset of 
reperfusion, infarct size was significantly increased in the β1/β2-PC +ZM241385 R10 group 
(40.95±0.52%, p<0.001 vs β1/β2-PC). This means loss of cardioprotection and illustrates the 
involvement of this receptor only at the onset of reperfusion in β1/β2-PC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.7:   The effect of A2A-AdoR inhibition with ZM 241385 on infarct size in  
                  β1/β2-PC  
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5.2.3 c   The effect of A2A-AdoR inhibition with ZM 241385  on PKB/Akt   
               and ERK p44 / p42 MAPKinase (Fig. 5.8 A, B, C and D) 
 
Western blot analysis for phosphorylated PKB/Akt of hearts subjected to β1/β2-PC (fold 
increase: 2.18±0.16, <0.001 vs control), was significantly altered (fold increase:1.49±0.49, 
p<0.01 vs β1/β2-PC) by the application of the adenosine A2A receptor antagonist, ZM 241385 
(1 µM) prior to global ischaemia (Fig. 5.8 A). In addition, the activation of PKB/Akt was found 
to be significantly reduced and to a greater extent (0.43±0.02, p<0.001 vs β1/β2-PC), when the 
A2A-AdoR
 
antagonist, ZM 241385 (1 µM) was applied at the onset of reperfusion (Fig. 5.8 B). 
Interestingly, the drug also caused a significant inhibition of PKB/Akt phosphorylation when 
added to NPC hearts during reperfusion. 
 
Western blot analysis for phosphorylated ERK p44/p42 MAPKinase of hearts subjected to 
β1/β2-PC, illustrated the characteristic significant increase of ERK p44 (fold increase: 
2.49±0.10, p<0.001 vs control) and p42 (2.33±0.04, p<0.001 vs control) MAPKinase, 
respectively. Only ERK p44 MAPKinase was appreciably altered by the administration of ZM 
241385 prior to global ischaemia (fold increase: 1.85±0.07, p<0.05 vs β1/β2-PC), whereas the 
ERK p42 MAPKinase showed no significant change (Fig. 5.8 C). 
 
In contrast, inhibition of the A2A-AdoR
 
at the onset of reperfusion, reversed the significant 
increase of ERK p44 (2.44±0.08, p<0.001 vs control) and p42 (2.33±0.05, p<0.001 vs control) 
MAPKinase observed in β1/β2-PC hearts. ERK p44 (1.04±0.15, p<0.001 vs β1/β2-PC) and p42 
(1.56±0.19, p<0.001 vs β1/β2-PC), phosphorylation was significantly lowered in the presence 
of A2A-AdoR
 
blockade (Fig. 5.8 D). As previously observed, the expression of total PKB/Akt 
and ERK p44/p42 MAPKinase remained unchanged in all experiments. 
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Western blot analysis
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Fig. 5.8 A:   The effect of ZM 241385 applied prior to global ischaemia on PKB/Akt 
                     expression during early reperfusion  
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Fig. 5.8 B:   The effect ZM 241385 applied after global ischaemia on PKB/Akt expression 
                     during early reperfusion  
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Western blot analysis
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Fig. 5.8 C:  The effect of ZM 241385 applied prior to global ischaemia on ERK p44 
                    / p42 MAPKinase expression during early reperfusion  
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 Fig. 5.8 D:  The effect of ZM 241385 applied after global ischaemia on ERK p44 / p42  
                      MAPKinase expression during early reperfusion 
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5.2.4 a   The involvement of A2B-AdoR in β1/β2-PC  
 
The A2B-AdoR antagonist, MRS1754 (1µM), applied prior to regional ischaemia (trigger 
phase) caused a small, but significant decline in functional recovery of β1/β2-PC hearts. 
Inhibition of this receptor at the start of reperfusion of hearts exposed to β1/β2-PC, 
significantly reduced haemodynamic parameters such as AO, CO and total work, illustrating a 
definite role of this receptor in the trigger phase as well as at the onset of reperfusion of β1/β2-
PC (Table 5.4).  
 
 
Table 5.4:   Effect of A2B-AdoR antagonist, MRS1754, on mechanical recovery during  
                  reperfusion of β1/β2-PC hearts 
 
 
β-AR agonist: Isoproterenol 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI (n=18) 
15.00±0.0.40 40.00±1.18 54.72±0.96 273±4.15 101.80±2.00 12.60±0.47 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
# 
β1/β2-PC  
Before RI (n=18) 
15.71±0.22 39.24±1.06 55.00±1.16 247±9.07 98.97±1.76 12.34±0.35 
β1/β2-PC  
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.53±0.70 
 
# P< 0.05 vs β1/β2-PC After RI 
 
 
A2B-AdoR antagonist: MRS 1754 (Trigger)  (1 µM)  
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+MRS1754 
 After RI (n=6) 
5.53±2.39 6.60±2.94 12.00±5.27 217.10±19.18 62.49±2.30 3.72±0.75 
       
β1/β2-
PC+MRS1754 
After RI (n=6) 
10.00±1.00 
 
12.50±1.97
 
22.50±2.77
 
239±20.77 85.94±1.93 4.35±0.62 
 
p<0.05 vs β1/β2-PC After RI   
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Table 5.4:   (continued) 
 
A2B-AdoR antagonist: MRS 1754 (Reperfusion)  (1 µM)   
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+MRS1754 
After RI (n=6) 
8.75±1.87 4.83±1.79 13.53±2.87 223±50.47 70.95±14.28 2.59±0.55 
       
β1/β2-
PC+MRS1754 
After RI (n=6) 
7.75±2.43 
¥ 
6.83±2.78 
¥ 
14.58±5.10 
¥ 
170.00±54.27 85.03±18.38 2.69±0.95 
€ 
 
¥ P< 0.05 vs β1/β2-PC After RI                                
 
€ P<0.01 vs β1/β2-PC After RI 
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5.2.4 b   The effect of  MRS 1754 on IS in β1/β2-PC (Fig. 5.9) 
 
The small infarct size of hearts exposed to β1/β2-PC (19.55±1.19%, p<0.001 vs NPC) was 
significantly increased (24.86±1.17, p<0.05 vs β1/β2-PC) by the application of the A2B-AdoR 
antagonist, MRS 1754 (1 µM) prior to regional ischaemia, as well as at the onset of reperfusion 
(32.55±1.17%, p<0.001 vs β1/β2-PC).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.9:   The effect of A2B-AdoR inhibition with MRS 1754 on infarct size in β1/β2-PC 
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5.2.4 c   The effect of A2B-AdoR inhibition with MRS 1754 on PKB/Akt and  
                    ERK p44 / p42 MAPKinase (Fig. 5.10 A, B, C and D) 
 
Phosphorylated PKB/Akt expression of hearts subjected to β1/β2-PC (2.18±0.11, p<0.001 vs 
control) was significantly reduced by the application of the adenosine A2B receptor antagonist, 
MRS1754 (1 µM) prior to global ischaemia (1.43±0.07, p<0.001 vs β1/β2-PC) (Fig. 5.10 A). 
Similarly, when this antagonist was applied at the onset of reperfusion, the activation of 
PKB/Akt of hearts subjected to β1/β2-PC (2.18±0.11, p< 0.001 vs control), was significantly 
altered and to a greater extent than when the antagonist was applied prior to sustained 
ischaemia (0.65±1.18, p<0.001 vs β1/β2-PC) (Fig. 5.10 B). 
 
Western blot analysis for phosphorylated ERK p44/p42 MAPKinase of hearts subjected to 
β1/β2-PC , illustrated a significant fold increase of ERK p44 (2.49±0.10, p<0.001 vs control) 
and p42 (2.33±1.52, p<0.001 vs control) MAPKinase, which was appreciably reduced by the 
administration of MRS1754 prior to global ischaemia (ERK p44 1.59±0.05, p<0.001 vs β1/β2-
PC) and ERK p42 (1.52±0.08, p<0.01 vs β1/β2-PC), (Fig. 5.10 C). Likewise, with the 
application of MRS1754 at the onset of reperfusion (Fig. 5.10 D), ERK p44 (1.53±0.10, 
p<0.001 vs β1/β2-PC) and ERK p42 (1.59±0.06, p<0.001 vs β1/β2-PC) MAPKinase, revealed a 
similar trend, respectively. As seen previously, expression of total PKB/Akt and ERK p44/p42 
MAPKinase, was similar in all experimental groups. 
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Western blot analysis
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Fig. 5.10 A:  The effect of MRS 1754 applied prior to global ischaemia on PKB/Akt  
                      expression during early reperfusion  
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Fig. 5.10 B:  The effect of MRS 1754 applied after global ischaemia on PKB/Akt  
                      expression during early reperfusion  
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Western blot analysis
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 Fig. 5.10 C:  The effect of MRS 1754 applied prior to global ischaemia on ERK p44 / p42  
                       MAPKinase expression during early reperfusion   
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Western blot analysis
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Fig. 5.10 D:  The effect of MRS 1754 applied after global ischaemia on ERK p44 / p42  
                      MAPKinase expression during early reperfusion   
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5.2.5 a   The involvement of A3-AdoR in β1/β2-PC (Table 5.5) 
 
The A3-AdoR antagonist, MRS1191 (1µM), applied prior to regional ischaemia (trigger phase) 
or at the onset of reperfusion of hearts exposed to β1/β2-PC, significantly reduced 
haemodynamic parameters such as AO, CO and total work, illustrating a definite role of this 
receptor in the cardioprotection of β1/β2-PC.  
 
 
Table 5.5:   Effect of A3-AdoR antagonist, MRS1191 on mechanical recovery during  
                    reperfusion of β1/β2-PC hearts 
 
 
β-AR agonist: Isoproterenol 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI (n=18) 
15.38±0.34 41.83±0.68 56.33±0.64 275±4.33 102.2±1.50 13.24±026 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
# 
β1/β2-PC  
Before RI (n=18) 
16.11±0.19 41.55±0.80 57.56±0.85 268±5.18 102.4±1.11 13.36±0.28 
β1/β2-PC  
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
# P< 0.05 vs β1/β2-PC After RI 
 
 
A3-AdoR antagonist: MRS1191 (Trigger)  (1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+MRS1191  
After RI (n=6) 
12.92±0.76 2.33±0.33 14.33±0.45 300±3.45 83.05±1.47 2.75±0.08 
       
β1/β2-PC + 
MRS1191 
After RI 
9.00±2.84 
 
3.33±1.11 
Փ 
12.67±4.03 
Փ 
176±57.39 62.26±19.69 2.61±0.83 
Փ 
 
Փp<0.001 vs β1/β2-PC After RI 
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Table 5.5:  (continued) 
 
 
A3-AdoR antagonist: MRS1191 (reperfusion)  (1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+MRS1191  
After RI (n=6) 
12.92±0.76 2.33±0.33 14.33±0.45 300±3.45 83.05±1.47 2.75±0.08 
       
β1/β2-PC + 
MRS1191 
After RI 
9.41±3.00 
 
3.00±1.23 
¥ 
12.38±3.96 
¥ 
191±60.77 54.15±17.66 2.45±0.78 
¥ 
 
¥p<0.001 vs β1/β2-PC After RI 
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5.2.5 b   The effect of MRS 1191 on IS in β1/β2-PC (Fig. 5.11) 
 
The infarct size of NPC hearts indicates a large IS of 39.20±1.24% compared to the 
significantly reduced infarct size of hearts exposed to β1/β2-PC (20.72±0.99%, p<0.001). A3-
AdoR inhibition, with MRS 1191 (1 µM) of hearts exposed to β-adrenergic preconditioning, 
prior to regional ischaemia or at the onset of reperfusion, significantly increased infarct size in 
both experimental settings (40.32±2.36% and 42.12±1.17%, p<0.001, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.11:  The effect of A3-AdoR inhibition with MRS 1191 on infarct  size in β1/β2-PC  
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 5.2.5 c   The effect of A3-AdoR inhibition with MRS 1191 on PKB/Akt and  
               ERK p44 / p42 MAPKinase (Fig. 5.12 A and B) 
 
Western blot analysis for phosphorylated PKB/Akt of hearts subjected to β1/β2-PC (2.18±0.11, 
p< 0.001 vs control), showed that it was significantly altered (1.43±0.07, p<0.001 vs β1/β2-PC) 
by the application of the A3-AdoR antagonist, MRS 1191 (1 µM) prior to global ischaemia 
(Fig. 5.12 A). 
 
Similarly, Western blot analysis for phosphorylated ERK p44/p42 MAPKinase of hearts 
subjected to β1/β2-PC, illustrated a significant fold increase of ERK p44 (2.49±0.10, p<0.001 
vs control) and p42 (2.33±0.04, p<0.001 vs control) MAPKinase. This was significantly altered 
by the administration of the A3-AdoR antagonist prior to global ischaemia, ERK p44 
(1.49±0.05, p<0.01 vs β1/β2-PC) and p42 (1.56±0.04, p<0.05 vs β1/β2-PC)  (Fig. 5.12 B). 
 
  
 183 
 
Western blot analysis
 
-Ve C NPC NPC+ B1/B2-PC B1/B2-PC+
Co
ntr
ol
NP
C
NP
C+
MR
S1
19
1
B1
/B2
-
PC
B1
/B2
-
PC
+M
RS
11
91
0.0
0.5
1.0
1.5
2.0
2.5
3.0


p<0.01 vs NPC
p<0.001 vs B1/B2-PC
PK
B 
Ac
tiv
at
io
n
 
(F
o
ld
 
In
cr
ea
se
)
 
Phospho-PKB / Akt 
Total PKB / Akt 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.12 A:  The effect of MRS 1191 applied prior to global ischaemia on PKB/Akt 
                      expression during early reperfusion 
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Western blot analysis
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Fig. 5.12 B:  The effect of MRS 1191 applied prior to global ischaemia on ERK p44 / p42  
                      MAPKinase expression during early reperfusion  
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5.3   Discussion 
 
The role of adenosine in the mechanism of ischaemic preconditioning has been studied by many 
workers [for reviews see Downey, Krieg and Cohen, 2008; Cohen and Downey, 2008; Yang, 
Cohen, and Downey, 2010]. It is released by short episodes of ischaemia in sufficient quantities 
to trigger cardioprotection. β-adrenergic stimulation of hearts with isoproterenol has also been 
shown to cause adenosine release, suggested to be due to an imbalance between oxygen supply 
and demand (demand ischaemia) [Deussen and Schrader, 1991]. The results obtained in this 
study suggest that sufficient adenosine was released during isoproterenol stimulation to elicit 
cardioprotection via its receptor subtypes. A preliminary study showed that elimination of 
adenosine by adenosine deaminase, significantly increased infarct size and reduced 
cardioprotection (Fig. 5.3), suggesting the involvement of adenosine in this cardioprotective 
phenomenon. Although these observations were not associated with significant changes in 
functional recovery, it was decided to evaluate the respective roles of the Ado-R subtypes in β-
adrenergic preconditioning, on the premise that infarct size is perhaps the better indicator of 
cardioprotection. 
 
The salient findings were: (i) the triggering of isoproterenol-induced protection is mainly 
dependent on endogenous adenosine acting on the adenosine A3 receptor, with the A2B receptor 
making a minor contribution; (ii) the mediator phase is dependent on the activation of the 
adenosine A3 receptor in conjunction with mainly the adenosine A2A receptor during reperfusion 
and to a lesser extent the adenosine A2B receptor; (iii) the signal transduction pathways during 
both phases involve the PKB/Akt and ERK p44 / p42 pathways. 
 
 
5.3.1   The role of A1-AdoR in β-adrenergic preconditioning  
 
The adenosine A1 receptor is the most extensively studied adenosine receptor subtype within the 
context of cardioprotection and cardioprotection due to A1 receptor agonism has been observed 
in many species examined [Morrison et al., 2006; for review see Headrick and Lasley, 2009]. 
Although there is some controversy regarding the role of this receptor in ischaemic 
preconditioning, there is very convincing evidence for a crucial role for adenosine in ischaemic 
preconditioning in the rat [Headrick et al., 1996] and it is generally accepted that adenosine and 
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the adenosine A1 receptor are essential in the mechanism of cardioprotection in multiple species 
[for review see Peart and Headrick, 2007]. It must be noted that this
 
receptor triggers both 
PKB/Akt and ERK p44/p42 MAPK activation, yet only ERK p44/p42 and not PKB/Akt was 
shown to be involved in cardioprotection such as IPC [Germack et al., 2004; Germack and 
Dickenson, 2005].  
 
In contrast to its proven role in ischaemic preconditioning, the adenosine A1 receptor is not 
involved in β1/β2-PC with isoproterenol: the infarct size and haemodynamic parameters of 
hearts exposed to β-adrenergic preconditioning (β1/β2-PC) were not affected by inhibition of 
the adenosine A1 receptor with DPCPX, a highly selective A1-AdoR blocker, prior to index 
ischemia or at the onset of reperfusion (Table 5.2 and Fig. 5.5). In addition, adenosine A1 
receptor inhibition during preconditioning prior to index ischaemia had no significant effect on 
PKB/Akt or ERK p44/p42 MAPK activation of β1/β2-PC hearts during reperfusion, which 
further indicates that this receptor did not contribute to the cardioprotective effects of β1/β2-PC 
(Fig. 5.6 A and B).  
 
 
5.3.2   The involvement of A2A-AdoR in β-adrenergic preconditioning  
 
To elucidate the role of the A2A-AdoR in β1/β2-PC, use was made of the selective A2A-AdoR 
antagonist ZM 241385, which is >200 more potent for the A2A- than the A2B-Ado receptor [Kis, 
Baxter and Yellon, 2003]. In this study, it was illustrated that ZM 241385 administered prior to 
index ischaemia (trigger phase) had no effect on mechanical recovery or infarct size in β1/β2-
PC hearts (Table 5.3 and Fig. 5.7): showing that the A2A-AdoR was not involved in the 
triggering stage of β1/β2-PC. 
 
On the other hand, in this study it was illustrated that A2A-AdoR inhibition at the start of 
reperfusion caused significant inhibition of functional recovery when compared with β1/β2-PC 
(Table 5.3), associated with an increase in infarct size (Fig. 5.7). Interestingly, A2A-AdoR 
inhibition resulted in a significant inhibition of the PKB/Akt as well as ERK p44/p42 MAPK 
phosphorylation during reperfusion, regardless of the time of administration.  
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The finding that the A2A-AdoR antagonist, when added prior to ischaemia, had no effect on the 
reduction in infarct size but was associated with a reduction in the activation of the RISK 
pathway, was surprising and in contrast with our other data where a reduction in infarct size 
was found to occur concomitantly with the activation of the RISK pathway.  
 
Although there are many studies confirming the association between cardioprotection and 
activation of PKB/Akt and ERK p44/p42 MAPK, the question has been raised whether 
activation of the RISK pathway is indeed mandatory for cardioprotection. There are several 
studies that could not confirm this association and this problem has been the topic of a recent 
editorial by Heusch, 2009, namely: “No RISK, no cardioprotection ? A critical perspective”. 
However, apart from the above mentioned discrepancy, the results obtained in the present study 
showed a good correlation between cardioprotection and activation of the RISK pathway, as 
well as visa versa. 
 
Generally, the A2-AdoRs are located on smooth muscle and endothelial cells of blood vessels 
mediating the vascular effects of adenosine (Li and Fredholm, 1985). Thus, A2-AdoR agonism 
in an experimental setting [Maddock et al., 2001] would lead to enhanced vasodilation. Vinten-
Johansen et al., 1999 identified a role for the this receptor subtype in the phenomenon of 
postconditioning [Kin et al., 2005], the protection of which was evident in the presence and 
absence of blood cells [Zhao et al., 2003; Kin et al., 2005; Yang et al., 2005]. The possibility 
that the adenosine A2A receptor has a more prominent role in cardioprotection at reperfusion is 
more likely, because it was shown that this receptor subtype regulates inflammatory tissue 
damage and remodeling associated with ischaemia and reperfusion [Peart and Headrick, 2007].  
 
However, controversy also highlights the adenosine A2A receptor downstream signaling and 
activation of PKB/Akt and ERK p44/p42 MAPK. A2A-AdoRs are coupled to adenylyl cyclase- 
cAMP- PKA pathway via the stimulatory Gs protein and is consequently linked to the 
modulation of contractility [Cannell et al., 1995; Lindemann et al., 1983; Zhang et al., 1995]. 
PKA in turn, could activate PKB. However, the connection between cAMP – PKA and 
PKB/Akt activation is another subject of controversy since it was shown that cAMP could 
activate PKB/Akt independent of PKA [Meroni et al., 2002]. Recently, another cAMP binding 
protein was cloned and named Epac (Exchange protein directly activated by cAMP) [de Rooij 
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et al., 1998; Kawasaki, 1998]. Epac is a GTPase factor activating Rap1, and there is growing 
evidence that cAMP-mediated PKB activation requires the presence of Epac [Mei et al., 2002].  
 
Similarly, the connection between cAMP - PKA and ERK p44/p42 and the role of small 
GTPase proteins are subjects of intense discussion and disparity [Vossler et al., 1997; Stork and 
Schmitt, 2002; Norum et al., 2003]. It was proposed that the A2A adenosine receptor couples to 
the G12/13 protein instead of Gs [Sexl V et al., 1997]. Thus, the A2A receptor-mediated activation 
on ERK p44/p42 may occur also via the involvement of the Ras –Ras– Sos pathway [Seidel et 
al., 1999]. 
 
 
5.3.3   The role of A2B-AdoR in β-adrenergic preconditioning 
 
Presently, there is no definitive evidence that functional A2B or A3 adenosine receptors are 
expressed in adult mammalian myocytes [Marala and Mustafa, 1998; Kilpatrick et al., 2002]. 
Thus, the effects of the adenosine receptors on myocardial responses to ischaemia may not 
necessarily reflect direct myocyte responses but indirect actions of other cell types [Peart and 
Headrick, 2007].  The adenosine A2B receptors are defined as the low affinity receptor [Beukes, 
2000] and thus, significant adenosine A2B receptor activation will occur only at times of 
excessive adenosine accumulation, such as during ischemia, which is discharged at the onset of 
reperfusion.  
 
In this study, it was illustrated that the selective adenosine A2B receptor blocker, MRS 1754 
administered prior to index ischaemia had no effect on functional recovery during reperfusion, 
whereas infarct size was significantly increased, when compared with the values obtained with 
β1/β2-PC (Table 5.4 and Fig. 5.9). In addition, it was found that inhibition of this receptor prior 
to sustained ischaemia, significantly reduced PKB/Akt (Fig. 5.10A) and ERK p44/p42 MAPK 
(Fig. 5.10 D) activation during reperfusion. Thus, it was concluded that activation of the 
adenosine A2B receptor plays a role in the trigger phase of β-adrenergic preconditioning. 
 
Similarly, in the present study it was shown that inhibition of the adenosine A2B receptor at the 
beginning of reperfusion, significantly decreased mechanical recovery and elevated infarct size 
(Table 5.4 and Fig. 5.9), illustrating that the this receptor may have a more prominent role at 
this stage of β1/β2-PC. The significance of A2B-AdoR activation at the onset of reperfusion was 
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further demonstrated by the finding that the inhibitor MRS 1754 also abolished the activation of 
PKB/Akt and ERK p44/p42 MAPK, characteristic of the cardioprotection of β1/β2-PC. 
 
The adenosine A2B receptor is generally coupled to the Gs-AC-PKA pathway [Mutafova-
Yambolieva and Keef, 1997] and modulates contractility. Several other studies implicated A2B-
AdoR signaling to the phosphoinositide metabolism via Gq/11 [Yakel et al., 1993; Feoktisov and 
Biaggioni, 1995]. In studies of IPC and postconditioning, it was illustrated that activation of this 
receptor subtype during early reperfusion lead to the activation of PKC. It was noted that PKC 
activation lowered the threshold of the A2B receptor for adenosine [Kuno et al., 2007] and it has 
been suggested that these receptors can only respond to the heart’s endogenous adenosine after 
sensitization by PKC. In summary the data obtained suggest a definite role for the adenosine 
A2B receptor during both the triggering and mediator phases of β1/β2-PC. 
 
 
5.3.4   The contribution of the adenosine A3 receptor to the cardioprotection  
           of β1/β2-PC  
 
It has almost uniformly been shown that the adenosine A3 receptor mediates cardioprotection in 
multiple species and models [for review see Peart and Headrick, 2007]. Also, in the present 
study, it was illustrated that inhibition of the adenosine A3 receptor subtype with the specific A3 
inhibitor, MRS 1191 either prior to index ischaemia or at the start of reperfusion, caused 
significant inhibition of cardiac function during reperfusion and significantly increased infarct 
size as compared with the data obtained after β1/β2-PC. Thus, cardioprotection of β1/β2-PC 
was abolished by administration of the inhibitor at both time intervals of the experimental 
protocol (Table 5.5 and Fig. 5.11). This is in contrast with ischaemic preconditioning where 
roles for both A1- and A3-AdoR during the triggering phase only was reported in the rat heart 
[de Jonge et al., 2002; Peart and Headrick, 2007]. 
 
The results obtained with adenosine A3 receptor
 
blockade, suggest a major role for the 
activation of the RISK pathway in β1/β2-PC: activation of PKB/Akt and ERK p44/p42 
MAPKinase at the onset of reperfusion of hearts subjected to β1/β2-PC was significantly 
reduced by adenosine A3 receptor inhibition either prior to global ischaemia or at the onset of 
reperfusion (Fig. 5.12 A and B). This finding emphasizes the role of the adenosine A3 receptor 
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mediated activation of PKB/Akt and ERK p44/p42 MAPKinase in the cardioprotective 
response of β-adrenergic preconditioning as well as the required pre-ischaemic A3 receptor 
agonism required for cardioprotection [Thourani et al., 1999; Flood et al., 2003].  
 
Interestingly, the work of Germack et al (2004, 2005) suggests that although the adenosine A3 
receptor can trigger both PKB/Akt and ERK p44/p42 MAPKinase activation, only the latter is 
required for the protective actions of this receptor during hypoxia-reoxygenation. Results 
presented in chapter 4 also confirm the importance of ERK p44/p42 MAPKinase activation 
during reperfusion of β1/β2-PC hearts, since inhibition of this MAPKinase completely 
abolished cardioprotection induced by isoproterenol. 
 
In view of the significant role that the A3-AdoR plays in both ischaemia and β1/β2-PC, it is 
surprising that the myocardial expression of this receptor appears to be exceedingly low in 
murine myocardium [Black et al., 2002]. It was suggested to be present in dog, rabbit and rat 
cardiac tissues [Auchampach et al., 1997; Takano et al., 2001], but there is presently very little 
direct evidence of its expression in mammalian cardiomyocytes [Headrick and Peart, 2005]. 
Thus, precisely how and where it mediates its protective effects remains unclear. 
   
Earlier studies, illustrated that selective A3-AdoRs agonists could trigger a potent protective 
response in isolated cardiomyocytes [Armstrong and Genote, 1994; Lee et al., 2001; Chaudary 
et al., 2004; Germack et al., 2004]. It was also indicated that acute treatment with A3-AdoR 
agonists produced  cardioprotection characterized by reduced infarct size [Auchampach et al., 
1997; Maddock et al., 2001], decreased apoptotic death [Maddock et al., 2002] and enhanced 
contractile function [Maddock et al., 2003; Gardner et al., 2004]. Some reports suggested that 
the A3-AdoRs mediated protection occur post-ischaemia [Jordan et al., 1999; Maddock et al., 
2002], while others indicate that pre-ischaemic agonism is required for cardioprotection 
[Thourani et al., 1999; Flood et al., 2003]. 
 
Research has also shown that resveratrol-induced cardioprotection was A3-AdoR dependent, 
associated with phosphorylation of PKB/Akt and cAMP response element binding protein 
(CREB) [Das et al., 2005]. The individual inhibition of PI3-Kinase or MEK1/2 only partially 
limited CREB activation and protection, whereas simultaneous inhibition of PI3-Kinase and 
MEK completely blocked CREB activation and protection [Das et al., 2005].  
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In both A1- and A3-AdoRs mediated responses, there is evidence of convergence on common 
mediators / end-effectors such as the mitochondrial KATP channel [Tracey et al., 1998; Thourani 
et al., 1999]. In summary, results indicate a major role for both the A3- and A2B-AdoR subtype, 
in the trigger as well as mediatory phases, while the A2A subtype only becomes important 
during the onset of reperfusion. The data in this chapter strongly suggests a role for endogenous 
adenosine produced during the triggering phase, as well as during reperfusion, in the 
cardioprotection elicited by transient administration of isoproterenol. At least three AdoR 
subtypes appear to be involved in different stages of this cardioprotective phenomenon.  
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Chapter 6 
 
Investigation of the roles of the mitochondrial KATP channel, reactive oxygen 
species (ROS) and nitric oxide in β-adrenergic preconditioning  
 
The mitochondrial KATP channel (mitoKATP channel) and the production of reactive oxygen 
species have been shown to be involved in the cardioprotection of ischaemic preconditioning 
[for reviews see Downey, Krieg and Cohen, 2008; Cohen MV and Downey, 2008]. Non-
adenosine mediated activators of ischaemic preconditioning, such as opioids and bradykinin, 
have been shown to utilize a signaling pathway that involves endothelial nitric oxide synthase 
(eNOS) activation. The resulting nitric oxide (NO) activates soluble guanylyl cyclase resulting in 
cGMP-dependent protein kinase (PKG) activation through the production of cyclic guanosine 
monophosphate. PKG initiates opening of the mitoKATP channels, which in turn results in ROS 
generation and activation of protein kinase C (PKC) during the triggering phase of ischaemic 
preconditioning for [Downey, Krieg and Cohen, 2008; Cohen and Downey, 2008]. Thus, the 
production of ROS in the context of ischaemic preconditioning acted as a second messenger to 
activate PKC and it is thought that PKC activation could be the end of the trigger phase and the 
first step of the mediator phase of ischaemic preconditioning. Both ROS and NO have been 
shown to lead to the cardioprotective state of ischaemic preconditioning (Garlid et al., 2003). 
Interestingly, in contrast to opioids and bradykinin, adenosine has a second direct coupling to 
PKC that bypasses the mitochondrial or redox signaling pathway [Downey, Krieg and Cohen, 
2008]. The mediator phase occurs during the first minutes of reperfusion following lethal 
ischaemic insult and is still poorly defined. 
 
Based on the knowledge that is available regarding events during ischaemic preconditioning and 
the similarities between ischaemic and pharmacological preconditioning, the question arose 
whether ROS, NO or the mitoKATP channels are involved in beta-adrenergic receptor stimulated 
cardioprotection with isoproterenol.  
 
Evidence exists that both the β1- and β2-receptor subtypes could be involved in ROS production 
[Opie, Thandroyen and Muller, 1979; Zhang et al., 2005]. 
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β-adrenergic mechanisms have been shown to be involved in the control of NO generation in 
cardiomyocytes [Slezak et al., 2004] and isoproterenol is capable of activating eNOS via Gαi 
[Balligand et al., 1999]. As far as we know, the role of the mitochondrial KATP channel in β1/β2-
PC has never been investigated. In view of the above, in this chapter the respective roles of ROS, 
NO and the mitoKATP channels in β1/β2-PC with isoproterenol were investigated. 
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6.1   Methods 
 
Inhibitors of NOS, L-NAME (N-nitro-L-arginine methyl ester hydrochloride) (50 uM)  and L-
NNA (N-nitro-L-arginine) (50 uM), the mitochondrial KATP-channel blocker 5-HD (5-
hyroxydecanoate) (100 µM) or the oxygen radical scavenger NAC, (N-acetyl cysteine) (300 
µM), were dissolved in distilled water and applied in Krebs-Henseleit buffer for 5 min prior to 
and during the 5 minute isoproterenol administration which was followed by a 5 min washout 
episode. Hearts were then subjected to 35 min regional ischaemia and reperfusion after which the 
infarct size was determined, as previously described in chapter 2. In a separate group of 
experiments, NAC was infused at the onset of reperfusion for 10 minutes, following regional 
ischemia. Haemodynamic parameters were recorded at the end of the 15 minute working heart 
mode prior to regional ischaemia and compared with haemodynamic parameters and infarct size 
at the end of reperfusion following regional ischaemia (Fig. 6.1). 
 
 
Experimental protocol: (Fig. 6.1) 
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6.2   Results 
 
6.2.1 a  The role of nitric oxide in β1/β2-PC  (Table 6.1) 
 
Haemodynamic parameters such as AO, CO and total work were significantly reduced after the 
application of NOS inhibitors, L-NNA or L-NAME, during the triggering phase of β1/β2-PC, 
prior to regional ischaemia. 
 
 
Table 6.1:  Effect of NOS inhibitors on mechanical recovery during reperfusion of  
                   β1/β2-PC hearts 
 
 
β-AR agonist: Isoproterenol (0.1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC   
Before RI (n=18) 
15.39±0.31 41.50±0.77 56.08±0.78 251±6.91 103.0±1.34 13.03±0.31 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
# 
β1/β2-PC    
Before R I (n=18) 
15.67±0.18 40.67±0.68 56.25±0.73 245±7.39 101.7±1.24 12.92±0.31 
β1/β2-PC  
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
# P< 0.05 vs β1/β2-PC After RI 
 
 
NOS inhibitor: L-NAME (50 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+LNAME  
After RI  (n=6) 
8.60±2.07 9.58±3.73 19.17±5.63 196±40.22 70.01±14.20 3.29±0.89 
 
       
β1/β2-PC+ 
LNAME  
After RI  (n=6) 
8.27±1.97 7.91±3.15 
 
16.25±4.69 
 
152±36.79 69.90±14.18 3.20±0.88 
 
 
p<0.05 vs β1/β2-PC After RI 
 
p<0.01 vs β1/β2-PC After RI 
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Table 6.1:  (continued) 
 
NOS inhibitor: L-NNA (50 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+LNNA  
After RI  (n=6) 
11.92±1.16 14.00±2.96 27.83±4.54 246±3.21 88.61±1.59 4.88±0.67 
       
β1/β2-PC+LNNA  
After RI  (n=6) 
8.58±1.95 5.00±2.29 
Փ 
13.58±3.81 
Փ 
189±43.53 70.60±14.23 2.76±0.76 
Փ 
 
Փ p<0.01 vs β1/β2-PC After RI 
 197 
 
NP
C
B1
/B2
-
PC
B1
/B2
-
PC
+L
NA
ME
B1
/B2
-
PC
+L
NN
A
0
5
10
15
20
25
30
35
40
45
50

p<0.001 vs NPC
%
 
In
fa
rc
t o
f t
he
 
a
re
a
 
a
t r
is
k:
6.2.1 b   The effect of  nitric oxide inhibition on infract size in β1/β2-PC   
               (Fig. 6.2) 
 
The small infarct size of hearts exposed to β1/β2-PC (20.30±1.510%) was not affected when 
the NOS inhibitors L-NNA or L-NAME were applied prior to regional ischemia (15.18±1.43%  
and 18.65±1.59%, respectively) which suggests that nitric oxide did not play a role in the  
cardioprotective effects of in β1/β2-PC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.2:  The effect of NOS inhibitors, L-NNA or L-NAME on infarct size in β1/β2-PC 
Infarct size
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6.2.2 a  Role of the mitochondrial KATP  channel in β1/β2-PC (Table 6.2) 
   
The mitoKATP channel blocker, 5-HD applied prior to RI had no significant effect on any of the 
haemodynamic parameters at the end of reperfusion, when compared with those of hearts 
preconditioned with isoproterenol. In this study 5-HD was administered during the trigger 
phase only, since the mitoKATP channel have been shown to be involved during the triggering 
phase only of ischaemic preconditioning. 
 
Table 6.2:  Effects of the mitoKATP channel blocker on mechanical recovery during 
                   reperfusion of β1/β2-PC hearts 
 
 
β-AR agonist: Isoproterenol (0.1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI  
14.67±0.55 42.00±0.77 55.30±1.41 270±5.41 104.1±2.10 13.27±0.49 
NPC 
After RI (n=6) 
10.25±0.90 
 
7.250±1.01 
# 
19.01±1.02 
# 
235±15.30 86.80±2.13 3.61±0.22  
#  
β1/β2-PC  
Before RI 
15.83±0.47 39.33±2.73 55.25±1.30 253±9.07 101.8±2.64 12.95±1.30 
β1/β2-PC  
After RI (n=6) 
13.58±1.11 18.00±2.78 
 
31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
# P< 0.05 vs β1/β2-PC After RI 
 
 
mitoKATP channel blocker: 5-HD (100 µM)  
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+5-HD  
After RI (n=6) 
6.90±2.90 5.90±2.95 12.80±5.34 232.2±15.95 83.51±2.96 2.93±1.17 
       
β1/β2-PC+ 
5-HD  
After R(n=6)  
11.42±1.26 13.50±1.29 24.92±1.63 240±8.65 89.70±1.98 4.95±0.19 
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6.2.2 b   The effect of  mitochondrial KATP  channel inhibition on infarct size  
               in β1/β2-PC  (Fig. 6.3) 
 
The mKATP channel blocker, 5-HD applied prior to regional ischemia in β1/β2-PC had no 
significant effect on the infarct size reducing capabilities of β1/β2-PC. This suggests that the 
mitochondrial KATP channel does not play a role in the protective effects of β-adrenergic 
preconditioning.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.3:  The effect of the mitochondrial KATP channel blocker, 5-HD on infarct size in  
               β1/β2-PC  
Infarct size
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6.2.3 a   The role of reactive oxygen species in β1/β2-PC (Table  6.3) 
 
The oxygen radical scavenger NAC, (N-acetyl cysteine) applied prior to RI (trigger phase) or at 
the onset of reperfusion had no significant effect on any of the haemodynamic parameters at the 
end of reperfusion, when compared with those obtained in hearts pre-treated with isoproterenol 
(0.1 µM). 
 
Table 6.3:  Effect of the ROS scavenger NAC on mechanical recovery during 
                   reperfusion of β1/β2-PC hearts 
 
β-AR agonist: Isoproterenol (0.1 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC 
Before RI (n=18) 
15.53±0.28 39.10±0.92 54.43±0.81 271±5.10 102.3±1.52 12.63±0.38 
NPC 
After RI 
10.25±0.90 
 
7.250±1.01 
#  
19.01±1.02 
#  
235±15.30 86.80±2.13 3.61±0.22  
#  
β1/β2-PC  
Before RI (n=18) 
16.28.±0.24 40.50±0.70 56.69±0.80 268±5.48 105.2±1.98 13.54±0.31 
β1/β2-PC  
After RI 
13.58±1.11 18.00±2.78 31.58±3.53 240±19.69 87.36±1.81 6.43±0.70 
 
# P< 0.05 vs β1/β2-PC After RI  
 
 
ROS scavenger: NAC (Trigger) (300 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+NAC 
After RI (n=6) 
8.00±4.09 4.00±2.30 12.67±6.43 169±54.87 55.29±27.67 2.36±1.21 
       
β1/β2-PC +NAC 
After RI (n=6) 
11.17±2.55 13.50±3.50 24.58±6.00 201±41.56 76.57±13.37 4.98±1.30 
 
 
ROS scavenger: NAC (Reperfusion) (300 µM) 
 
 CF 
(ml/min) 
AO 
(ml/min) 
CO 
(ml/min) 
Heart rate 
(beats/min) 
PSP 
(mmHg) 
Total work 
(mW) 
NPC+NAC 
After RI (n=6) 
9.25±2.90 4.33±4.27 13.58±4.50 168±53.60 59.47±18.11 2.70±0.59 
       
β1/β2-PC +NAC 
After RI (n=6) 
14.17±.0.88 12.58±1.50 27.58±1.96 280.2±12.29 88.74±2.81 5.46±0.40 
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6.2.3 b   The effect of reactive oxygen species inhibition on infarct  
                     size in β1/β2-PC (Fig. 6.4) 
 
The role of ROS in β-adrenergic preconditioning was clearly illustrated when the ROS 
scavenger, NAC was applied, prior to or at the onset of reperfusion of hearts preconditioned 
with isoproterenol. At both time intervals infarct size was significantly increased 
(25.97±2.41%, p<0.05 and 33.99±2.80% vs β1/β2-PC 16.71±.088, p<0.001, respectively) 
suggesting that ROS generation plays a role in both the triggering and mediator phases of 
β1/β2-PC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.4:  The effect of ROS scavenger, NAC on infarct size in β1/β2-PC  
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6.3   Discussion 
 
The results obtained in this chapter indicated that (i) NO plays a role in improving functional 
recovery in β-PC, while having no effect on infarct size; (ii) the mitoKATP channel has no role 
in β-PC and (iii) blocking ROS generation either during the triggering phase or reperfusion was 
without effect on functional recovery, but significantly increased infarct size. 
  
6.3.1   The role of Nitric Oxide (NO) in the cardioprotective effects of  
             β1/β2-PC  
 
The effect of NO on a given cell type will largely depend on the NO concentration, the 
duration of NO exposure and the composition of the microenvironment. As stated in the 
introduction, cardioprotection can be elicited by the administration of NO donors. Thus, 
pharmacological mimicking with NO donors can bring about the same cardioprotection as 
present in ischaemic preconditioning (IPC) (Lochner et al., 2000). From this study of β1/β2-
PC, it has emerged that the application of NOS inhibitors L-NAME / L-NNA during the 
triggering phase of β1/β2-PC had no effect on the infarct limiting effect of β1/β2-PC (Fig. 6.2). 
On the other hand, haemodynamic parameters obtained were significantly reduced (Table 6.1), 
suggesting that NO generated had an effect on alleviating stunning during reperfusion of 
β1/β2-PC. Thus, inhibition of NO formation with NOS inhibitors, led to a further depression in 
functional recovery. This is in contrast with ischaemic preconditioning where activation of the 
bradykinin and opioid receptors via NO and PKG, mediates opening of the KATP channel 
[Cohen and Downey, 2006]. The absence of overt effects of NOS inhibition on β1/β2-PC is 
also surprising in view of the fact that isoproterenol activates eNOS via Giα, causing an 
increase in cGMP [Balligand et al., 1999]. However, the contribution of NOS activation and 
NO generation in β1/β2-PC appears unlikely in view of the putative harmful effects of NO 
generated by β3-AR signaling [Gauthier et al., 1998; Moens, 2010]. 
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6.3.2   The role of mitochondrial KATP (mitoKATP) channel in β1/β2-PC  
 
The role of the mitoKATP channel in cardioprotection has been intensely investigated and was 
first illustrated in a canine model when the mitoKATP blocker, glyburide (glybenclamide) 
abolished IPC [Gross and Auchampach, 1992]. It was also found that the structurally distinct 
blocker 5-HD (5-hydroxydecanoic acid) abolished IPC in a similar model [Auchampach et al., 
1992]. The ability of KATP blockers to abolish IPC in rats has been variable and may be model 
dependent. However, it is accepted by most that the mitoKATP channel is involved in ischaemic 
preconditioning and it has been demonstrated that the critical time for opening of the mitoKATP 
channel is during the brief preconditioning protocol.  It has also been shown that transient 
opening of this channel prior to ischaemia mimics ischaemic preconditioning and the 
protection could be blocked by a free radical scavenger [Pain et al., 2000]. 
 
In this study of β1/β2-PC, it was illustrated that the application of 5-HD in β1/β2-PC had no 
effect on the beneficial effects of this cardioprontection (Table 6.2 and Fig. 6.3), showing that 
the mitoKATP channel does not play a role in the signaling pathways of β1/β2-PC, which is in 
contrast to its important role in ischaemic preconditioning. This significant observation lends 
support to the major role of adenosine in β1/β2-PC, since adenosine triggered protection is 
known not to be mitoKATP channel dependent as previously outlined in the introduction of this 
chapter. 
 
 
6.3.3 The role of Reactive Oxygen Species (ROS) in the Cardioprotective  
           effects of β1/β2-PC   
 
Oxygen free radicals / reactive oxygen species (ROS) and their metabolites have received 
much attention because they are known to play an important role in many biological reactions 
which maintain normal cell function. Biological systems have substantial ability to tolerate 
ROS under normal conditions. It is well established in the setting of ischaemia / reperfusion 
that the generation of ROS becomes deleterious and may contribute to cell damage [Hess and 
Manson, 1984; Park and Lucchesi 1999; Zughaib et al., 1993; Opie, 1991; Ambrosio and 
Tritto, 1999; Zweier et al., 1987].  
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Despite the notion that ROS are produced primarily with the reintroduction of oxygen 
following ischaemia, several investigators observed ROS generation also during ischaemia 
[Hess and Manson, 1984; Nohl and Jordan1986; Kevin et al., 2003] and studies in 
cardiomyocytes showed that the mitochondria may be the major source of these substances 
[Vanden Hoek et al., 1998]. This concept is of major importance because ischaemia-generated 
ROS play an important signaling role [Carmody and Cotter, 2001], which may contribute to 
direct cellular oxidant damage. It is likely, that this is the same source of ROS that has been 
reported to trigger the cardioprotection of ischaemic preconditioning (IPC) [Vanden Hoek et 
al., 1998].  
 
It is well established that chronic activation of the β-AR pathway can lead to increased ROS 
production. This effect is most probably mediated via downregulation of antioxidants such as 
copper-zinc-superoxide dismutase [Srivastava et al., 2007]. In another study of chronic β-AR 
stimulation, it was shown that it may induce oxidative damage through reactive intermediates 
resulting from auto-oxidation, irrespective of their interaction with adrenergic receptors, thus 
representing an important aspect in the pathogenesis of catecholamine-induced cardiotoxicity 
[Yogeeta et al., 2006]. In the acute phase of isoproterenol infusion (intravenous infusion for 30 
min), ROS are important activators of cardiac MAPKinase cascade; while in the chronic phase 
(intravenous infusion for 10 days) ROS may participate in cardiac remodeling, especially in 
respect to wall stiffness, based on fibrogenesis [Zhang et al., 2005]. Shorter episodes of β-AR 
stimulation also lead to ROS formation: It has been demonstrated that stimulation of the β2-AR 
with 10 µM isoproterenol for 10 min leads to ROS formation [Moniri and Daaka, 2007]. In 
view of the above, it is possible that during acute administration of isoproterenol for 5 min, 
generation of ROS may occur, which in turn participates in signaling processes.    
 
In this study of β-adrenergic preconditioning it was shown that the free radical scavenger NAC, 
(N-acetyl cysteine) applied prior to RI (trigger phase) or at the onset of reperfusion (mediatory 
phase) had no significant effect on any of the haemodynamic parameters at the end reperfusion 
(Table 6.3). However, when using infarct size as a endpoint, a role of ROS in β1/β2-PC could 
be clearly illustrated since the ROS scavenger, NAC when applied prior to or at the onset of 
reperfusion, significantly increased infarct size (25.97±2.41%, p<0.05 and 33.99±2.80%, 
p<0.001, respectively), thereby attenuating the protective effect of β1/β2-PC (Fig. 6.4). 
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Interestingly, although the application of the free radical scavenger, NAC prior to and more so, 
at the start of reperfusion increased the IS, the haemodynamic parameters during reperfusion 
remained unaffected and not different from those of β1/β2-PC hearts.  
 
Changes in infarct size is not often associated with the expected changes in mechanical 
function during reperfusion due to concomitant stunning [Ovize et al., 1992; Lochner, Genade 
and Moolman, 2003; Cohen, Yang and Downey, 1999]. Since infarct size is generally regarded 
as the golden index of cell injury, the results obtained in this study therefore suggest that ROS 
generation during both the trigger and mediator phases of β1/β2-PC contribute to its anti-
necrosis effects, while having no effect on stunning. In summary, β1/β2-PC can be triggered by 
adenosine and ROS generation, but not by NO production or opening of the mitochondrial 
KATP channel.  
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Summary and Conclusions 
 
In our early studies we showed that transient β-AR activation with ligands such as isoproterenol and 
forskolin mimicked ischaemic preconditioning and consequently elicited protection against a 
subsequent period of sustained ischaemia. The necessary component in both ischaemic and 
pharmacological preconditioning is the washout period applied before the onset of sustained 
ischaemia. If washout or reperfusion is not performed in either cardioprotective method, the 
technique would be termed pretreatment and not preconditioning. Consequently, the brief 
washout/reperfusion episode prior to sustained ischaemia is essential to these cardioprotective 
strategies, since crucial signal-transduction pathways could be activated and maintained during this 
period and this may affect the subsequent response of the heart to ischaemia. For example, cAMP is 
generated [Lochner et al., 1999], p38MAPK [Marais et al., 2001] and CREB are activated [Marais, 
Genade, and Lochner, 2008] during a β-PC protocol, to name but a few.  In the present study it was 
shown that also significant activation of ERK and PKB/Akt occurred during washout after 
isoproterenol administration. This phenomenon is of particular importance since inhibition of these 
kinases during the triggering phase, completely inhibited β1/β2-PC. 
 
At the onset of the present study it was not clear which of the three β-AR receptors (β1-, β2- or β3-
AR) present in heart muscle, was involved in β-PC. Therefore the first aim was to determine which 
of the three receptor subtypes are involved in this process. Throughout this study the isolated 
working rat heart, subjected to 35 min coronary ligation followed by reperfusion, was used as model 
with functional recovery during reperfusion and infarct size as endpoints. The results showed that 
transient β-AR stimulation with isoproterenol (β1/β2-AR agonist) (β1/β2-PC) effectively induced 
cardioprotection as indicated by a significant improvement in functional recovery and reduction in 
infarct size.  Similar cardioprotection was achieved with formoterol hemifumarate, a β2-AR agonist, 
(β2-PC) but not with BRL 37344, a β3-AR agonist (β3-PC) (Fig.6.5).  
 
The relative importance of adrenergic stimulation and demand ischaemia as important 
preconditioning stimuli remains unclarified. In this study, it was demonstrated that β1/β2-AR 
stimulation by isoproterenol caused an increased workload with possibly demand ischaemia and 
thus concomitant adenosine production. The role of adenosine in eliciting the cardioprotection of 
IPC is well-established. 
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The data obtained in this study showed that, as in the case in IPC, adenosine generation during 
β1/β2-PC is involved in eliciting cardioprotection. Using appropriate antagonists, it was shown that 
the A1-AdoR was not involved in β1/β2-PC, nor did it have any effect on ERK p44/p42 or PKB 
activation. The data obtained suggest that the triggering of isoproterenol-induced protection (β1/β2-
PC) is mainly dependent on endogenous adenosine acting on the A3-AdoR; while the mediatory 
phase is dependent on the activation of the A3-AdoR in conjunction with mainly the A2A-AdoR, but 
also the A2B-AdoR during this phase. It should be noted that the A2A-AdoR are located on smooth 
muscle and endothelial cells of blood vessels mediating the vascular effects of adenosine. Also, it 
was shown to regulate inflammatory tissue damage and remodeling associated with ischaemia and 
reperfusion and the possibility that the A2A-AdoRs may have a more prominent role in 
cardioprotection at reperfusion is more likely. On the other hand, the low sensitivity A2B-AdoR is 
responsive to increased adenosine levels only, such as occurs during sustained ischaemia or at the 
onset of reperfusion. Thus, as expected this receptor type was shown to be involved, largely at 
reperfusion following sustained ischaemia in β1/β2-PC (Fig.6.5).  
 
However, the role of demand ischaemia and adenosine in eliciting β-PC needs to be further 
evaluated, since β2-AR preconditioning with formoterol did not affect mechanical performance 
during the triggering phase. 
 
IPC-induced cardioprotection is now known to be associated with activation of the RISK pathway 
during reperfusion. It is has been shown that pharmacological manipulation and up-regulation of 
these kinases as an adjunct to reperfusion may protect the myocardium from lethal reperfusion–
induced cell death and provide a novel approach to salvage viable myocardium and limit infarct 
size. Similar to IPC, β1/β2-PC and β2-PC were also associated with significant activation of the 
prosurvival kinases in the early mediatory phase following sustained ischemia. The latter 
phenomenon appears to be of particular significance since inhibition of these kinases during the 
triggering phase, completely inhibited subsequent cardioprotection (Fig.6.5). 
 
The involvement of established role players in IPC such as the Gi/o protein, PKA, mitoKATP 
channel, reactive oxygen species (ROS) and nitric oxide (NO) in the mechanism of β-adrenergic 
induced cardioprotection were also evaluated. In contrast to IPC, inhibition of the mitoKATP channel 
by using 5-hydroxy-decanoate during the triggering phase had no effect on IS limiting capabilities 
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of β1/β2-PC – indicating that it had no part in this cardioprotective phenomenon. Cardioprotection 
of β1/β2-PC was abolished by ROS inhibition in the triggering phase as well as at the start of 
reperfusion after sustained ischaemia, indicating its importance in both phases of the experimental 
protocol.  In addition, it appears that NO is also involved in β1/β2-PC. The Gi protein may play a 
role in β2-PC, since prior treatment with pertussis toxin had no effect on the reduction in infarct size 
induced by either isoproterenol or formoterol, but reduced functional recovery after β2-PC. 
 
Using appropriate inhibitors (Rp-cAMP and wortmannin respectively) PKA as well as PI3-K 
activation were illustrated to be essential components of cardioprotection prior to sustained 
ischaemia (trigger phase) and at the onset of reperfusion (mediatory phase) of β1/β2-PC. However 
the mechanism whereby PKA activation mediates cardioprotection as well as the downstream events 
involved remains to be established (Fig.6.5).  
 
The results obtained in this study again demonstrate how application of one of the triggers released 
during an IPC protocol, when administered alone, can elicit cardioprotection similar to that of IPC.  
Other similarities are involvement of the adenosine A3, A2A and A2B receptors, ROS, NO and to a 
lesser extent, the Gi protein (Fig.6.5).   
 
Finally, the results obtained in this study stress the significance of the endpoints used in the 
interpretation of data. Infarct size is by many workers regarded as the “gold standard” for evaluation 
of cardioprotection and in many studies, it is the only endpoint used in the interpretation of results. 
Reperfusion function is more complex and may be influenced by amongst others, stunning apoptosis 
and arrhythmias. By using two different endpoints, we expected a reduction in infarct size (i.e. less 
necrosis) to be associated with increased functional recovery and vise versa. Indeed, this was 
observed in the case of β1/β2-PC, β2-PC as well as in the studies where inhibitors of the
 
A2A-, A2B-  
and A3-AdoR subtypes were used. However, in a number of studies a dichotomy was observed, 
where (i) studies an increase in infarct size was not associated with changes in functional recovery 
(for example in the studies with adenosine deaminase, PD and NAC) or (ii) an unchanged infarct 
size was associated with a reduction in functional recovery (for example Pertussis toxin pretreatment 
and formoterol; L-NAME and L-NNA), suggest an effect on stunning. These observations stress the 
potential danger of using one endpoint only in the interpretation of data in studies such as the 
present. 
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Fig. 6.5: Cartoon showing the sequence of signaling events involved in triggering the 
preconditioned state prior to the ischemic insult (events above the dividing line) and those that 
mediate protection in the first minutes of reperfusion (events below the dividing line), refer to text, 
section 1.3, page 5 [Tissier R, Cohen, and Downey, 2007; Downey, Krieg, Cohen, 2008; Lohse, 
Engelhardt and Eschenhagen, 2003; Zheng et al., 2005]. Also included in this cartoon are the 
receptors and signaling cascades that were shown to be involved in the cardioprotective strategy of 
β-PC prior to the ischemic insult in blue and those that mediated protection at the onset of 
reperfusion in yellow. 
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Future directions: 
 
One of the most interesting observations made during the course of this study, was the fact that 
transient activation of the β2-AR with formoterol was the most effective trigger of cardioprotection. 
It is envisaged that use of this agonist may shed more light on the mechanism whereby β-AR 
stimulation triggers the cardioprotective process, since formoterol per se had no effect on 
mechanical activity of the isolated rat heart. As yet, no information is available regarding its 
mechanism of action. For clinical application in the future, it is essential that its effects are also 
evaluated in an in vivo model. 
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